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Matrix metalloproteinases (MMP’s) and cathepsins are thought to play key roles in 
oral squamous cell carcinoma (OSCC) invasion and metastasis. Three OSCC human cell 
lines, BHY, HN and HSC-3, have been studied based on their reported ability to invade 
adjacent bone or metastasize to lymph nodes and/or distant organs. The working 
hypothesis of this study is that OSCC that demonstrate different actions have different 
proteolytic enzyme and gene expression profiles. 
Immunocytochemistry and flow cytometry were used to determine the expression 
levels of certain proteolytic enzymes. Complementary DNA (cDNA) microarray 
technique was used to determine the gene expression profiles of each of the three OSCC 
cell lines. 
The immunocytochemistry and flow cytometry results showed that the BHY cell 
line expresses MMP- 9 and extracellular matrix metalloproteinase inducer (EMMPRIN). 
The BHY cell line expressed 139 upregulated genes and 117 downregulated genes. The 
HN cell line expressed 214 upregulated and 262 downregulated genes. Finally, the HSC-
3 cell line expressed 128 upregulated and 117 downregulated genes. There were 13 genes 
that were upregulated and 83 genes that were downregulated in all three OSCC cell lines. 
Eight pathways were upregulated and 3 pathways were downregulated in the BHY cell 
line. In the HN cell line 10 pathways were upregulated and 9 were downregulated. 
Finally, in the HSC-3 cell line 3 pathways were upregulated and 6 pathways were 
downregulated.  
 iv
MMP-1, MMP-9 and EMMPRIN appear to play a role in the invasion of OSCC to 
bone. KIAA, was upregulated in our study in the HN cell line. Upregulation of KIAA 
may be involved in the late stage of OSSC. PAM gene was the only downregulated gene 
in the HN cell line. The TM4SF10 gene was downregulated in all three OSCC cell lines. 
The COL1A2 and COL4A1 genes were upregulated in the HSC-3 cell line and they may 
cause the lymph node metastasis of OSCC. Based on this study OSCC involves multiple 
molecular genetic events that take place in many chromosomes and genes. Upregulation 
of the Jak-STAT signaling pathway may be involved in bone invasion of OSCC. The 
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Oral squamous cell carcinoma (OSCC) is the most common cancer of the oral 
cavity accounting for ninety percent of all diagnosed oral malignancies. OSCC accounts 
for approximately 6 % of all human malignancies (6, 96). There is little published 
information on the capability of some OSCC to invade adjacent bone while other OSCCs 
do not. Additionally, some OSCCs exhibit metastasis to cervical lymph nodes and/or 
distant organs while others do not readily metastasize. 
In the United States, OSCC is the sixth most common cancer in males (6, 57) and 
the twelfth most common cancer in females. Approximately 21,000 new cases are 
diagnosed annually in the United States, and 6,000 of these patients die of this disease 
each year.  Some risk factors for developing OSCC include tobacco use, alcohol 
consumption, human papilloma virus and syphilis. Other intrinsic factors may include 
general malnutrition such as vitamin A deficiency and iron deficiency anemia. The 
treatment of OSCC is radical surgical excision and/or radiation therapy, depending on the 
clinical stage of the disease. A variety of chemotherapeutic agents are used as adjunctive 
therapies, but none of them has significantly improved survival rates. As with most 
tumors, the survival rate decreases with evidence of bone invasion and cervical 
metastases (6).  OSCC may invade tissue locally (1, 2, 3), and often to adjacent bone (1, 
4, 7).  Also, OSCC often metastasizes to cervical lymph nodes (1, 2, 3) and distant organs 
(5). In addition, if the tumor invades nearby bone the survivability is significantly lower 
(6). Resection of OSCC with bone invasion dramatically affects functions such as 
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swallowing and speaking, and patient esthetics. Thus, reconstruction of the area is a 
necessity. Tumor usually invades bone through osteolysis, by greatly increasing the 
number of active osteoclasts at the invasion site (7).  This strongly suggests that tumor 
cells involved with bone invasion promote differentiation and activation of osteoclasts 
(7).  Proteolytic enzymes such as various matrix metalloproteinases (MMP’s) (1, 2, 3, 8, 
13) and cathepsins (1, 4) are thought to play key roles in OSCC invasion and metastasis, 
and have been shown to be expressed by OSCC cells (4, 8, 9, 10).   
Some studies have focused on the effect MMP-1 (1, 10, 18), MMP-2 (1, 9, 10, 17), 
MMP-3 (2, 17, 18) and MMP-9 (1, 9, 10, 19) along with cathepsin B, H, L, and D (1, 4) 
on the ability of OSCC to invade bone. Production of MMP-1 and MMP-9 appear to play 
a role in the invasion of OSCC to bone (8, 10). These two metalloproteinases are 
necessary for the complete degradation of the collagen matrix of bone, and have been 
shown to be expressed by OSCC (10). MMP-2 does not appear to be related to OSCC 
invasion, but is highly expressed in some OSCCs (9). Over expression of MMP-3 in 
OSCC is associated with diffuse invasion and a high incidence of metastasis (2). In tumor 
cells, extracellular matrix metalloproteinase inducer [EMMPRIN (CD 147)] can stimulate 
the production of MMPs. It also participates in invasion and metastasis by facilitating 
tumor cell motility though the surrounding matrix (13). Cathepsin B, H and D have been 
strongly implicated in the invasion of OSCC, with over expression of these proteins 
thereby appearing to promote tumor growth and invasion (4). Cathepsin B and L are the 
two most important cysteine proteinases implicated in tumor cell invasion and metastasis 
(12).  
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Why does one patient with a certain type of cancer respond well to treatment, while 
other patients with histologically and anatomically identical disease do not? Why do 
some tumors grow more aggressively than others even though they are the same type of 
tumors? The key to resolving the enigma of individual tumor behavior clearly lies in 
understanding its molecular structure. cDNA microarray analysis is one of the strongest 
tools for mapping molecular signatures because with this technique, instead of working 
on a "one gene in one experiment", it is possible to observe the whole human genome on 
a single chip. Thus, researchers can have a better picture of the interactions among 
thousands of genes simultaneously. Briefly, with this technique it is possible to evaluate 
the gene expression profile of any type of cell or tissue. 
In this study, 3 OSCC human cell lines, BHY, HN and HSC-3, were chosen for 
study based on their reported ability to invade adjacent bone or metastasize to cervical 
lymph nodes and/or distant organs. Also, a normal human nasal epithelial cell line 
(HNEC) was chosen as a control group. The working hypothesis of this study was that 
OSCC’s that demonstrate different actions have different proteolytic enzyme, gene and 
pathway expression profiles. OSCC’s that invade adjacent bone will have different 
expression profiles from OSCC’s that metastasize to cervical lymph nodes and/or distant 
organs. Thus, identification of the gene expression differences of these three cell lines 
will help to determine which genes and pathways are responsible for lymph node or 
distant organ metastasis or bone invasion of OSCC. Genes, pathways or their related 
proteins that are associated with tumor metastasis or invasion will provide a basis for 
further studies investigating metastatic progression and local invasiveness of this tumor, 
and can be evaluated as therapeutic targets. 
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The four cell lines; BHY, HN, HSC-3 and HNEC were morphologically 
characterized and the level of differentiation and any possible organelle abnormalities 
studied using transmission electron microscopy. Micro positron emission tomography 
(PET)/computerized tomography (CT) imaging techniques were used to image the 
invasion and/or metastatic potential of each cell line in immuno-compromised scid mice.  
This technique also showed the differences in jaw bone invasion and distant organ 
metastasis of these three OSCC cell lines in a biological system. The 3 OSCC cell lines 
and HNEC were studied in vitro with both immunocytochemistry and flow cytometry to 
determine if MMP-1, MMP-2, MMP-3, MMP-9, and EMMPRIN and cathepsin B and L, 
were expressed. Finally, gene regulation of the three OSCC cell lines was investigated 
















2.1. Oral Squamous Cell Carcinoma (OSCC) 
Oral squamous cell carcinoma (OSCC) is a malignant transformation of 
keratinocytes in stratified squamous epithelium (6). It is the most common cancer of the 
oral cavity (6, 9, 46, 52). This malignancy is an important public health problem 
worldwide with more than 500,000 new cases diagnosed each year (6). OSCC can 
metastasize to cervical lymph nodes (1, 2, 3, 9, 52) and distant organs (5, 9), and invade 
the jawbone which results in significantly decreased survival (6, 9).  
The etiology of OSCC can be genetic from alterations of proto-oncogenes and 
tumor suppressor genes (25, 58, 70, 104, 107). Other common etiologies of OSCC are:  
• Alcohol consumption and smoking (58, 104). Smoking and drinking alcohol in 
combination increases the risk of developing oral cancer by 15 times (6). 
• Viral infections such as; Human Papilloma Virus (HPV), Herpes Viruses, Epstein 
Barr Virus (EBV), Human Immunodeficiency Virus (HIV).  
• Candidiasis (58, 104). 
• Exposure to high amounts of X-rays and UV rays (104). 
Diagnosis of OSCC can be made by intraoral examination and biopsy, PET/CT 
imaging, and toluidine blue staining. Toluidine blue staining may permit early diagnosis 
of OSCC. The development of OSCC occurs in a stepwise fashion. It begins with 
dysplasia, progressing to carcinoma in situ, and finally to invasive and metastatic 
squamous cell carcinoma (10). 
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Clinically, early OSCC may present as a white lesion (leukoplakia), a red lesion 
(erythroplakia), or a combination of both (erythroleukoplakia). Superficial ulceration of 
the mucosal surface may develop. As the lesion progresses, it may become an exophytic 
mass with a fungating or papillary surface. Some tumors demonstrate an endophytic 
growth pattern that is characterized by a depressed, ulcerated surface with a raised, rolled 
border (6). Pain is not a reliable indicator because most oral cancers are asymptomatic, or 
may be associated with only minor discomfort in the early stages (6). Head and neck SCC 
mainly occurs in the oral cavity and larynx. Two thirds of the patients diagnosed with this 
tumor are in advanced stages (III and IV). OSCC is generally seen after the age of 40 and 
2/3 of the cases occur in males (6). 
Histopatologically, OSCC demonstrates larger nucleii and cell size, and prominent 
nucleoli. The nucleus-to-cytoplasm ratio is increased in OSCC. Hyperchromatic 
(excessively dark-staining) nuclei, dyskeratosis (premature keratinization of cells), and 
increased and / or aberrant mitotic activity are also common pathological chacteristics of 
OSCC (6). 
The treatment of OSCC is complex and multidisciplinary. Surgery, radiotherapy, 
and chemotherapy or the combinations of these are the mainstay of treatment (100). 
During surgical treatment, resection of the tumor with an uninvolved margin is vital to 
success (6). If there is invasion of underlying bone, resection of bone with its periosteum 
should be performed. Instead of surgery, radiation and chemotherapy may be employed. 
Multiple chemotherapeutic agents and combinations can be used. Platinuim and 5-
fluorouracil are the common drugs that have been used for chemotherapy. Following 
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surgical treatment, 6000-6400 cGy of external beam radiation therapy is commonly 
administed in daily 200 cGy fractions. (209). 
The prognosis of OSCC is poor (9, 44). Early recurrence and rapid progression is 
common (3) and the 5-year survival rate is approximately 50% (93, 97).  Twenty five 
percent of all patients develop a second cancer within 5 years from diagnosis (97). The 
prognosis of patients with OSCC is directly correlated with the histologic status of the 
cervical lymph nodes (9). Proteolytic degradation of the extracellular matrix (ECM) is 
required for tumor cells to invade the basement membrane, stromal matrix and vascular 
tissue (8, 33). 
2.2. BHY, HN, HSC-3 and HNEC Cell Lines 
 
The 3 OSCC cell lines chosen for this project included BHY, HN, and HSC-3. As a 
control group, normal human nasal epithelial cell (HNEC) was chosen.  
2.2.1. BHY cell line 
 
The BHY cell line was isolated from a 52-year-old Japanese male. The primary 
squamous cell carcinoma was located on the lower alveolus, and the tumor was highly 
differentiated. In this patient the tumor invaded the mandible but did not metastasize.   
Kawamata et al. showed that BHY cells actively invade mandible when injected into the 
masseter muscle of nude mice, but did not metastasize to cervical lymph nodes or any 
distant organs (1). 
2.2.2. HN cell line 
 
The HN cell line was isolated from a 60-year-old Japanese male.  The primary 
squamous cell carcinoma was located on the soft palate, and was moderately 
differentiated.  The tumor had metastasized to cervical lymph nodes, lungs and brain but 
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had not invaded bone. Kawamata et al. reported that HN cells injected into the masseter 
muscle of nude mice weakly invaded the surrounding masseter muscle but not the 
mandible; however, these cells did metastasize to cervical lymph nodes (1). 
2.2.3. HSC-3 cell line 
 
The HSC-3 cell line was isolated from a 64-year-old Japanese male.  The primary 
squamous cell carcinoma was located on the tongue with lymph node metastasis, and was 
moderately differentiated. This cell line is highly metastatic to cervical lymph nodes (10, 
23, 52). 
2.2.4. HNEC cell line 
 
The HNEC cell line was isolated from a 27-year-old Caucasian male, and represents 
a normal human nasal epithelial cell line.   
2.3. Invasion and Metastasis of OSCC 
 
Metastasis is the process by which cancers spread to regional and distant sites in the 
body (110). Invasion is the movement of cancer cells into the surrounding normal tissues. 
Both metastasis and invasion are multi-step processes that require a variety of genetic 
alterations in the tumor cells. Bone is one of the most common sites of tumor metastasis 
(7). In the oral cavity, OSCC frequently invades maxillary and/or mandibular bone. 
However, the metastatic and invasion mechanisms of OSCC are poorly understood. It has 
been shown that bone resorption by osteoclasts is an important step of bone invasion and 
metastasis in OSCC (14, 15, 16). Osteoclasts, rather than carcinoma cells, mediate bone 
destruction in carcinoma invasion and metastasis (7, 14, 15). In so doing, tumor cells 
promote differentiation and activation of osteoclasts (7). Osteoclast precursor cells are 
directly apposed to tumor cells in some instances, which means that tumor cells may 
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participate in the differentiation of osteoclasts. However, stromal cells or extracellular 
matrix (ECM) usually exist between these two cells (Figure 11). Direct contact of 
osteoblasts or stromal cells with stem cells is needed for osteoclast differentiation. 
Therefore, the interaction between stromal cells and osteoclast precursor cells is 
important in the process of osteoclast formation. Heparin-sulfate proteoglycan (HSPG) 
and fibronectin are the two representatives of the components of the extracellular matrix. 
HSPG can be observed in the stroma around the tumor nests, but not in the tumor cells. 
HSPG is also positive in the stroma away from the bone surface. HSPG binds a bone 
resorption-activating factor that is released from osteoblasts. Fibronectin shows the same 
pattern of localization as seen with HSPG. Since many osteoclast precursor cells can be 
observed in a stroma rich ECM component, they may play an important role in providing 
a micro-environment for osteoclast differentiation and activation (7). In addition, 
interleukin-6 (IL-6) secreted by oral cancer cells may enhance bone invasion of cancer 
cells mediated by induction and activation of osteoclasts (7, 20).  
The proliferation and progression of cancer may be caused by abnormalities in 
various positive and negative cell cycle regulators (25, 68, 133). Cell cycle progression is 
positively regulated by multiple cyclins and cyclin-dependent kinases (CDKs). 
Cyclin/CDK complexes are activated through phosphorylation by the CDK-activating 
kinase, but are negatively regulated by a number of CDK inhibitors including p27 (25, 
68). In oral carcinogenesis, p53 over-expression is an early event (25, 46, 68, 70). Loss of 
the p27 protein is also closely associated with early invasion and metastasis in OSSC. 
Aggressive cancers express low levels of p27 because of its decreased stability. Thus 
 
1 All figures are located in the Appendix B. 
 24
metastatic OCSS shows reduced expression of p27 in comparison with that in the primary 
lesion as well as in non-neoplastic mucosa (25, 26, 27, 28, 29, 30, 31, 32, 68). 
Tumor growth, invasion and metastasis also depend upon angiogenesis, formation 
of new blood vessels from pre-existing endothelium (46, 51, 52, 55). Vascular endothelial 
growth factor (VEGF) (50, 51, 52, 53, 56) and fibroblast growth factor (FGF) (50) are 
considered the most important mediators in tumor angiogenesis. Shang et al. showed that 
VEGF concentration is increased in patients with OSCC (51). Moriyama et al. reported 
that the intensity of VEGF expression is significantly higher in metastatic positive 
patients than in metastatic negative patients with OSCC (53). VEGF promotes 
angiogenesis both in vivo and in vitro (46, 47, 50, 51). In addition to inducing cascades of 
angiogenic events, VEGF is also known as a vascular permeability factor (46, 50, 52, 56). 
When blood vessel permeability increases, VEGF permits creation of an extravascular 
fibril gel that supports endothelial cell growth and thus the tumor (50, 51). The tumor 
suppressor gene, p53 is a cell cycle regulator and DNA damage sensor. Loss of p53 
function is associated with increased angiogenesis by upregulation of VEGF expression 
(46). There are 4 members of VEGF family, including VEGF A, B, C, and D. Shintani et 
al. found that VEGF A and B can be detected on both lymph node positive and negative 
cases, whereas VEGF C and D can only be detected in lymph node positive tumors. This 
suggests a possible relationship between the expression level of VEGF C and D and 
development of lymphatic tumor spread (47). Thrombospondin-1 (TSP-1) is a 450 kd 
glycoprotein synthesized and incorporated into ECM by numerous cell types and reported 
to suppress tumor growth and progression by its inhibition of angiogenesis. The level of 
TSP-1 is inversely associated with the pattern of tumor invasion and lymph node 
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metastasis. The reason for this might be that TSP-1 suppresses the proliferation and 
migration of vascular endothelial cells in vitro, and suppresses neovascularization in vivo 
(54). 
In addition to VEGF, interleukin-8 (IL-8) is also a potent angiogenic factor and it 
plays an important role in cancer progression and metastasis (48, 125, 126). IL-8 is 
responsible for most of the angiogenic activity induced by human OSCC (49, 126). Lalla 
et al. showed that at a specific dose, fibrin causes upregulation of IL-8 expression in 
human OSCC cells in vitro, whereas it doesn’t stimulate IL-8 formation in non-
tumorigenic oral epithelial cells. This means that fibrin can be a pluripotent activator in 
OSCC. IL-8 transfected cells, show an upregulation in MMP-2 and MMP-7 levels that 
causes the enhancement of invasion and metastasis (48, 126). Beside this, perilymphatic 
recombinant interleukin-2 (IL-2) application combined with surgery and radiotherapy 
increases the disease free interval and survival of OSCC patients with T2-T4, N0-N3, M0 
staging (127).  
2.3.1. The effect of MMPs and EMMPRIN on invasion and metastasis of OSCC 
 
Proteolytic enzymes play an important role in tumor invasion and metastasis by 
degrading the ECM (9, 13, 41, 42, 97). They are secreted by a variety of normal cells and 
tumor cells; however, the difference between normal and pathological processes is in the 
regulation of their activity (1). One of the groups of proteolytic enzymes is the matrix 
metalloproteinase (MMP) family, which is a family of zinc-dependent proteinases (9, 38, 
42). The MMP family consists of 16 related members. Based on their structural and 
functional properties, they can be classified as collagenases, gelatinases, stromelysins, 
and membrane type MMPs (MT-MMPs) (9, 10, 42). In addition, there are 4 different 
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tissue inhibitor matrix metalloproteinases (TIMPs-1 to -4) that inhibit the function of 
MMPs (22). MMPs have specific functions in turnover of ECM. They play an integral 
role in the biological processes of development, tissue repair, and metastasis by 
regulating cell proliferation, differentiation, adhesion and migration. The production of 
these proteins by normal cells is regulated by growth factor and cytokines (42).  It has 
been shown that they play a key role in promoting invasiveness of both normal and 
neoplastic cells (13, 21, 38, 42). Also, they play important roles in wound healing, tissue 
repair, bone resorption, angiogenesis and developmental tissue morphogenesis (10, 38, 
42). Table 12 summarizes the role of MMPs in normal and pathological processes (21). 
 To establish invasion and metastasis, the first step is the active migration of cancer 
cells from their tissue of origin. This process involves the degradation of underlying 
basement membrane, which is made of collagens, laminin, and heparin sulfate 
proteoglycans (42, 44). OSCC can produce several collagen and gelatin-degrading 
enzymes such as MMP-1, MMP-2, MMP-7 and MMP-9 (1). Also, tumor cells can 
activate the proMMPs (zymogen forms) that are released mainly by the peritumor 
fibroblasts and/or the tumor cells themselves at the invasive edge of the tumor (1, 13). 
Several mechanisms can account for the secretion of MMPs and thus their mediation in 
tumor cell invasion. First, tumor cells can produce MMPs themselves, thus facilitating 
their own invasive behavior. Second, the neighboring stromal cells may produce the 
proteases required for tumor cell invasion. Third, an interaction between stromal and 
tumor cells may exist, resulting in increased MMP production and activation which 
enhances invasion (10, 44). After the tumor cells degrade the ECM, they enter the 
 
2 All tables are located in the Appendix A. 
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circulation. They then penetrate through the sub-endothelial basement membrane of 
lymphatic channels and capillary vessels (9, 44). This event largely depends on the 
activation of ECM degrading enzymes, such as MMPs that are produced by the tumor 
cells and the stromal cells (1, 9, 44). The MMPs that are synthesized by stromal cells are 
the proforms of MMPs. Then, the tumor cells receiving the proenzymes from the 
surrounding stromal cells activate them by their own MT1-MMP (44). Epidermal growth 
factor (EGF) has been shown to be a major constituent of serum to induce MMP-1, and to 
enhance ECM collagen degradation (2, 10). Collagenase MMP-1 initiates the degradation 
of type I collagen, which is one of the most abundant proteins of the ECM. Once cleaved, 
type I collagen denatures into gelatin and ultimate degradation of gelatin is accomplished 
by the action of gelatinases, which are MMP-2 and MMP-9 (9, 10, 44). Production of 
MMP-1 is required for complete collagen matrix degradation and is expressed in OSCC. 
Thus, MMP-1 appears to be a major factor in invasive OSCC (10). Another essential step 
in the invasive and metastatic nature of tumor cells is the degradation of type IV collagen 
in the basement membrane by MMP-2 and MMP-9 (9, 38, 41, 42, 44). However, tumor 
cells must also traverse interstitial stroma, composed of collagen III and I. Thus, to be 
invasive the tumor cells must be able to degrade interstitial collagen. Degradation of 
interstitial collagen is most effectively accomplished by collagenases MMP-1, MMP-8, 
MMP-13 and to some extent MMP-2 and membrane type 1 MMP (MT1-MMP) (10, 
112). 
Similar to other MMPs, MMP-2 is secreted in an inactive form (proMMP-2). Its 
conversion to an active form (MMP-2) is due to the MT1-MMP. In fact, proMMP-2 
binds to TIMP-2 in combination with the MT1-MMP on the cell surface, forming a 
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ternary complex. Then, proMMP-2 in the complex is activated by adjacent MT1-MMP 
that is freed from TIMP-2 (43).  
Hong et al. reported that the total activity of MMP-2 in OSCCs was 3.64 times 
higher than in normal mucosa, but in OSCC without metastasis it was similar to that in 
OSCC with metastasis (9). On the other hand, the total activity of MMP-9 in OSCCs was 
2.81 times higher than in normal mucosa and in OSCC with metastasis, this was 1.54 
times higher than when there was no metastasis (9). Although cancer cells that secrete 
MMP-2 and MMP-9 can become invasive, Hong et al. suggest that MMP-9 might play a 
more important role than MMP-2 during this process (9). According to the results of 
another study, OSCC patients with T3 and T4 tumors had significantly higher MMP-2 
levels than T1 and T2 tumors. Also MMP-2 proportion in lymph node metastasis cases 
was significantly higher than that in non-lymph node metastasis cases. In contrast to 
MMP-2, the activated form/proform ratio of MMP-9 was very low, suggesting that 
MMP-9 is not activated in the matrix degrading of OSCC, although both MMP-2 and 
MMP-9 protein expression are present in the tumor cells (44).  MMP-2 and MMP-9 are 
highly expressed in human OSCC with metastasis compared to normal oral keratinocytes 
(38, 97). MMP-2 and MMP-3 expression in OSCC is closely related to lymph node 
metastasis and vascular invasion (34). In addition, it has been reported that OSCC 
producing MMP-2 is prone to metastasize to lymph nodes more frequently than OSCC 
with no MMP-2 expression (35). Miyajima et al. showed that MMP-9 production is 
closely related to lymph node metastasis (36). Charous et al., however, found that there is 
no difference in MMP-2 and MMP-9 expression levels between primary and metastatic 
OSCC (37). 
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Besides MMP-2 and MMP-9, MMP-3 can also degrade collagen type IV. Thus, it is 
important to analyze the expression of MMP-3 in OSCC. EGF stimulates the production 
of MMP-3 coordinately with MMP-1 (2). Interestingly, the over expression of the EGF 
receptor (EGFR) is a remarkable property of squamous cell carcinoma (2, 56, 70). It is 
not clear, however, whether EGFR overexpression is implicated in the increased 
production of MMP-3 by oral squamous carcinoma. The expression of the EGFR has a 
significant correlation to the T-category of the primary tumor, pathological stage, and 
neck metastasis (2). This explains why tumors with EGFR over expression have a poor 
prognosis when compared to EGFR negative tumors (56, 133). On the other hand, there 
is a significant correlation between the expression of MMP-3 and pathological stage, 
mode of invasion and neck metastasis. EGF, platelet-derived growth factor (PDGF), 
interleukin-1 (IL-1), oncogenes such as v-src and ras, can induce the production of 
MMP-3. The more MMP-3 produced by oral carcinoma cells, the more diffusely and 
aggressively the tumor invades to adjacent normal tissue, including lymphatic and blood 
vessels (2).  
E1AF is an ets-oncogene family transcription factor that is located on chromosome 
17q21 and can upregulate the promoter activities of MMP-1, MMP-3 and MMP-9 in 
highly invasive OSCC. Cells transfected with an antisense E1AF expression vector cause 
down regulation of MMP-1, MMP-3, and MMP-9 and reduce the invasive ability of 
cancer cells. Therefore, this gene is closely associated with invasion and metastasis of 
cancer cells by activating MMP genes. It has been found that the incidence of E1AF 
expression is more frequent in invasive tumors than in expanding tumors. Also, E1AF 
mRNA can be detected in cancer cells invading into stromal connective tissue (8). Over 
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expression of the integrin αvβ6 (a receptor for fibronectin, vitronectin, tenascin and TGF-
β latency-associated peptide) is found consistently in OSCC (116, 117, 123) whereas, it is 
not detectible in normal oral epithelium (113, 114, 115). The upregulation of integrin 
αvβ6 promotes OSCC invasion, which is associated with upregulation of urokinase-type 
plasminogen activator (uPA)/plasmin system, thus the proteases including MMP-9 and 
MMP-3 (113, 114). However, integrin αvβ6 does not activate collagenases (MMP-1, 
MMP-8 and MMP-13) but down regulates MMP-13 activation (112).  
Extracellular matrix metalloproteinase inducer (EMMPRIN [CD147]) is a 
transmembrane glycoprotein that belongs to the immunoglobulin superfamily and can 
induce the production of MMPs and VEGF by both the stromal and tumor cells (13, 40, 
134). It can also mediate a wide range of tumor-promoting molecular events that include 
acquisition of anchorage-independent growth and invasive phenotype by tumor cells as 
well as tumor-cell-induced angiogenesis (134). Bordador et al. showed that EMMPRIN is 
highly expressed in OSCC and may help to regulate OSCC invasion, and modulate the 
expression of MMP-2 (13). EMMPRIN is not only highly expressed in OSCC but also in 
oral premalignant cells. Even though the level of EMMPRIN is high in oral premalignant 
cells, they do not release it to the microenvironment as OSCC does. Primary and 
metastatic OSCC show strong cell surface expression of EMMPRIN. Its overexpression 
occurs at a very early stage of oral carcinogenesis and plays a contributing role in OSCC 
tumorigenesis. Abnormal high levels of EMMPRIN expression by cancer cells have been 
attributed to dysregulation of EGFR signaling (134). Generally fibroblasts produce low 
level of MMPs, however, tumor associated fibroblasts do produce high levels of MMPs 
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as they are stimulated or influenced by EMMPRIN (39). Chromosome 19p13.3 is the 
location for the EMMPRIN gene with the size of 10.8 kb (40).  
BHY and HN OSCC cell lines both express a large amount of matrix-degrading 
enzymes, such as proMMP-1, proMMP-2, proMMP-9, MT1-MMP and uPA, which 
converts plasminogen to plasmin (1). Induction of tissue-type plasminogen activator 
(tPA) and uPA can mediate the activation of proMMP-2 and proMMP-9 in OSCC and 
thus enhance invasiveness (3, 97). In addition, BHY cells can secrete proMMP-7, while 
HN cells secrete active MMP-2 (1), which plays an important role in lymph node 
metastasis of OSCC (3). Thus, MMPs play an important role in the invasion and 
metastasis of oral cancer cells. The level of TIMP-1 mRNA in BHY cells and TIMP-2 
mRNA in HN cells is low (1). Although both HN and BHY cells express MT1-MMP 
mRNA, the level of MT1-MMP is much lower than that in HT1080 cells, which is a 
human fibrosarcoma cell line (1).  
Another OSCC cell line used in this study is HSC-3. In response to EGF, HSC-3 
cells are able to degrade type I collagen matrix, suggesting that EGF can induce the 
secretion and activation of the type I collagen proteolytic enzyme MMP-1 (10). Both 
HSC-3 cells grown without EGF and with EGF can produce MMP-9, proMMP-2 and 
MMP-2. In the absence of EGF, the MMP-2 and the MMP-9 secreted from HSC-3 are 
not capable of degrading type I collagen. In HSC-3, EGF increases the secretion of 
collagenase, MMP-1. Then, MMP-1 changes collagen I to gelatin. The gelatinases, 
MMP-2 and MMP-9, complete the collagen I degradation by breaking down the gelatin 
(10). HSC-3 does not produce MMP-1 constitutively but it is up regulated in response to 
EGF and collagen I (10).    
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2.3.2. The effect of cathepsins on invasion and metastasis of OSCC 
Cathepsins are another group of proteolytic enzymes that are responsible for tumor 
invasion and metastasis. There are 13 different cathepsins which are located in 
lysosomes. Cathepsin B, H, and L are expressed in all tissues, while cathepsin S is 
selectively expressed in antigen presenting cells. Cathepsins become mature enzymes 
either by other proteinases or by autocatalysis. Cathepsin K is highly expressed in 
osteoclasts and may play a major role in bone resorption. Also, there are low levels of 
cathepsin L, S and B in osteoclasts. Catalytic activity of cathepsins is dependent on a pH 
below 7.0. They are unstable at neutral and alkaline pH values. Cathepsins are associated 
with cancer, inflammation, rheumatoid arthritis, osteoarthritis, multiple sclerosis, 
muscular dystrophy, pancreatitis, liver disorders, lung disorders, diabetes, and myocardial 
disorders. Cathepsin B cleaves pro-urokinase type plasminogen activator (pro-uPA) and 
converts it to active form, which is uPA. uPA activates plasmin-plasminogen, which then 
participates in cellular invasion processes including tumor invasion. Increased expression 
of cathepsin B correlates with carcinoma progression. It has both endopeptidase and 
exopeptidase activity and can degrade multiple components of ECM including laminin, 
fibronectin, and type IV collagen. In normal cells cathepsin B is localized in lysosomes in 
the perinuclear region. In carcinoma cells lysosomes containing cathepsin B are localized 
both perinuclearly and at the cell periphery. Cathepsin L is a lysosomal cysteine 
proteinase with a major role in intracellular protein catabolism. Cathepsin L has 
endopeptidase activity and is involved in epidermal homoeostasis (24).  
Cystatins are specific endogenous inhibitors of lysosomal cysteine proteinases, 
namely cathepsins B, C, F, H, L, O and X. Vigneswaran et al. found that both cathepsin B 
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and L do not show any significant differences in their expression levels between 
metastatic and primary OSCC cell lines at mRNA and protein levels. However, they also 
found that the cystatin M gene is elevated 40-fold in a metastatic OSCC cell line 
compared to the primary OSCC cell line. Increase in cystatin M mRNA, results in a 
decrease in the cathepsin B to cystatins ratio in the metastatic cell line relative to the 
primary OSCC cell line. It is possible that cystatins, when over-expressed in tumor cells, 
may facilitate metastasis by interfering with TNF-related apoptosis inducing ligand 
(TRAIL). TRAIL is a type-II transmembrane protein that induces apoptotic cell death in 
tumor cells but not in normal cells. Over expression of cystatins in oral cancer cells can 
enhance their metastatic potential by rescuing them from NK-cell mediated apoptosis, an 
event mediated by inhibiting the pro-apoptotic function of cathepsin B in these cells. 
Cystatins may have bivalent effects in the progression of malignant tumors. On one hand, 
reduced expression of cystatins, when combined with over expression of cysteine 
proteases cathepsin B and/or L, can lead to deregulated proteolytic imbalance promoting 
tumor growth and invasion. However, over expression of cystatins, combined with 
normal expression levels of cathepsin B in tumor cells can augment their metastatic 
potential by protecting them against TRAIL-mediated apoptosis (12).  
Cathepsin L has a major role in the process of bone resorption by activating 
osteoclasts (1). It is known that procathepsin L can be activated in acidic conditions. 
Thus, procathepsin L secreted from BHY cells can be activated at the point of bone 
invasion, and the activated cathepsin L might degrade the demineralized bone matrix (1).  
BHY cells express a large amount of procathepsin L, whereas HN cells don’t express any 
detectable level of cathepsin L (1).  
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Kawasaki et al. found that cathepsin D and B expression are closely correlated with 
OSCC invasion and progression. They could not find any relation between cathepsin L 
expression and invasion of OSCC (4). Cathepsin B is active against large substrates such 
as laminin and fibronectin under physiological conditions of pH and temperature. It can 
degrade extracellular matrix components. Turk et al. showed that cathepsin B, H, and L 
are involved in cancer progression by either direct degradation of extracellular matrix or 
by activation of other proteases, such as uPA (45). A requirement for cathepsin D to be 
active is a value of pH <5.5; however, cathepsin B can work at neutral pH. Thus, 
cathepsin B mainly degrades the basement membrane (4).  
2.4. Microarray Studies on OSCC   
When oral mucosa is exposed to mutagens, OSCC may arise. This mainly happens 
if metabolism of carcinogen or pro-carcinogen, repairing mechanism of DNA damage, 
controlling mechanisms of cell signaling and cell cycling are defective (58, 70). Genetic 
damage affects many chromosomes and genes, and in some cases it ends up activating 
oncogenes and inactivating tumor suppressor genes (96). Cancer arises from damage to 
the DNA of genes located at various points on the short (p) or long (q) arms of a number 
of chromosomes. OSCC is a consequence of multiple molecular genetic events in many 
chromosomes and genes (58). The consequence of this chromosomal damage is cell 
dysregulation with disruption in cell signaling, the cell growth cycle, and mechanisms to 
repair cell damage or eliminate dysfunctional cells (58, 70, 94, 133). After the formation 
of such chromosomal changes, cell growth becomes autonomous, and invasive 
mechanisms develop leading to malignant lesions (58, 133). 
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Carcinogen residues bind to DNA or surrogate proteins and can cause carcinogen 
exposure.   The most important carcinogens are aromatic amines found in tobacco smoke 
and cooked foods. Various enzymes known as xenobiotic-metabolising enzymes, are 
involved in the activation or degradation of carcinogens and pro-carcinogens. The most 
common of these enzymes are: alcohol dehydrogenase, cytochrome p450, glutathione-S-
transferases, and N-acetyl transferase. Alcohol dehydrogenase catalyses the oxidative 
metabolism of a range of chemicals and activates the pro-carcinogens (58).  Alcohol 
dehydrogenase type 3 genotypes appear predisposed to OSCC (59, 60, 61). Cytochrome 
p450 can activate many environmental pro-carcinogens by exposing or adding functional 
groups. Glutathione-S-transferase is involved in the detoxification of activated 
metabolites of carcinogens (58). This enzyme is also present in oral tissue (62).  N-acetyl 
transferase deactivates carcinogenic aromatic amines through N-acetylation (58).  
There is clear evidence of cellular DNA damage in patients with oral cancer. 
Damage to DNA can be repaired by several mechanisms, the main of which include 
nucleotide excision repair, base excision repair and O6-methylguanine DNA 
methyltransferase. DNA repair capacity varies between individuals as a result of 
inheritance, environmental factors, and physiological factors (58). In OSCC, several 
chromosomes, including those involved in the repair of DNA damages, show changes 
(63, 64, 65, 66, 67).  
Cell signaling is important for messages to be able to pass from the plasma 
membrane to the nucleus. Harvey ras gene (H-ras) and epidermal growth factor receptor 
gene (erbB1) are two important genes involved in cell signaling, cell growth control and 
cancer (58, 124). H-ras gene may activate MMP-9 and MMP-13, which are involved in 
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angiogenesis of the tumor itself (135). It is reported that Rab-Ia, which is a member of the 
Ras oncogene, is highly over expressed in squamous cell carcinoma of the tongue and 
oral premalignant lesions (109). The H-ras gene is located on chromosome 17p and is 
responsible for protein p21, which is an enzyme with guanosine triphosphatase activity. 
p21 acts like a signal transduction protein, transmitting mitogenic signals from the cell 
surface to the cell interior.  erbB1 which maps to 7p13-q22, encodes a receptor involved 
in cell signaling (58, 124). H-ras shows antitumorigenic response mediated by the up-
regulation of both p14ARF and p16INK4A, which activate the tumor suppressor genes, p53 
and retinoblastoma (Rb). The p16INK4A tumor suppressor gene product acts as a negative 
regulator of cellular proliferation by interacting with CDK4 and inhibits its kinase 
activity (94, 118). Its inactivation is frequent (94, 106) and is one of the earliest events in 
head and neck cancers (118). p15INK4B displays high homology to p16INK4A, acts as an 
inhibitor of CDK4 and CDK6 and shows a tumor suppressor role. p15INK4B is 
transcriptionally activated by transforming growth factor-β (TGF-β) (94) and is most 
frequently inactivated in OSCC (106).  
The cell cycle consists of a series of phases that take place during cell division. By 
using a number of proteins, cell regulatory genes modulate the cell cycle in a highly 
sophisticated way (68). During cell division, the transition from one phase to the next is 
checked at a checkpoint before the cycle can progress. The cell cycle consists of a 
stationary G0 phase, which upon receipt of appropriate cell signals, is followed by G1, S, 
G2 phases, and mitosis. Checkpoint genes not only control transition between phases of 
the cell cycle but also coordinate cell cycle progression with cell signals. When DNA is 
damaged, there may be an arrest of the cell cycle which can facilitate DNA repair. G1 
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arrest prevents replication of a damaged DNA template and G2 arrest allows segregation 
of damaged chromosomes (58). 
One of the main factors that regulates the cell cycle includes cyclins and their 
kinases that are called cyclin dependent kinases (69, 94). Protein kinase complex consists 
of a cyclin, CDK, and proliferating cell nuclear antigen (PCNA). Progression from the 
G0 phase of the cell cycle through the G1 phase is mediated by two CDK complexes, 
which are CDK4-cyclin D, and CDK2-cyclinE (69). These complexes are regulated by 
phosphorylation/de-phosphorylation. Cyclin D1 takes place in controlling of cell cycle by 
transiting the cells from G1 to S phases by regulating CDK-4 (119). Thus, cyclin and 
CDK are the most important regulators of cell cycle progression (58, 68, 94). The 
upregulation of cyclin D1 is commonly seen in OSCC, especially in patients with tobacco 
chewing history. Its’ over expression is related to high cell proliferation activity, poor 
survival and progression of lymph node spread in OSCC. In mammalian cell cycle 
control, disorder takes place more commonly in G1 phase. Cyclin D1 expresses in G1 
phase and accelerates the cell cycle progression. Human cyclin D1 maps to chromosome 
11q13 (119).  Another important pathway for cell proliferation is extracellular-signal 
regulated kinases (ERK MAPKs) pathway, which is one of the mitogen-activated protein 
kinases (MAPKs). The activation and over expression of ERK MAPKs play an important 
role in cancer progression (129). 
Retinoblastoma (Rb), p21, p27 and p53 are the other factors that regulate the cell 
cycle (58, 68). Loss of the functional Rb gene is one of the initial genetic events in 
malignant transformation (108, 118). Rb is a key component of the G1 checkpoint (58, 
68, 94). p21 binds to and inhibits cyclin/CDK complexes (58) to effect arrest of the G1/S 
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phase of the cell cycle (68). It is regulated by p53 in response to DNA damage (68, 94), 
interacting with PCNA to block its DNA synthesis function (70). A major effect of p53 is 
to block the cell cycle by stimulating the p21 gene (68). p27 also plays a role in G1 arrest  
induced by TGF-β in normal cells. It regulates proliferation by binding and inhibiting the 
G1 cyclin/CDK complexes. The product of the p53 gene is a main inhibitor of the cell 
cycle. It acts as a transcription factor and controls cell cycle progression and thus cell 
replication (58, 96). If a cell is damaged and repair is impossible, p53 triggers apoptosis 
(68). Loss of heterozygosity and mutation at the p53 gene are frequent events in OSCC 
(94, 105). Mutational inactivation of p53 has been reported to be the determinant of 
resistance to anticancer agents or radiation treatment (105). p53 blocks the cell cycle by 
switching on the GADD45 gene in cells when the cell is under stress. The GADD45 
protein product binds PCNA and inhibits entry into the cell cycle S phase (58). Also, 
p14ARF and p16INK4A play active roles in the p53 and Rb growth-control pathway (95).  
In OSCC, changes in chromosomes 3, 9, 11 and 17 are common (70, 96). The main 
targets of these changes are in chromosome 3, 3p24, 3p21.3, and 3p14, where the tumor 
suppressor genes are located; in chromosome 9, 9p21 where p16 is located; in 
chromosome 17, 17p13 where p53 is located. Over-expression of oncogenes, genes 
mainly involved in cell signaling like the ones on chromosome 11 and 17, are common in 
OSCC (70). In head and neck squamous cell carcinoma there are frequent structural 
rearrangements of the following chromosomal regions: 3q, 5p13-q11.2, 5q32-q34, 7p12-
q11.2, 8p12-q12, 9p, 10p, 13p13-q12, 14q11.1-q11.2, 15p13-q11.2, 16p11.1-q11.1, 
18q22-q23, and 22p13-q11.2. Loss of heterozygosity on regions of chromosomes 3, 4, 5, 
6, 8, 9, 11, 13, 17, and 19 are common in head and neck squamous cell carcinoma (103, 
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107, 122), especially on the long arms of the loci (107). Chromosome 3 aberrations can 
be identified on both potentially malignant oral lesions (71, 72, 73) and OSCC (74, 75, 
76, 77, 78, 79, 96). The short arm of this chromosome (3p) is often deleted in OSCC (80, 
81). In 31% of OSCC cases there is an abnormality in the long arm of chromosome 4 (4q) 
at 4q25 (82, 83, 96) and 4q31-32.1 (84). Chromosome 5 anomalies can be seen in 25-
73% of OSCC (77, 85, 86, 87, 107). There are changes at both 5q and 5p (88). These 
changes may be early in carcinogenesis, preceding p53 mutations (89). In chromosome 6, 
loss of heterozygosity can be found in 21-38% of OSCC on 6p (84, 90, 96) and 23-25% 
on 6q (84, 90). Genotypic changes in chromosome 7 have been described in OSCC, 
tissue adjacent to OSCC, and oral premalignant tissue.  The EGFR, on 7p, is over 
expressed in epithelium adjacent to and in OSCC (70).  Chromosome 8p deletions and 
loss of heterozygosity have been reported in 40 % of OSCC (70, 96). The most common 
chromosomal defect in OSCC can be seen on chromosome 9, specifically the loss of 
heterozygosity on 9p.  Deletion of the long arms of chromosomes 10, 11 and 13 and 
frequent loss of heterozygosity have been identified in OSCC on 10q, 11q and 13q in 
50% of cases (70, 107). A small number of OSCC appear to lose heterozygosity on 12p 
and 12q, and 16p and 16q. p53, which is located on chromosome 17, is a tumor 
suppressor gene with one of the highest frequency of mutations in cancers (70). Almost 
60 % of OSCC cases have p53 gene mutations (70, 92). In carcinomas, the mutations of 
p53 are often the same in the primary tumor and lymph node metastasis and in 
immediately adjacent epithelium as well as in recurrences (70). Loss of heterozygosity at 
various genetic loci is a sign of losing tumor suppressor genes, as is microsatellite 
instability causing nucleotide expansion or deletion (111). Loss of heterozygosity has 
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been detected in OSCC mostly at 18p (91), 21q and with 73% at chromosome 22 (70). 
Allelic imbalance, especially on chromosome arms 3p, 9p, 11q, 13q and 17p, is an early 
event in oral carcinogenesis (70, 92, 111). In more advanced stages with invasion loss of 
heterozygosity of 6p, 8p, 8q, and 4q is commonly seen (111). Allelic loss on several 
chromosomes, together with the sequence loss of several tumor suppressor genes is 
consistent with the hypothesis that oral carcinogenesis involves multiple molecular steps 
(70, 92). Allelic imbalance can be detected in the plasma/serum DNA of OSCC, 
suggesting that circulating tumor-associated DNA in the blood of patients with OSCC 
can be a key determinant in predicting tumor recurrences or metastasis (106). 
Only 10% of the genes encoded by the human genome are expressed in any given 
cell type. A small subset of these genes, with a role in normal housekeeping functions, 
are expressed in abundance, the vast majority are present in a very low copy number. 
This makes the task of detecting tissue specific genes much more difficult. It is essential 
to understand which genes are responsible for normal cell physiology and which ones are 
responsible for the disease process. In this regard identification of genes that are 
expressed in normal, precancerous, and cancer cells may help us discover the molecules 
that are related with tumor development, invasion and metastasis. Leethanakul et al. 
found that at least 168 novel genes are responsible for formation, metastasis, and invasion 
of OSCC. The most common and highly expressed genes in both normal oral squamous 
epithelium and OSCC are shown in table 2 and 3 (93).  
A cluster of genes located at 1q21 region (involucrin, SPRR 1A, 1B, 2B, 3, NICE-
1, S100 A1, 6, 8, 9, 14) are responsible for epidermal differentiation and are 
downregulated in OSCC compared to normal oral mucosa. Downregulation of these 
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genes is consistent with dedifferentiation of squamous epithelial cells, which is associated 
with malignant transformation. Another cluster of genes (tenascin X, dermatopontin, and 
collagen 14) downregulated in OSCC includes several extracellular matrix proteins 
regulating epithelial adhesion and collagen fibril formation. Genes that are upregulated in 
OSCC are associated with extracellular matrix function, interferon response, 
proliferation, and immune response. Also, genes implicated in invasion (snail homologue 
2, met proto-oncogene), RAS signaling, (r-ras homologue 2), cell surface/extracellular 
matrix interaction (collagen type IV α5 and α6, laminin γ2, α3, β3, integrin α3, α6, β4, β6), 
and angiogenesis (VEGF C, placental growth factor) are highly expressed in OSCC (98, 
128).  
Irie et al. found that there are 86 genes that are upregulated and 67 genes 
downregulated in metastasis negative cases. However, in metastasis positive cases 183 
genes are upregulated and 96 genes are downregulated. The prognosis of the patient is 
directly related to the expression level of the VEGF gene. When the expression level of 
this gene is elevated, the prognosis of the patient is worse. In metastatic cases the 
expression of neutrophil gelatinase-associated lipocalin (NGAL) is high. NGAL 
modulates MMP-9 activity, which is important during the formation of metastasis in 
OSCC (99). 
In oropharyngeal squamous cell carcinoma, calgranulin B (CAGB), CD24, 
lymphoepithelial kazal-type-related inhibitor (LEKTI), zinc finger protein (ZNF-185), 
transglutaminase-3 (TGM3), ETS homololous factor (EHF) and headpin are 
downregulated. In contrast, periostin and human homologue of the Drosophila white gene 
(ABCG1) are found to be upregulated by microarray analysis (100). LEKTI and headpin 
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are known to be proteinase inhibitors and periostin and CD24 have been involved in cell 
adhesion. It is known that proteinases and cell adhesion molecules play important roles in 
the biological processes of cancer including cell adhesion and metastasis. TGM3 is 
involved in stabilizing the cell cornified envelope. This process causes the transition of 
keratinocytes to become corneocytes by apoptosis. Therefore the downregulation of 
TGM3 could interrupt a critical step to apoptosis, thereby tumor cell survival. ABCG1 
belongs to the family of adenosine triphoshate-binding cassette transporters. Upregulation 
of this gene can cause the resistance to chemotherapy. The function of ZNF-185 is 
unknown, however, it may play a role in regulating cellular proliferation and 
differentiation (100). TNFRSF5, which encodes CD40, is involved in proapoptosis 
signals in cancer cells when they are treated with chemotherapeutic drugs (132).  
Decorin is associated with negative regulation of cell growth. It has a prominent 
role in TGF-β and EGFR activation pathways. These pathways are important in cellular 
proliferation, angiogenesis, and immunomodulation. The expression level of this gene is 
extremely high in dysplastic oral epithelial cells and oral cancer cells (101). The 
GALNT6 and SMARCC2 genes, mapping to 12q13.13 and 12q13-q14, respectively, are 
upregulated with poor prognosis and metastasis in lung, and head and neck cancer 
patients. Upregulation of PRKAR2A and CLDN1 genes, which are located on 
chromosome 3 regions: 3p21.3 and 3q28-q29 respectively, is commonly seen in head and 
neck cancers. Gain of 3q is one of the earliest genetic markers for invasion and metastasis 
and correlates with a poor prognosis (102, 122).   
Shimada et al. compared 4 tongue SCC patient tissues with normal tissues by using 
cDNA microarray technique. This comparison showed that 16 genes are highly 
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upregulated in all cases (Table 4) (109). Genes differentially regulated in metastases have 
been identified and the expression of 17 genes that is common to both primary tumors 
and metastasis have been found. Therefore primary tumors may carry expression patterns 
for the presence of lymph node metastasis or the potential for metastasis (110). 
In OSCC the genes that are most commonly found with altered expression are those 
that encode cytoskeletal and extracellular matrix protein, inflammatory mediators, 
proteins involved in epidermal differentiation, and cell adhesion molecules. The 
downregulation of genes that encode ribosomal proteins, and upregulation of genes that 
encode MMPs and inflammatory response can be seen in almost every OSCC (111). In a 
study on 9 OSCC patients using microarray technique, 47 genes have altered expression 
with 28 being upregulated and 19 downregulated. The list of these genes is in table 5 
(136).  
Choi et al. reviewed more than 20 current articles that incorporated cDNA 
microarray analysis in the study of head and neck SCC. They identified 84 genes with 
common alterations; 32 of them are upregulated (Table 6), 33 of them are downregulated 
(Table 7) and 19 of them have conflicting expression data (Table 8) (111). Several major 
biological systems or pathways are altered in head and neck SCC. These include cell 
cycle control, MMP, and inflammatory response systems. Genes encoding for ECM and 
integral membrane proteins, proteins involved in epidermal development and 
differentiation, and cell adhesion molecules most frequently have altered expression in 
head and neck SCC (Table 9) (111). 
There is a significant difference in macrophage content between normal epithelium 
and OSCC tissue. There is also a marked difference in the macrophage content of 
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primary OSCC tissue between patients with positive lymph nodes and patients with 
negative lymph nodes. Despite correlations with lymph node metastasis of OSCC, the 
macrophage count does not correlate directly with survival or recurrence (120).  
Chen et al. found that the highest frequency of gene gain is for TP63, Serpine1, 
FGF4/FGF3, c-Myc, and DMD whereas the highest deletion is for Caspase8 and MTAP. 
The gained genes are mainly located on 17q21, 20q, 11q13, 3q27-29 and X 
chromosomes. Among these, gains of EGFR at 7p; FGF4/FGF3, CCND1 and EMS1 at 
11q13; and AIB1 at 20q are significantly associated with lymph node metastasis (121).  
The expression level of ECM glycoproteins tenascin and osteopontin increases 
during tumor progression. Tumor derived osteopontin is able to inhibit macrophage 
function and enhance survival of OSCC metastasis. Also, the expression level of 
arachidonate 5-lipoxygenase increases during OSCC progression and metastasis. 
However, 4 potential tumor suppressor genes, which are BRUSH-1, MXI1, oxidative 
stress response (OSR1) gene, and occluding, expression levels decrease (122). There is a 
great frequency of minichromosome maintenance protein 2 (MCM-2), which is essential 
for DNA replication, expression in surface layers of moderate/severe dysplasia and 
OSCC compared to benign keratosis/mild dysplasia. Thus, MCM-2 can be a marker for 
early detection of OSCC and dysplasia (130).     
By using proteomic analysis Turhani et al. found that there were 14 proteins with 
increased expression and 6 proteins with decreased expression in OSCC (Table 10). 
These proteins have various functions. They are involved in cellular transport, like 
HSP27 and heat shock 20 kDa like protein p20; in regulatory functions, like creatine 
kinase, pyruvate kinase M1, and NME1; and glycolic pathway, like phosphoglucerate 
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mutase 1. Also, some of the proteins are highly tissue specific, like galectin-7, which is 





MATERIAL AND METHODS 
3.1. Cell Lines and Cultures 
3.1.1. HNEC cell line 
The cryopreserved HNEC cell line was obtained from PromoCell, Germany. This 
cell line was isolated from a 27-year-old Caucasian male. Five ml of Airway Epithelial 
Cell Growth Medium (PromoCell) with 100μg/ml streptomycin and 100 U/ml penicillin 
was incubated in a 25 cm2 coring cell culture flask with a vent cap (Fisher) in a 
humidified atmosphere of 95% air and 5% CO2 at 37°C for 30 minutes. The frozen cells 
were thawed in a 37°C water bath until about 90% of the contents were thawed. The tube 
was removed from the water bath and agitated until all the contents were completely 
thawed. 250,000 to 375,000 suspended cells were distributed in the pre-incubated 5ml 
medium in a 25cm2 cell culture flask and incubated for 5 to 6 days in a humidified 
atmosphere of 95% air and 5% CO2 at 37°C. After the first 24 hours, 80% of the cells 
were adhered to the surface of the flask, and the medium was replaced with the fresh 30 
minute pre-incubated airway epithelial cell growth medium with 100μg/ml streptomycin 
and 100 U/ml penicillin. Replacement of medium was then repeated every 2 to 3 days. 
After 5 to 6 days the cell culture was examined under an inverted microscope. If the 
monolayer was sub-confluent (60-80%) and many mitotic figures were visible, cells were 
sub-cultured. During sub-culturing HepesBSS, trypsin and trypsin neutralizing solution 
(TNS) at room temperature were used. First, the medium was replaced with 5 ml 
HepesBSS and cells were washed for 30 seconds by gently swirling the culture flask. 
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Then, the HepesBSS was removed and the cell monolayer was covered with 2.5ml 
trypsin/EDTA solution and incubated at room temperature untill the cells were released 
form the floor of flask. When the cells were completely detached, 2.5ml TNS was added. 
The cell suspension was removed, placed into a centrifuge tube and centrifuged at about 
220xg for 4 minutes at room temperature. Supernatant was removed and 1.5ml pre-
incubated medium was added and re-suspended. Cell suspension was distributed in the 
usual way and in the required density as stated above into the new flasks with pre-
incubated cultures. The medium replacement and incubation were scheduled as 
mentioned previously.  
3.1.2. BHY cell lines 
The cryopreserved BHY cell line was obtained from DSMZ, Germany. This cell 
line was isolated from a 52-year-old Japanese male with highly differentiated squamous 
cell carcinoma of the lower alveolus that was highly invasive to the mandibular bone and 
the muscle layer of the oral floor; however, it did not metastasize (1). Frozen cells were 
thawed in a 37°C water bath. Approximately 1x106 cells were cultivated in 75cm2 coring 
cell culture flask with a vent cap in a humidified atmosphere of 95% air and 5% CO2 at 
37°C for 3 to 5 days. Fifteen ml Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% fetal bovine serum, 100 μg/ml streptomycin and 100 U/ml penicillin was used as the 
medium. Following the formation of a monolayer at the bottom of the flask, cells were 
sub-cultured. Trypsinization was performed as follows: Media was poured off of the flask 
into a 15ml centrifuge tube. Three ml of trypsin/EDTA was placed in the flask and 
swirled and poured into a centrifuge tube. Five ml fresh trypsin/EDTA was placed into 
the flask and the flask was incubated in humidified atmosphere of 95% air and 5% CO2 at 
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37°C for 3 minutes. The warmth of the incubator enhanced the action of trypsin. At the 
end of three minutes the flask was removed from the incubator and gently agitated to aid 
in the dispersal of the cells. 6-8ml of medium from the centrifuge tube was placed back 
into the flask. The serum in the media stopped the reaction of trypsin. Then the media 
containing the cells was transferred back into the 15ml centrifuge tube and centrifuged at 
1200 rpm for 4 minutes. Supernatant was removed and 5ml medium was added and re-
suspended. The cell suspension was distributed in the usual way and in the required 
density into the new 75cm2 flasks with 15 ml medium.     
3.1.3. HN cell line 
The cryopreserved HN cell line was obtained from DSMZ, Germany. The HN cell 
line was isolated from a 60-year-old Japanese male with moderately differentiated 
squamous cell carcinoma of the soft palate that metastasized to cervical lymph nodes, 
lungs and brain, but did not invade bone (1). The same media, number of cells, 
incubation conditions, cell culturing and trypsinization method was used as stated in the 
BHY cell line. However, the incubation period for this cell line was 5 days.  
3.1.4. HSC-3 cell line 
The cryopreserved HSC-3 cell line was obtained from Japan Health Science 
Research Resources Bank (HSRRB) The HSC-3 cell line was isolated from a 64-year-old 
Japanese male. The primary tumor was on the tongue with lymph node metastasis, and 
was moderately differentiated. This cell line is highly metastatic (10, 23, 52). 
Approximately 1x106 cells were cultivated in a 25cm2 coring cell culture flask with a 
vent cap. Cells were cultivated in 5ml Eagle’s Minimal Essential Medium (EMEM) with 
10% calf serum, 100μg/ml streptomycin and 100 U/ml penicillin in a humidified 
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atmosphere of 95% air and 5% CO2 at 37°C for 7 days. The same cell culturing and 
trypsinization method was used as stated in the BHY cell line. However, for the first 
trypsinization instead of 3ml, 1.5ml was used and for the second trypsinization instead of 
5ml, 2.5ml trypsin was used.   
3.2. The Invasion and/or Metastatic Characteristics of OSCC Cell Lines 
All three OSCC cell lines have different invasion and/or metastatic characteristics 
(Figure 2). Micro positron emission tomography (PET)/computerized tomography (CT) 
imaging techniques were used to image the invasion and/or metastatic capability of each 
of the cell lines in scid mice. The advantage of micro-imaging technology is the ability to 
monitor tumor growth in vivo. Immuno-compromised scid mice were used to show the 
differences in jaw bone invasion and distant organ metastasis of these three different 
OSCC cell lines in a biological system. 5 study groups each with 3 scid mice were 
involved in the study. These 5 groups were: BHY group, HN group, HSC-3 group, 
human normal nasal epithelial cell line (HNEC) group, and Matrigel only group. The 
OSCC cell lines and HNEC cell line were induced in the left masseter muscles of the scid 
mice by injecting a suspension of 1x107 cells in Matrigel with a 26G needle. Control 
mice received matrigel only in their left masseter muscles. The HNEC group served as a 
non-OSCC control group, and the Matrigel only group was included in the study to show 
that this gel does not have any effect on the formation of OSCC. Tumors were allowed to 
grow for 30 days. On day 30, mice were anesthetized and the tumor characteristics were 
evaluated using microPET/CT imaging. Mice were administered 300 μCi of [18F] fluoro-
D-glucose (18FDG) i.p. and 30 minutes thereafter received an i.v. injection of vascular 
CT-contrast agent.  The animals were euthanized using an overdose of isoflurane 
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inhalation and imaged by micro PET and microCT. MicroPET images were acquired 
using a P4 or Focus 220 imaging system, followed by a microCT scan using a MicroCAT 
II imager. To reduce the experimental stress and discomfort associated with tumor 
formation on the left cheek of the mice, they were put on a soft food diet (ground lab 
blocks mixed with water). The clinical conditions of animals were monitored 3 times 
each day and the tumors were never allowed to develop more than 0.5 cm in diameter. 
Their eating and drinking habits and activity levels were observed 3 times daily. Mice 
that developed infection at the injection site, did not eat for 1-2 days, or had tumor 
growth greater than 0.5 cm in diameter were excluded from the study.  
3.3. Immunocytochemistry  
After removal of the monolayer of cells by trypsinization, samples from each cell 
line were transferred to microscopic slides by cytospining for 5 minutes at 500 r.p.m. 
Slides were fixed in acetone for 10 minutes and then air dried. Cells were rinsed in 
10mM phosphate-buffered saline (PBS) for 2 minutes for 3 times. Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxide and then cells were washed 
with PBS for 2 minutes 3 times. Samples were incubated in 5% non-immune goat serum 
for 10 minutes to block non-specific proteins. All samples were washed with PBS 
solution for 2 minutes 3 times prior to incubation with the primary antibodies. For each 
primary antibody, one sample from each cell line was incubated with that primary 
antibody and rinsed in PBS for 5 minutes 3 times. All samples were then incubated with a 
proper secondary antibody and rinsed in PBS for 5 minutes 3 times. Finally a 
strepABComplex (Vector) was applied and samples were stained with diaminobenzidine 
for 10-12 minutes and rinsed with distillated water (Vector). So as to obtain acceptable 
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contrast and stain, the nucleus of cells slides were placed in gill hematoxylin for one 
minute. For each cell line a negative control sample was prepared which received all of 
the steps in the immunostaining process except for application of primary antibody.  
The following primary and secondary antibodies were used:  
1) For MMP-1; rabbit anti-human MMP-1 polyclonal primary antibody 1:10 
(Chemicon International) and anti-rabbit Ig G secondary antibody ABC Kit (Vector) 
2) For MMP-2; rabbit anti-human MMP-2 polyclonal primary antibody 1:10 
(Chemicon International) and anti-rabbit Ig G secondary antibody ABC Kit (Vector).  
3) For MMP-3; rabbit anti-human MMP-3 polyclonal primary antibody 1:10 
(Chemicon International) and anti-rabbit Ig G secondary antibody ABC Kit (Vector).  
4) For MMP-9; goat anti-human MMP-9 polyclonal primary antibody 1:25 (R&D 
Systems) and anti-goat Ig G secondary antibody ABC Kit (Vector).  
5) For cathepsin L; goat anti-human cathepsin L polyclonal primary antibody 1:15 
(R&D Systems) and anti-goat Ig G secondary antibody ABC Kit (Vector).  
6) For cathepsin B; rabbit anti-human cathepsin B polyclonal primary antibody 
1:15 (Serotec) and anti-rabbit Ig G secondary antibody ABC Kit (Vector).  
7) For EMMPRIN; mouse anti-human EMMPRIN monoclonal primary antibody 
1:20 (Chemicon International) and anti-mouse Ig G secondary antibody ABC Kit 
(Vector). 
Slides were evaluated microscopically (Leica Leitz DM 12B) and using the SPOT 
advanced imaging program. The original magnifications were 100x and 200x. 
Immunostaining was scored according to the staining of HNEC cell line. All proteolytic 
enzyme expressions of HNEC were considered normal levels of expression, and OSCC 
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cell lines proteolytic enzyme expressions were measured accordingly. The same intensity 
in tumor cells as normal epithelium cells was designated by (-), less than 10% stronger 
intensity in tumor cells than normal epithelium cells was shown by (+), between 10% to 
50% stronger intensity in tumor cells than normal epithelium cells was shown by (++), 
between 50% to 90% stronger intensity in tumor cells than normal epithelium cells was 
shown by (+++) and more than 90% stronger intensity in tumor cells than normal 
epithelium cells was shown by (++++). 
3.4. Flow Cytometry  
Monolayer cells were removed from the flasks by trypsinization. Five groups, each 
with 1x105 cells in 0.1 ml of medium, from each cell line were incubated with the 10μl 
MMP-1, MMP-2, MMP-3, MMP-9 and EMMPRIN flow antibodies for 20 minutes at 
room temperature in the dark for surface staining. The following flow antibodies were 
used:  
1) For MMP-1; mouse anti-human MMP-1 phycoerythrin conjugated monoclonal 
antibody, R&D Systems.  
2) For MMP-2; mouse anti-human MMP-2 phycoerythrin conjugated monoclonal 
antibody, R&D Systems.  
3) For MMP-3; mouse anti-human MMP-3 phycoerythrin conjugated monoclonal 
antibody, R&D Systems.  
4) For MMP-9; mouse anti-human MMP-9 fluorescein conjugated monoclonal 
antibody, R&D Systems.  
5) For EMMPRIN; mouse anti-human EMMPRIN phycoerythrin conjugated 
monoclonal antibody, Chemicon International. 
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All samples were washed with 2ml PBS, centrifuged at 1200 rpm for 4 minutes and 
the supernatant was removed. Samples of each cell line that were incubated with MMP-1, 
MMP-2, MMP-3 and EMMPRIN antibodies were also incubated with 50μl of 
pholloidin/fix and perm solution (15μl pholloidin into 0.5 ml fix and perm solution); 
however, samples of each cell line that were incubated with MMP-9 were only incubated 
with fix and perm solution for 20 minutes at room temperature in the dark. All samples 
were washed with a 2ml permeabilization/wash buffer. Samples were incubated with 
10μl of each antibody for 30 minutes at room temperature.  Finally, samples were washed 
with buffer, centrifuged for 4 minutes at 1200 rpm and supernatants were removed. 0.5 
ml formalin (1% formaldehyde) was added and each sample was analyzed by flow 
cytometry. A sample from each cell line was prepared and treated only with buffer and 
1% formaldehyde as a control group.  From each sample 5000 cells were counted by flow 
cytometry.  
3.5. Ultrastructural Characterization of Three OSCC Cell Lines 
Each of the 3 cell lines was grown to confluence in culture flasks. The culture 
medium was decanted and the cells were immediately overlaid with 2.5% glutaraldehyde 
in cacodylate buffer, pH 7.2.  The cells were fixed overnight at 40C, and post fixed in 2% 
acqueous osmium tetroxide for 2 hrs. Cells were dehydrated in a graded acetone series 
and propylene oxide and embedded with Spurr’s plastic.  The embedded cells were cut 
out of the flasks with a jeweler’s saw, mounted on plastic studs, and cut for transmission 
electron microscopy (TEM) analysis.  Cells were stained with uranyl acetate and lead 
citrate and examined with a Hitachi H-800 TEM. 
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3.6. Total RNA Extraction From The Cell Lines  
Total RNA extraction was performed using a RNeasy Midi Kit (Qiagen). Each of 
the 4 cell lines was grown in proper culture flasks and media. From each cell line 
approximately 1x108 cells were used for total RNA extraction. Cells were trypsinized as 
mentioned previously. Cells were pelleted by centrifugation at 300xg for 5 minutes. 
Supernatant was aspirated and cells were disrupted by addition of 4ml buffer RLT with 
40µl β-ME. The cell pellets were loosened by flicking the tube. Cells were homogenized 
by vortexing the samples for 10 seconds, and passing the lysates at least 5-10 times 
through 18-20-gauge needle. 4ml 70% ethanol was added to homogenized lysates and 
mixed thoroughly by shaking vigorously. Samples were applied to midi columns placed 
in 15ml centrifuge tubes and centrifuged for 5 minutes at 3000-5000xg. The flows that 
passed through the column were discarded. After centrifugation, 4ml buffer RW1 was 
added to the columns and centrifuged for 5 minutes at 3000-5000xg to wash the columns. 
Columns were further washed twice by adding 2.5ml buffer RPE and centrifuging for 2 
minutes at 3000-5000xg. The RNeasy columns were removed from the centrifuge tubes 
and transferred to new 15ml centrifuge tubes. Finally, 250µl of RNase-free water were 
directly applied onto the columns and let stand for 1 minute. Tubes were then centrifuged 
for 3 minutes at 3000-5000xg in order to obtain the total RNA from the columns. This 
final process was performed twice to be able to get a higher amount of total RNA. Total 
RNAs were stored at -80˚C in RNA Storage Solution (Ambion) together with SUPERase 




3.7. Checking The Quality and Quantity of Total RNA.  
After the extraction of total RNA, 3µl total RNA from each cell line was diluted 
with distilled water. The dilution factor was 1:100. The diluted sample was used to 
measure the quantity of RNA with a spectrophotometer at 230nm-300nm. The following 
formula was used to find the quantity of total RNA:  
Dilution factor * Optimal Density at A260 * 40µg/ml.  
Aldolase and β-actin genes, which are housekeeping genes, and SuperScript III 
First-Strand Synthesis System for RT-PCR Kit (Invitrogen) was used to check the quality 
of total RNA of each cell line.  
3.7.1. Synthesis of cDNA from total RNA  
For each cell line, 1µl of oligo(dT)20 (50µM), 5µg total RNA, 1µl 10mM dNTP mix 
(10mM each dATP, dGTP, dCTP, dTTP at neutral pH), 1µl of random decomer and 
sterile distilled water to 13µl were added to a nuclease-free microcentrifuge tube. This 
mixture was heated to 65˚C for 5 minutes and incubated on ice for at least 1 minute. The 
contents of the tube were collected by centrifugation and 4µl 5X First-Strand buffer, 1µl 
0.1M DTT, 1µl RNaseOUT Recombinant RNase Inhibitor (Invitrogen), and 1µl of 
SuperScript III RT (200 units/µl) was added. By pipetting gently up and down the 
contents were mixed and incubated at 25˚C for 5 minutes. Then, a further incubation at 
50˚C for 90 minutes was done. The reaction was inactivated by heating the mixture at 
70˚C for 15 minutes. The synthesized cDNA was used as a template for amplification in 




3.7.2. PCR reaction 
50µl of PCR reaction for each cell line was prepared as follows: 5µl 10X PCR 
buffer [200mM Tris-HCl (pH 8.4), 500 mM KCl], 1.5µl 50mM MgCl2, 1µl 10mM dNTP 
mix, 1µl amplification primer 1, 1µl amplification primer 2, 0.4µl Taq DNA polymerase 
(5U/µl), 2µl cDNA, and 38.1 autoclaved distilled water were added in a PCR reaction 
tube and mixed gently. Denaturation of cDNA was done at 94˚C for 2 minutes. 
Annealing temperature was 88˚C for aldolase gene reaction and 62˚C for β-actin gene for 
30 seconds. 30 cycles of PCR reaction was performed. The PCR product of each cell line 
was run on a gel in order to observe the expression of aldolase and β-actin genes.  
The primers of the aldolase gene are 5'-GGAATTCCATATGCCCTACCAATAT 
CCAGC-3', and 5'-GGAATTCGGATCCTTAATAGGCGTGGTTAG-3. The primers of 
the β-actin gene are 5’-TCCTGGCCTCACTGTCCAC-3’, and 5’-GTCCGCCTAGAA 
GCACTT-3’. 
3.8. Synthesis of mRNA From Total RNA 
PolyATtract® mRNA Isolation Systems (Promega) was used to extract the mRNA 
from the total RNA. This procedure is designed for use with 1-1.5mg of total RNA. In a 
sterile, RNase-free 3ml tube, 1-1.5mg of total RNA and RNase-Free Water to a final 
volume of 2.43ml were combined. The tube was placed in a 65°C heating block for 10 
minutes. 10µl of the Biotinylated-Oligo(dT) Probe and 60µl of 20X SSC solution were 
added to the total RNA and mixed gently and incubated at room temperature until 
completely cooled. This is the annealing reaction. 
Stock solutions of 0.5X SCC (0.125ml of 20X SSC with 4.875ml of RNase-Free 
Water) and 0.1X SSC (50µl of 20X SSC with 9.95ml of RNase-Free Water) were 
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prepared. Streptavidin-paramagnetic particles, which come with the kit, were rinsed 3 
times with an equal volume of 0.5X SSC. Streptavidin-paramagnetic particles were 
resuspended by flicking the bottom of the tube until they were completely dispersed and 
captured by placing the tube in a magnetic stand for 30 seconds. Washed streptavidin-
paramagnetic particles were resuspended in 0.5ml of 0.5X SSC. 
The entire contents of the annealing reaction were added to the tube containing the 
washed streptavidin-paramagnetic particles. This mixture was incubated at room 
temperature for 10 minutes and gently mixed by inverting every 1-2 minute. Streptavidin-
paramagnetic particles were captured using a magnetic stand and the supernatant was 
carefully removed without disturbing the streptavidin-paramagnetic pellet. The particles 
were washed four times with 0.1X SSC by gently flicking the bottom of the tube. After 
the final wash the supernatant was removed as much as possible without disturbing the 
streptavidin-paramagnetic particles. To be able to elute mRNA, the final streptavidin-
paramagnetic pellet was resuspended in 1.0ml of the RNase-Free water. Streptavidin-
paramagnetic particles were magnetically captured and eluted mRNA was transferred to 
2ml tube. After synthesis of mRNA from each cell line, cDNA Synthesis System 
(Promega) was used to synthesize cDNA from mRNA. 
3.9. cDNA Microarray Analysis 
Each tumor cell line was compared with the HNEC cell line by using the cDNA 
microarray technique. Operon Human Version 3.0 microarray slides, which contains 
25.000 human genes, were used for this study (Figure 3). cDNA Synthesis System 
(Promega) was used to synthesize cDNA from mRNA.  From each cell line, 5 µg of 
cDNA was labeled and processed to hybridization. To be able to eliminate the Cy dye 
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bias reverse labeling was performed. Basically, for each tumor cell vs. HNEC cell, the 
cancer cells were first labeled as Cy5 dye and HNEC as Cy3 dye, and then the HNEC cell 
line as Cy3 dye and the tumor cell lines as Cy5 dye. Two microarray hybridizations were 
performed in parallel for each group. Reverse labeling has been proved to be important in 
improving data correlation between the samples and data quality as shown by statistical 
analysis. Labeled tumor cell lines and HNEC cell line cDNAs were hybridized on 
microarray slides by using the hybridization buffer. All slides were washed by using the 
washing buffer and scanned in a GenePix 4000 scanner (Axon Instrument). The images 
were saved for further data analysis. 
Typically, microarray data analysis includes image processing, data normalization, 
statistical analysis, data cluster and visualization, and data management. The microarray 
image was processed using the GenePix Pro software. The spots with fifty percent of 
pixels higher than two times background standard deviation were filtered to be positive 
and subjected to further analysis. Both bulk normalization and Lowess normalization 
were applied to analyze our data. With bulk normalization, we averaged all the filtered 
spot for each channel, and used the ratio to normalize the signal ratio at each spot. Bulk 
normalization is enough for most of the applications; however, we also considered using 
Lowess normalization, in which intensity dependent dye bias can be removed.  
Self-organizing maps and hierarchy clustering were performed to further understand 
gene function and interaction. We clustered the data by gene, which gives expression 
patterns among the different OSCC cell lines and helps to understand the gene interaction 
as well as shared pathways. We also clustered the data by OSCC cell lines, which 
provides the information about how each cell line is relevant to one another at the global 
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gene expression level. Based on the expression levels of the genes in microarray analysis, 
different pathways were analyzed on each OSCC cell lines by using Kyoto Encyclopedia 
of Gene and Genomes (KEGG). 
In order to narrow down specific genes, we used the ANOVA model to obtain the 
estimates and confidence intervals for all genes in each experiment set. For the genes of 
interest, the confidence intervals will help us to decide whether to choose this gene for 
further study or not. All of the above data analysis can be done in Bioconductor. 
Microarray data was confirmed by real-time PCR. We designed gene specific 
primers for genes of interest and performed the SYBR based RT-PCR to confirm the 
relative abundance of gene expression as observed in the microarray analysis. Ubiquitin 
was used as internal control. Standard curve analysis and an internal control were applied 
to obtain the absolute quantification.  
3.10. Real Time PCR Analysis 
The results of cDNA microarray analysis were confirmed to the most highly 
expressed three genes from each cell line by using Real Time PCR analysis. The 
expression level of MAGEA9, Q96AL8, and GFI1 genes in BHY cell line; NMES1, 
MAGEA1 and Q96AL8 genes in HN cell line; and MAGEA8, MAGEA1 and EREG 
genes in HSC-3 were compared with the expression levels of these genes in HNEC cell 
line. Glucose-6-phosphate gene was used as the control gene.  
The same total RNA samples, which were extracted from the cell lines for cDNA 
microarray analysis, were used for Real Time PCR analysis. Before the synthesis of 
cDNA from total RNA, the qualities of total RNA samples were examined by running the 
samples in the gel (Figure 4a). Synthesis of cDNA from total RNA was performed and 
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the quality and quantity of cDNA was checked by running the samples in the gel with 
their glucose-6-phosphate gene expression levels (Figure 4b).  
The total Real Time PCR reaction was 25µl, which contained 5µl of cDNA and 
20µl of the mixture. The Real Time PCR mixture was prepared as follows: 8µl primer 
mixture, 80µl IQSM (IQ Supermix, BioRad) and 72µl water. Human GFI1, MAGEA8, 
MAGEA1, MAGEA9, EREG, and NMES1 Real Time PCR primer sets (Superarray) 
were used. The forward and reverse primer of Q96AL8 gene was set up by using Blast 
Sequencing Computer Program. BioRad Real Time PCR machine iQ5 was used to run 
the 95°C, 15 minutes; 40 cycles of (95°C, 30 sec; 55°C, 30 sec; and 72°C, 30 sec) 
reaction. iQ5 RT-PCR data analyzing computer program was used to analyze the results. 
The forward and reverse primer sequences used for the Real Time PCR reactions 
were as follows:  
MAGEA1 forward primer sequence: 5’GGCCATTCTTCACTCTGAAGA3’. 
Reverse primer sequence: 5’TTGAACAATTCCAAAAGAGAACAAAG3’. 
MAGEA8 forward primer sequence: 5’GTTCCTGTTCTATTGGGCGATTT3’. 
Reverse primer sequence: 5’CCATTAGAAGGAACATTGGAACAA3’. 
MAGEA9 forward primer sequence: 5’GGCATGTCCTTCTGTTCCAT3’. Reverse 
primer sequence: 5’GGAGCTTGGCTCTTCCTCTT3’. 
Q96AL8 forward primer sequence: 5’CAACAGTGTGTTTCGTCAAAAGG3’. 
Reverse primer sequence: 5’CCACATGGCAGCCAGGAT3’. 
EREG forward primer sequence: 5’CAGGCAGTTATCAGCACAAC3’. Reverse 
primer sequence: 5’CACAGGATTCCATACCCAAG3’. 
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NMES1 forward primer sequence: 5’GGTTCAAATGTATTTTTCTCCCAT3’. 
Reverse primer sequence: 5’TTTGGGCTCTGGATAAGGAAT3’. 
GFI1 forward primer sequence: 5’TTCTCTCGCTGCGGAGTCT3’. Reverse 









4.1. The Invasion and/or Metastasis Characteristics of OSCC Cell Lines 
PET/ CT imaging techniques were used to image the invasion and/or metastatic 
capacities of each OSCC cell line in immuno-compromised scid mice. The 5 study 
groups included, BHY, HN, HSC-3, HNEC, and Matrigel only groups, with 3 scid mice 
each in the study. The HNEC group served as a non-OSCC control group, and the 
Matrigel only group was included in the study to show that this gel does not have any 
effect on formation of OSCC.  
The PET/CT images of HNEC and Matrigel only groups showed no evidence of 
tumor formation in any of the mice in these groups (Figures 5, 6, and 7). The PET images 
of these two groups showed no activity at the injection area due to the Matrigel or HNEC 
presence (Figures 5 and 6). Thus, these two different groups of animals served as reliable 
control groups. 
All three mice of the BHY cell line group showed invasion of the OSCC to the left 
mandibular bone in the images (Figures 8 and 9). However, only two mice of the HN 
group showed lymph node and distant organ metastasis, such as lung and kidney (Figures 
10 and 11). The other mouse in HN group had cervical lymph node metastasis of the 
OSCC. The HSC-3 cell line group represented lymph node metastasis in all three mice in 
the group (Figures 12 and 13). The results of the imaging study matched with the 
characteristics of the OSCC cell lines that have been reported (1, 10, 23, 52).  
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4.2. Immunocytochemistry 
Except for the MMP-9 expression of HSC-3, seven proteolytic enzyme expressions 
of OSCC cell lines were higher than HNEC.  The expression levels of proteolytic 
enzymes in the OSCC cell lines are shown in Table11.  
MMP-1 was expressed with 50-90% stronger intensity in OSCC cell lines, than in 
HNEC (Figure 14). MMP-2 was expressed with more than 90% stronger intensity in HN 
and HSC-3 than HNEC; however, in BHY this percentage was 83 (Figure 15). HSC-3, 
HN, and BHY showed 95%, 81%, and 73% stronger MMP-3 intensity than HNEC, 
respectively (Figure 16). MMP-9 expression of HSC-3 was the same with HNEC, HN 
had moderate MMP-9 expression (Figure 17). BHY showed the strongest EMMPRIN and 
MMP-9 expression with 93% and 58% respectively (Figure 18). Cathepsin B expressions 
of OSCC cell lines were higher than 90% (Figure 19). Cathepsin L expression was the 
highest in HSC-3 cell line with 96% and the lowest in BHY cell line with 72% (Figure 
20).   
4.3. Flow Cytometry 
Five thousand cells were evaluated from each cell line using flow cytometry.  The 
percentages of antibody-stained cells are shown in Table 12. MMP-1, MMP-2 and MMP-
3 were highly expressed in all three OSCC cell lines and the HNEC cell line (Figure 21). 
However, MMP-9 and EMMPRIN expression levels were highest in the BHY cell line 
(Figure 22). MMP-9 expression level in the BHY cell line was significantly higher, 
compared to the HNEC and HSC-3 cell lines. Also, the HN cell line showed elevated 
MMP-9 expression compared to HNEC and HSC-3 cell lines but it wasn’t as high as in 
the BHY cell line (Table 12).   
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Increased MMP-9 and EMMPRIN expression may play a role in bone invasion by 
OSCC. According to flow cytometry results 97-99.9% of OSCC and HNEC cells were 
stained with the MMP-1, MMP-2 and MMP-3 antibodies; however, 
immunocytochemistry staining for the same proteolytic enzymes showed stronger 
intensity in tumor cells than HNEC cells. Thus, normal epithelial cells and tumor cells 
secrete MMP-1, MMP-2 and MMP-3 but the difference is the regulation of their activity.  
4.4. Ultrastructural Characterization of Three OSCC Cell Lines  
At the ultrastructural level, the BHY cells were the most highly differentiated of the 
3 OSCC cell lines (Figure 23). There was interdigitation of adjacent cells and numerous 
cell junctions were present. HN cells had cytoplasmic projections, but did not show 
interdigitation of adjacent cells. Cell junctions were often seen between adjacent cells 
(Figure 24). The HSC-3 cells in culture were smaller than the other 2 OSCC cell lines. 
They possessed cytoplasmic projections but did not show any sign of interdigitation. Cell 
junctions were rarely seen (Figure 25). The control HNEC cell line showed obvious 
squamous cell features including interdigitation, numerous cell junctions, and occasional 
cytoplasmic tonofilaments (Figure 26).   
4.5. The Quality and Quantity of Total RNA 
After total RNA extractions from the cell lines, 3µl total RNA from each cell line 
was diluted with distilled water, and observed for the quality and quantity of RNAs. The 
quantity measurements of total RNA at spectrophotometer at 260nm and calculation of 
total amount of each cell line total RNAs are as follows: 
Dilution factor X Optimal Density at A260 X 40µg/ml 
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For the BHY cell line: the value of optimal density at 260nm at spectrophotometer 
is 0.16 (figure 27) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is 
0.16 X 40 X 100=640µg/ml. The total volume of BHY total RNA was 2ml, so the total 
amount for this cell line was 640µg/ml X 2ml=1280µg. 
For the HN cell line: the value of optimal density at 260nm at spectrophotometer is 
0.15 (figure 28) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is 
0.15 X 40 X 100=600µg/ml. The total volume of HN total RNA was 2ml, so the total 
amount for this cell line was 600µg/ml X 2ml=1200µg. 
For the HSC-3 cell line: the value of optimal density at 260nm at spectrophotometer 
is 0.08 (figure 29) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is 
0.08 X 40 X 100=320µg/ml. The total volume of HSC-3 total RNA was 4ml, so the total 
amount for this cell line was 320µg/ml X 4ml=1280µg. 
For the HNEC cell line: the value of optimal density at 260nm at spectrophotometer 
is 0.4 (figure 30) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is 
0.4 X 40 X 100=1600µg/ml. The total volume of HNEC total RNA was 2ml, so the total 
amount for this cell line was 1600µg/ml X 0.75ml=3200µg. 
cDNA of each cell line was synthesized from total RNA and aldolase and β-actin 
genes were run in PCR in order to check the quality of total RNA of each cell line. All 
cell lines showed the expression of both housekeeping genes on the electrophoresis gel 
(Figure 31).  
4.6. cDNA Microarray Analysis of Three OSCC Cell Lines 
The genetic structure comparison of tumor cell lines with HNEC cell line by using 
the cDNA microarray technique showed that each OSCC cell line has its unique gene 
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expression structure. After the normalization process each OSCC cell line demonstrated 
different upregulated and downregulated genes. The BHY cell line expressed 139 
upregulated genes and 117 downregulated genes (Table 13 and 14). The HN cell line 
expressed 214 upregulated and 262 downregulated genes (Table 15 and 16). Finally, the 
HSC-3 cell line expressed 128 upregulated and 117 downregulated genes (Table 17 and 
18).  
The clusterization of data showed that there were 13 genes that are upregulated and 
83 genes that were downregulated in all three OSCC cell lines (Figures 32 and 33). Each 
cell line was compared with the other two cell lines based on the most upregulated and 
the most downregulated 20 genes of that cell line. This permitted an understanding of the 
genetic differences between these three cell lines better and thus the most responsible 
genes that are related to the formation of their genetic characteristics. Figure 34 and table 
19 shows the 20 most upregulated and downregulated genes in the BHY cell line and the 
expression levels of these 20 genes in the other two OSCC cell lines, HN and HSC-3. 
Figure 35 and table 20 shows the 20 most upregulated and downregulated genes in the 
HN cell line and the expression levels of these 20 genes in the other two OSCC cell lines, 
BHY and HSC-3. And figure 36 and table 21 shows the 20 most upregulated and 
downregulated genes in the HSC-3 cell line and the expression levels of these 20 genes in 
the other two OSCC cell lines, BHY and HN.   
There were 57 genes that were upregulated and 42 genes that were downregulated 
in both BHY and HN cell lines (Figure 37).  The comparison of BHY with HSC-3 
showed that there were 24 upregulated genes and 49 downregulated genes on both BHY 
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and HSC-3 cell lines (Figure 38). Finally, there were 24 common upregulated and 44 
downregulated genes in HN and HSC-3 cell lines (Figure 39). 
Based on the expression levels of the genes in the microarray analysis, different 
pathways were analyzed on each OSCC cell line by using the Kyoto Encyclopedia of 
Gene and Genomes (KEGG). The pathway analysis was done based on the number of 
genes that were upregulated or downregulated within the pathway, the importance of the 
upregulated or downregulated genes for that specific pathway (impact factor) and how 
significant the change was of upregulated or downregulated gene expression (p values). 
First, both upregulated and downregulated genes’p values were considered in pathway 
analysis. Seven, 9 and 8 pathways were influenced in BHY (figure 40), HN (figure 43) 
and HSC-3 (figure 46) cell lines respectively (p<0.05). When only upregulated genes’ p 
values were evaluated 8, 10, and 3 pathways were upregulated in BHY (figure 41), HN 
(figure 44) and HSC-3 (figure 47) cell lines respectively (p<0.05). Finally, only 
downregulated genes’ p values were evaluated and 3, 9, and 6 pathways were 
downregulated in BHY (figure 42), HN (figure 45) and HSC-3 (figure 48) cell lines 
respectively (p<0.05). 
4.7. Real Time PCR Analysis 
Prior to cDNA synthesis, the quality of the extracted total RNA was determined 
using gel electrophoresis (Figure 4a). Also, the quality and quantity of cDNA, used for 
Real Time analysis, was checked by measuring the glucose-6-phosphate gene expression 
levels (Figure 4b).  
The Real Time PCR analysis results confirmed the cDNA microarray analysis 
results (Figure 49). The upregulation values of MAGEA9, Q96AL8 and GFI1 genes in 
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the BHY cell line were 3.34, 5.18 and 7.06 respectively. The upregulation values of 
NMES1, MAGEA1 and Q96AL8 genes in the HN cell line were 8.33, 3.58, and 10.67 
respectively. Finally, the upregulation values of MAGEA8, MAGEA1 and EREG genes 
in the HSC-3 cell line were 1.63, 0.90, and 3.71 respectively. When we compare the 
results of the Real Time-PCR with the results of the cDNA microarray analysis, the only 
questionable upregulation in the cDNA microarray analysis was the expression level of 
the MAGEA1 gene in the HSC-3 cell line with an error bar of 0.89 (Figure 49). However, 
all others have reasonable error bars as seen in figure 49, which means that the cDNA 
microarray analysis results in this study were reliable. The p values of all the Real Time 
PCR analysis results were <0.0001 except the value of the MAGEA1 gene in the HSC-3 






















CONCLUSIONS & RECOMENDATIONS 
5.1. The Invasion and/or Metastatic Characteristics of OSCC Cell Lines 
This part of the study examined the invasion and/or metastatic potentials of three 
different OSCC human cell lines, using micro positron emission tomography (PET) and 
computerized tomography (CT) imaging. The advantage of micro-imaging technology is 
the ability to monitor tumor growth in vivo. PET/CT revealed good image quality and 
allowed us to evaluate and correlate the metabolic alterations of cancer with anatomical 
findings. Thus, it is a good imaging technique of the tumors. PET is a method by which 
cellular and molecular events can be followed by using injected radiolabelled molecular 
probes. The addition of CT to PET is clearly helpful for a better anatomic delineation of 
the tumor, treatment monitoring, prognosis assessment and radiation treatment planing.  
Immunocompromised scid mice were used to show the differences in jaw bone 
invasion and distant organ metastasis of the three different OSCC cell lines in a 
biological system. Three animals per group was the minimum number required to 
demonstrate infiltrative bone lesions or metastases. There are three anatomical areas to 
form a tumor in the oral cavity. They are tongue, floor of the mouth and cheek (137, 
138). The masseter muscle is the ideal anatomical area for tumor growth due to its 
proximity to the jaw bones. Thus, we injected the cell lines into the masseter muscle. 
1x107 cells was the minimum acceptable amount to inject in each mouse according to the 
literature (139). As tumors in animals were clearly visualized by FDG-PET/CT (138, 
140), we decided to use 18FDG as the tracer.  18FDG is actively taken up and accumulates 
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in cancer cells (141). To the best of our knowledge, micro positron emission tomography 
(PET)/computerized tomography (CT) imaging has not been used to show the invasion 
and metastatic capacity of these three OSCC cell lines. 
The results of this experiment provided important information on the invasive and 
metastatic capacity of different OSCC cell lines that matched with their reported 
characteristics. It was determined that OSCC development can result in jaw bone 
invasion and/or distant organ metastasis. The BHY cell line invaded the mandible when 
they were injected in the masseter muscle of the scid mice (figure 8). This was also 
proven by Kawamata et al. (1). However, the HN cell line showed metastasis to cervical 
lymph nodes and distant organs both in our study and according to the literature (figure 
10 and 11) (1). The characteristics of the HSC-3 cell line in our study correlated with 
other reported studies (figure 12 and 13) (10, 23, 52). As we found differences based on 
the invasion and/or metastasis of these cell lines, we focused on the expression levels of 
proteolytic enzymes by using immunocytochemistry and flow cytometry, and gene 
regulations of these three OSCC cell lines by using the cDNA microarray technique. 
Thus, we might determine the genes that are upregulated or downregulated in the process 
of metastasis or bone invasion of OSCC.  
5.2. Characterization of The Oral Squamous Cell Carcinoma Cells  
MMPs play an important role in the invasion and metastasis of oral cancer. OSCC 
can induce the secretion of type I collagen proteolytic enzymes, most notably MMP-1 
(10). MMP-1 breaks down collagen I to gelatin. Then gelatinases, which are MMP-2 and 
MMP-9, complete the collagen I degradation by breaking down gelatin (10). Although 
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cancer cells that secrete MMP-2 and MMP-9 can invade bone, it is thought that MMP-9 
plays a more important role than MMP-2 during this process (9). 
 Several studies have focused on the effects of MMP-1 (1, 10), MMP-2 (1, 9, 10, 
17), MMP-3 (2, 17) and MMP-9 (1, 9, 10, 19) along with cathepsin B, H, L, and D (1, 4) 
on the ability of OSCC to invade bone. Production of MMP-1 and MMP-9 appear to play 
a role in the invasion of OSCC to bone (8, 10) and our results substantiate this finding. 
These two metalloproteinases are necessary for the complete collagen matrix degradation 
of bone, and have been shown to be expressed by OSCC (10). According to Hong et al. 
(9) and our study, although MMP-2 was highly expressed in OSCC it is not related to 
invasion. Over expression of MMP-3 in OSCC is associated with invasion and a high 
incidence of metastasis (2). Also, our results showed that MMP-3 has a stronger intensity 
in tumor cells than in HNEC cells. Cathepsin B and L are the two most important 
cysteine proteinases implicated in tumor cell invasion and metastasis (12). This study 
showed that all three OSCC cell lines highly express both cathepsin B and L. EMMPRIN 
is highly expressed in OSCC and may regulate OSCC invasion, and modulate the 
expression of MMP-2 (13). We also observed that EMMPRIN is highly expressed in 
tumor cells, particularly in BHY cell lines.  
MMP-2 expression is significantly higher in cases of lymph node metastasis than 
that in non-lymph node metastasis cases (34, 35, 44). This may explain the observation of 
the highest expression of MMP-2 in HN and HSC-3 cell lines. MMP-9 production is also 
closely related to lymph node metastasis (36) however, Charous et al. (37) found that 
there is no difference in MMP-2 and MMP-9 expression levels between primary and 
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metastatic OSCC. We believe that higher levels of MMP-2 might correlate with lymph 
node metastasis of OSCC. 
MMP-3 can degrade type IV collagen. Thus, it is important to analyze the 
expression of MMP-3 in OSCC. EGF stimulates the production of MMP-3 coordinately 
with MMP-1 (2). Interestingly, the over-expression of epithelial growth factor receptor 
(EGFR) is a remarkable property of squamous cell carcinoma (2, 56, 58). It is not clear, 
however, whether EGFR overexpression is implicated in the increased production of 
MMP-3 by OSCC (2).  
This study did not reveal any significant differences in the expression levels of 
cathepsin B and L in the three OSCC cell lines. Cathepsin L has a major role in the 
process of bone resorption by activating osteoclasts (1). Kawasaki et al. (4) found that 
cathepsin B expression is closely correlated with OSCC invasion and progression; 
however, they could not find any relationship between cathepsin L expression and 
invasion of OSCC. Turk et al. (45) showed that cathepsin B, H, and L are involved in 
cancer progression by either direct degradation of extracellular matrix or by activation of 
other proteases, such as uPA.  
In conclusion, proteolytic enzymes appear to play an important role in OSCC 
invasion and metastasis. Increased expression of MMP-9 and EMMPRIN may be 
associated with bone invasion of OSCC. We believe, however, that there are more genes 
and related proteins involved in the bone invasion pathway of OSCC. Future studies will 
refine gene profiles of OSCC’s with different biologic behavior leading to targeted 
clinical treatments.  
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5.3. cDNA Microarray Analysis of The Three OSCC Cell Lines and 
Comparison of The Results With Real Time PCR Analysis 
cDNA microarray analysis helped us better understand which genes are involved in 
bone invasion, lymph node metastasis and distant organ metastasis of OSCC. Regulation 
of gene expression is the cellular control via the functional product of the gene. It is the 
basis for cellular differentiation, morphogenesis and formation of the most significant 
pathology, such as cancer.  
5.3.1. The quality and quantity of total RNA 
Before the cDNA was synthesized from the total RNA, spectrophotometry was used 
to be ensured that there was enough total RNA. The quantity and the quality of the total 
RNA was important. Thus, aldolase and β-actin genes were two good housekeeping 
genes to use for checking the quality of total RNA. The first step was the synthesis of the 
cDNA from the total RNA and the second step was running a PCR reaction using the 
proper primers for aldolase and β-actin genes in order to observe their expressions 
(Figure 31).  
A housekeeping gene is typically a constitutive gene that is transcribed at a constant 
level. Its products are needed for maintenance of the cell and its expression level is 
unaffected by experimental conditions. Thus, the expression levels of housekeeping 
genes are a good source of evaluation of the quality of the total RNA. So far 575 
housekeeping genes have been identified (142). Aldolase and β-actin genes are in the 
group of the most commonly used housekeeping genes (143). The major function of the 
aldolase gene is in sugar metabolism in the cell in which they are expressed. Thus, this 
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gene is important in cell motility. The β-actin gene is one of the six different actin 
isoforms that is involved in cell  motility, structure and integrity. 
Column 1 in figure 31 did not show any band as it was the negative control group. 
However column 2, which was the positive control group, and columns 3 to 6, which 
were BHY, HNEC, HN and HSC-3 cDNA samples respectively, showed similar bands 
corresponding to the 161 kb molecular weight of the aldolase gene. Column 7 with the β-
actin negative group did not show any band. Columns 8 to 12, which were β-actin 
positive, BHY, HNEC, HN and HSC-3 cDNA samples respectively, showed the same 
bands with 42 kb which is the molecular weight of that gene. The gel electrophoresis in 
figure 31 showed that the total RNA samples that were used for cDNA microarray 
experiment was in good quality.   
5.3.2. cDNA microarray analysis of three OSCC cell lines 
Good quality and quantity of total RNA allowed us to obtain pure cDNA samples 
from each tumor cell lines and the HNEC control cell line. Each OSCC cell line cDNA 
was compared with the HNEC cell line based on the expression levels of  25,000 genes 
using the cDNA microarray technique. Operon Human Version 3.0 microarray slides 
were used for the cDNA microarray experiment. Any single microarray output is subject 
to substantial variability. Thus, the comparison of gene expression of each tumor cell 
lines was repeated four times using four microarray slides. By pooling data from 
replicates, we can provide more variable analysis of gene expression data. Based on the 
literature, in a microarray experiment at least 3 replicates produce more consistent and 
reliable findings (144), however, we preferred to do 4 replicates.  
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It has been shown that some genes have more affinity to Cy3- or Cy5 dyes (145). 
Reverse labeling has been proved to be important in improving data correlation, thus each 
group of cDNA was reverse labeled. Reverse labeling helped us to eliminate gene dye 
affinity error.  Also, the Lowess normalization method was used in order to remove 
intensity dependent dye bias.  
Based on the cDNA microarray results, each OSCC cell line has a unique gene 
expression structure. The HN cell line had the highest amount of gene alteration of all 
three OSCC cell lines with 214 upregulated and 262 downregulated genes (Table 15 and 
16). The BHY and HSC-3 cell lines had almost the same amount of upregulated and 
downregulated genes. This correlates with the metastatic and invasion capacities of these 
three cell lines (Figure 2). According to Leethanakul et al. study (93) the 23 genes that 
are most commonly expressed in normal oral squamous epithelium (table 2) were neither 
upregulated nor downregulated in any of the three OSCC cell lines. However, according 
to the same study the two genes of the 23 genes (table 3) that are most commonly 
expressed in OSCC were downregulated only in the HN cell line (table 16) and neither 
upregulated or downregulated in the BHY and HSC-3 cell lines. These two genes are 
RPS6KA2 and GSTP1. RPS6KA2 is a ribosomal protein S6 kinase, 90kDa, polypeptide 
2 and located at the 6q27. This gene is highly expressed in lung tissue and skeletal 
muscle. It may play an essential regulatory role in protein synthesis during cell 
proliferation. It was shown that this gene is downregulated in renal cell carcinomas (146). 
GSTP1 is glutathione S-transferase and located at 11q13. Its function is the conjugation 
of reduced glutathione to a wide number of exogenous and endogenous hydrophobic 
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electrophiles. Increased risk for oral cancer was observed in individuals who are 
homozygous for the GSTP1 gene and this risk increases with smoking (147).  
Shimada et al. found 16 genes that were upregulated in tongue cancer (table 4). 
Only one of these genes, which is KIAA, was upregulated in our study in the HN cell line 
(table 15), which is the most aggressive of the three OSCC cell lines. KIAA was found to 
be upregulated in OSCC tissues. The KIAA family of proteins bear a trans-membrane 
region capable of binding to other KIAA protein containing domains (such as PDZ, SH3, 
rhoGEF, and spectrin) known to be localized to sub-membranous sites indicating that 
they participate in cellular junction formation, receptor or channel clustering, and 
intracellular signaling events (148). Upregulation of KIAA may be involved in the late 
stages of OSSC.  
Tomioka et al. reported that 19 genes were downregulated in 9 patients with OSCC 
(136). CDH11, PAM, and TM4SF10 are the three genes of those 19 genes that were 
donwrregulated according to our results. CDH11 was downregulated in both HN and 
HSC-3 cell lines (table 16 and 18). CDH 11 is the cadherin 11 gene and has the 
chromosomal position of 16q22.1. Cadherins are calcium dependent cell adhesion 
proteins. They preferentially interact with themselves in a homophilic manner in 
connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. 
CDH11 is also downregulated in ameloblastoma (149). PAM (peptidylglycine alpha-
amidating monooxygenase) was only downregulated in the HN cell line. This gene is 
located at 5q14-q21. There is no study that has been performed that examines the 
relationship of this gene with OSCC. Gene TM4SF10, transmembrane 4 superfamily 
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member 10, was downregulated in all three OSCC cell lines. Its location is on the short 
arm of human chromosome X at p21.1 (150).  
Choi et al. listed 32 genes (table 6) that were upregulated in head and neck SCC 
(111). COL1A1, COL4A1, COL4A2, and COL5A1 are four of these genes (111, 151). 
According to our study, however, COL7A1, COL8A1, COL4A1, and COL16A1 were 
downregulated in the HN cell line (table 16). In the BHY cell line COL5A1 was 
upregulated (table 13) and COL8A1 was downregulated (table 14) and in the HSC-3 cell 
line COL4A1 was downregulated (table 18). The LY-2 cell line which was isolated from 
lymph node metastases of OSCC expressed down regulation of the COL1A2 and 
COL4A1 genes (152). This correlates with our HSC-3 cell line gene expression results. 
COL4A1 is collagen, type IV, alpha 1 and located at 13q34. Type IV collagen is the 
major structural component of glomerular basement membranes, forming a meshwork 
together with laminins, proteoglycans and entactin/nidogen. COL5A1 is collagen, type V, 
alpha 1. Type V collagen is a member of group I collagen (fibrillar forming collagen). It 
is a minor connective tissue component of nearly ubiquitous distribution. Type V 
collagen binds to DNA, heparan sulfate, thrombospondin, heparin, and insulin. The 
genomic location of the gene is 9q34.2-q34.3. COL8A1 is collagen, type VIII, alpha 1. 
The molecular function of this gene is unknown. The genomic location of the COL8A1 is 
3q12.3. COL1A2 is collagen, type I, alpha 2. Its genomic location is 7q22.1. Type I 
collagen is a member of group I collagen (fibrillar forming collagen). COL1A2 are 
specifically repressed by EGFR signaling, thereby facilitating oncogenic transformation. 
Therefore, it is likely that COL1A2 interferes with the progression of human carcinomas 
expressing aberrant forms of one or more EGFR family receptor tyrosine kinases (153). 
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COL1A1 is collagen, type I, alpha 1 with location of 17q21.33. Type I collagen is a 
member of group I collagen (fibrillar forming collagen). COL7A1 is collagen, type VII, 
alpha 1. The genomic location of this gene is 3p21.1. It is a stratified squamous epithelial 
basement membrane protein that form anchoring fibrils which may contribute to 
epithelial basement membrane organization and adherence by interacting with 
extracellular matrix proteins such as type IV collagen. COL5A2, COL3A1, COL10A1, 
COL4A1, FN1, and INHBA were well correlated with periostin expression. Higher 
expression of periostin was frequently observed in HNSCC tissues compared with normal 
tissues. By evaluation of periostin expression in HNSCC patients, a strong correlation of 
periostin expression with FAP, SULF1, COL5A2, COL3A1, COL10A1, COL4A1, FN, 
and INHBA was observed (154). However, in our study none of these genes and periostin 
were upregulated in any of the three OSCC cell lines.  
Other upregulated genes that were listed by Choi et al. (table 6) were FN1, ITGA6, 
IL-6, IL-8, POSTN, SERPINE1, SOD2, and THBS2. FN1, which is fibronectin 1, is 
located at 2q34. Fibronectin binds cell surfaces and various compounds including 
collagen, fibrin, heparin, DNA, and actin. It is involved in cell adhesion, cell motility, 
wound healing, and maintenance of cell shape. The upregulation of this gene in head and 
neck SCC was shown (151), however, according this study this gene was downregulated 
in all three OSCC cell lines (tables 14, 16 and 18). Neither upregulation nor 
downregulation of ITGA6 was observed in this study, whereas the downregulation of 
ITGB6 in BHY and HSC-3 cell lines were recorded (table 16 and 18). ITGB6 is the 
integrin beta-6 precursor that is Located at 2q24.2. It is a fibronectin receptor for 
carcinoma cells and plays a critical structural role in the hemidesmosome of epithelial 
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cells (155). Both IL-6 (interleukin 6) and IL-8 (interleukin 8) genes were upregulated in 
the three OSCC cell lines in this study (tables 13, 15, and 17). The genomic location of 
IL-6 is at 7p.21. It is a cytokine with a wide variety of biological functions: it plays an 
essential role in the final differentiation of B-cells into Ig-secreting cells, it induces 
myeloma and plasmacytoma growth. It is also involved in the regulation of immune 
response, hematopoiesis, platelet production, acute phase reaction and bone resorption 
(susceptibility factor for osteopenia), playing a role in the aggressiveness of non-
Hodgkin’s lymphoma by stimulating MMP-2 and MMP-9. IL-8, which is located at 
location 4q13-q21, is a chemotactic factor that attracts neutrophils, basophils, and T-cells, 
but not monocytes. It is released from several cell types in response to an inflammatory 
stimulus. IL-6 and IL-8 are important cytokines involved in tumor growth and 
angiogenesis in a variety of cancers, including OSCC (49, 126).  The impact of IL-6 and 
IL-8 expression in cancer cell lines has been reported. But the in vivo relationship 
between the IL-6/IL-8 expression and clinical parameters is still unknown (156). POSTN 
(periostin) is located at 13q13.3. It binds to heparin and induces cell attachment and 
spreading and plays a role in cell adhesion.  Periostin overexpression enhances 
invasiveness in oral cancer as its expression is well correlated with the invasion pattern 
and metastasis. Moreover, blood vessel density of periostin-positive cases was higher 
than those of periostin-negative cases (157), however, in this study it was downregulated 
(tables 14, 16 and 18). SERPINE1 (serpin peptidase inhibitor, clade E member 1) is 
located at 7q21.3-q22. Both SERPINE1 and SOD2 expression increase in OSCC with a 
poor prognosis (121). These two genes were only upregulated in the HN cell line (table 
15) that has the most aggressive metastatic behavior. No THBS2 upregulation was found 
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in this study, but downregulation of the THBS1 gene was observed in the HSC-3 cell line 
(table 18). The THBS1 gene product is an adhesive that mediates cell-to-cell and cell-to-
matrix interactions. It can bind to fibrinogen, fibronectin, laminin, type V collagen and 
integrins. Downregulation of this gene was observed in human lung and breast cancer cell 
lines and associated with the malignant progression of murine melanoma cell lines. 
Although the role of THBS1 in cancer progression is not yet clear, it is suggested that 
production of THBS1 by tumor cells is correlated with a reduction in angiogenesis (158).  
Choi et al. also listed the 33 most common downregulated genes of head and neck 
SCC (table 7) (111). AIM1, ALDH9A1, ANXA1, DUSP5, IL1RN, KRT13, KRT15, 
KRT4, and ZNF185 are some of them. We did not appreciate any remarkable change in 
expression level of the AIM1 gene, but the expression level of AIM2 (Absent in 
melanoma 2) gene, located at 1q22, was upregulated according to this study’s results 
(table 13, 15, and 17). Although AIM2 is known to inhibit fibroblast cell growth in vitro, 
its antitumor activity has not been shown. The expression level of ALDH9A1 gene was 
not downregulated but ALDH1A3 (aldehyde dehydrogenase 1 family, member A3) gene 
which is located at 15q26.3, was downregulated in HN cell line (table 16). The ALDH 
family consists of 16 different enzymes in the human. Several of these have been 
characterized in recent years but for many, a specific function remains to be revealed. The 
function for ALDH1A3 may be a back-up enzyme in retinoid metabolism. Apart from 
ALDH1A3, no true retinoid-metabolising enzyme was identified. Downregulation of the 
ANXA1 gene in OSCC was shown previously (table 7) (111). Our study confirmed the 
downregulation of the ANXA6 (annexin A6) gene in the HN cell line (table 16). The 
location of this gene is 5q32-q34. This gene may regulate the release of Ca2+ from 
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intracellular stores. ANXA1 is overexpressed in breast cancer and hepatocellular 
carcinoma but markedly down-regulated in esophageal, prostate, gastric carcinomas and 
HNSCC. The loss of the ANXA1 protein expression is an early event in the initiation of 
premalignant lesions in HNSCC. Also, possible tumor suppressor roles have been 
proposed for the ANXA6 gene in melanoma and squamous cell carcinoma (159).  
DUSP6, which was downregulated in the HN cell line (table 16), is located at 12q22-q23. 
Its function is to inactivate MAP kinases. There are five studies that have been performed 
regarding the expression levels of DUSP6 in head and neck SCC. Four of these studies 
showed downregulation of this gene whereas one of them showed the upregulation of the 
gene (table 8) (111). Of the down-regulated genes, DUSP1, which has known 
proliferation and differentiation functions, has been shown previously to be down-
regulated in follicular carcinomas and in advanced epithelial ovarian cancer. Individual 
genes that differentiate between papillary and follicular carcinomas are the DUSP6 and 
DUSP5. DUSP5 has been reported previously to be upregulated in premalignant lesions 
and underexpressed in invasive pancreatic carcinoma (160). IL1RN was only 
downregulated in the HN cell line (table 16). This gene (interleukin 1 receptor antagonist) 
is located at 2q14.2. It inhibits the activity of IL-1 by binding to its receptor, however it 
has no IL-1 like activity. It is downregulated in OSCC (151). KRT23 in the BHY cell line 
(table 14); KRT8, KRT16, and KRT6B in the HN cell line (table 16) and KRT23, 
KRT15, and KRT6B (table 18) were downrregulated in the HSC-3 cell. There are six 
studies that have been performed regsarding the expression levels of KRT16 in head and 
neck SCC. Four of these studies showed downregulation of this gene whereas two of 
them showed the upregulation of the gene (table 8) (111). KRT genes are basal cell 
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epithelial markers. Immortal OSCC show increased expression of genes encoding several 
cell cycle regulators, compared with mortal OSCCs (e.g., CCNA2, CCNB1, CCNB2; 
CDC2, CDC6, CDC20, CDCA7; CDKN3; several MCMs; PCNA; BIRC5), but reduced 
expression of genes encoding terminal differentiation markers such as several keratins, 
involucrin (IVL), and the family of small proline-rich proteins (SPRR), as well as the 
S100 family of calcium-binding motility proteins. In contrast, a variety of adhesion, 
invasion, and extracellular matrix proteins are upregulated in mortal OSCC (161). ZNF25 
and ZNF625 gene were downregulated in the BHY cell line and ZNF569, ZNF606 and 
ZNF83 genes were downregulated in the HSC-3 cell line. ZNF genes are located at 19q. 
These genes are involved in the regulation of cellular proliferation, differentiation and 
transcriptional regulation. Downregulation of ZNF 185 in head and neck cancers has 
been shown previously (100). 
Other common genes that are altered in head and neck SCC are MMP-1, MMP-2, 
MMP-3, MMP-9, MMP-10, MMP-13, MMP-25, LAMP3, LAMA3, LAMB3, LAMC2, 
CDH2, CXCL6 and HRAS . MMP-13 is an important matrix matelloproteinase, which is 
known also as collagenase 3. The collagenases can mediate tumor invasion through 
several mechanisms, which include constitutive production of enzymes by the tumor 
cells, induction of collagenase production in the neighboring stromal cells, and 
interactions between tumor/stromal cells to induce collagenase production by one or both 
cell types. Thus, evidence indicates that elevated expression of the interstitial 
collagenases is associated with a poor prognosis in a variety of cancers, and therefore, 
these MMPs can serve as a marker of tumor progression. Human MMP-13 was first 
identified in breast carcinoma. Squamous cell carcinomas of the head and neck, in 
particular, are noted for their propensity to rapid progression and poor clinical outcome. 
In these tumors, MMP-13 has been seen mostly in tumor cells at the invading front. Only 
malignant squamous cell tumors, but not premalignant and benign lesions, express MMP-
13, supporting the concept that MMP-13 can serve as a prognostic marker in these 
carcinomas with characteristically poor outcomes (162). Recently, MMP-1 has been 
described in a wide variety of advanced cancers. Some reports document MMP-1 
production by tumor cells and correlate this with the invasive potential of the tumors, 
whereas other investigations support the belief that MMP-1 is predominantly expressed 
by the surrounding stromal fibroblasts. Tumor cells are constantly changing both their 
genotype and their phenotype as they respond to genetic, physiological, and 
pharmacological pressures. As a result of this genetic instability, errors in gene regulation 
accrue as the tumor continues to metastasize and progress (162). Many matrix 
metalloproteinases (MMPs), such as MMP-1, -2, -7, -9, -13, and -14 have been 
implicated in cancer invasion. The absence of MMP-7, -9 and -12 from epithelial cells 
may serve as a good prognostic marker of non-invasive oral carcinoma (163). Blocking 
the activity of invasion-specific MMPs might offer novel therapeutic modalities in early-
stage oral carcinoma. The tissues of OSCCs with lymph node metastasis exhibited 
increased expression levels of MMP-1, MMP-3, uPA, integrin- 3, paxillin, tenascin C 
and IL-6 transcripts. Functional gene groups of proteolytic enzymes and integrin-related 
molecules are involved in cervical lymph node metastasis. MMP-1 and integrin-3 in 
particular can provide an accurate biomarker system for predicting the risk of cervical 
lymph node metastasis in OSCC (164). Previous studies have indicated that E1AF 
transactivates multiple MMP genes, such as MMP-1, MMP-3 and MMP-9, and plays an 
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important role in tumor invasion. Expression of MMP-1, MMP-9 and E1AF has been 
found to be correlated with the invasive potential of oral squamous cell carcinoma (165). 
According to our cDNA microaray analysis study in the BHY cell line MMP-1, MMP-3, 
MMP-9 and MMP-10 (table 13); in HN cell line MMP-2, MMP-13, and MMP-25 (table 
15); and in HSC-3 cell line MMP-2 and MMP-3 (table 17) were highly expressed. 
LAMP3, lysosomal-associated membrane protein 3, is another gene that is altered in 
OSCC. Its location is 3q27 and it may change the lysosome function after the transfer of 
peptide-MHC class II molecules to the surface of dendritic cells. LAMP3 expression is 
upregulated in laryngeal squamous cell carcinoma (166). LAMP3 might also play an 
important part in metastasis (167). In our study this gene was upregulated both in the 
BHY and HN cell lines (table 13 and 15). LAMA3, laminin alpha 3, gene is located at 
18q11.2. It mediates the attachment, migration and organization of cells into tissues 
during embryonic development by interacting with other extracellular matrix 
components. Functions of this gene include adhesion or migration, depending on whether 
or not it has been proteolytically remodeled by MMPs such as MMP-2 and/or MT1-
MMP. This gene expression upregulates in wound sites (168). It has an important role in 
regulating tissue organization, gene expression, and survival of epithelium (169). A 
number of reports suggest its involvement in the spread and metastatic activities of cancer 
cells (170). The HN cell line was the only one of the three cell lines that showed 
upregulation of LAMA3 gene (table 15). CDH2, cadherin 2, type 1, is located at 18q11.2. 
It is one of the first to be considered as an invasion-promoter gene. The upregulation of 
this gene is common in diffuse type gastric cancer and lobular breast cancer (171). This 
gene was only upregulated in the HN cell line (table 15). CXCL6, chemokine (C-X-C 
 85
motif) ligand 6, is located at 4q21. Mortal SCC cultures express a variety of chemokines 
in culture, such as IL-8, CXCL5, CXCL6, CXCL7, and CCL20, in contrast to immortal 
SCCs (161). This may be one reason why this gene is only upregulated in HN cell lines. 
HRAS, Harvey-ras, gene is involved in cell signaling, cell growth, and cancer (58, 124). 
This gene was upregulated in BHY and HN cell lines.   
Based on this study OSCC involves multiple molecular genetic events that take 
place on many chromosomes and genes. Also this study showed that the loss of 
heterozygosity on regions of chromosomes 3, 4, 5, 6, 8, 9, 11, 13, and 19 is common in 
OSCC. The genes that showed alterations in this study have a role in extracellular matrix 
degradation, cell adhesion, epidermal development and differentiation, signal 
transduction, transcriptional regulation, cell growth and proliferation, proteolysis, 
basement membrane degradation, and cytoskeleton.  
Thirteen of the 20 most upregulated BHY genes were upregulated, and the other 7 
were neither upregulated nor downregulated in the HN cell line. However, only 3 of the 
20 most upregulated BHY genes were upregulated, and the other 17 were neither 
upregulated nor downregulated in the HSC-3 cell line. When the 20 most downregulated 
BHY genes were evaluated, 11 of them in the HN cell line and 14 of them in HSC-3 cell 
lines were also downregulated. The other 9 in the HN, and the other 6 in the HSC-3 cell 
lines were neither upregulated nor downregulated (table19). Twelve of the 20 most 
upregulated  HN genes were upregulated, 7 of them were neither upregulated nor 
downregulated and one of them was downregulated in the BHY cell line. However, only 
5 of the 20 most upregulated HN genes were upregulated, 14 of them were neither 
upregulated nor downregulated and one of them was downregulated in the HSC-3 cell 
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line. When the 20 most downregulated HN genes were evaluated, 9 of them in the BHY 
and 10 of them in HSC-3 cell lines were also downregulated. Ten of them were neither 
upregulated nor downregulated and one of them was upregulated in the BHY cell line. 
Ten genes of the 20 most downregulated HN genes were neither upregulated nor 
downregulated in HSC-3 cell lines (table 20). Ten of the 20 most upregulated HCS-3 
genes were upregulated, and the other 10 were neither upregulated nor downregulated in 
the BHY cell line. Nine of the 20 most upregulated HSC-3 genes were upregulated, and 
the other 11 were neither upregulated nor downregulated in the HN cell line. When the 20 
most commonly downregulated HSC-3 genes were evaluated, 13 of them in BHY and 14 
of them in HN cell lines were also downregulated. The other 7 of them in BHY, and the 
other 6 of them in HN cell lines were neither upregulated nor downregulated (table 21). 
These comparisons and the microarray gene clusterizations in figures 34, 35, and 36 
showed that the upregulated genetic structure of the BHY cell line was more similar to 
the upregulated genetic structure of the HN cell line (Figure 34A and 35A). Whereas the 
upregulated genetic structure of the HSC-3 cell line showed more similarity to the 
upregulated genetic structure of the BHY cell line (Figure 36A). Based on the gene 
clusterization, the downregulated genetic structure of the BHY cell line was more similar 
to the downregulated genetic structure of the HSC-3 cell line (Figure 34B, 35B and 36B).  
The results of this study represented thirteen genes that were upregulated in all of 
the three OSCC cell lines (figure 32). Twelve of them were known genes whereas one of 
them has not been previously described. Basically, the functions of these genes are: 
mitotic progression and chromosome segregation, apoptosis inhibition, cell growth, 
transduction and intercellular transmission of polarity information during tissue 
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morphogenesis and/or in differentiated tissues, embryonal development and tumor 
transformation and progression, condensation of nucleosome chains into higher order 
structures.  
There were 83 genes that were downregulated in all three OSCC cell lines (figure 
33). Most of the genes have vital functions for cell function. Some of these 83 genes, 
such as EVA1, DSC2, POSTN, CSPG2, SRPX, ANGPTL4, FN1, ITGAV, COL8A1 and 
AMPH have important functions related to cell-cell or cell-basement membrane 
interaction (figure 33). Downregulation of such genes in malignancies helps the tumor 
cells to spread to surrounding tissues and organs. The EVA1 gene is involved in the 
formation of homotypic adhesion molecules that help the cells attach to the extracellular 
matrix. The DSC-2 gene is a component of intercellular desmosome junctions. It is 
involved in the interaction of plaque proteins and intermediate filaments mediating cell-
cell adhesion. It may also contribute to epidermal cell positioning by mediating 
differential adhesiveness between cells. POSTN induces cell attachment and adhesion. 
The CSPG2 gene may play a role in intercellular signaling and in connecting cells with 
the extracellular matrix. It may take part in the regulation of cell motility, growth and 
differentiation. The SRPX gene is also involved in cell-cell adhesion. The ANGPTL4 
gene inhibits proliferation and migration of cells and reduces vascular leakage. FN1 is 
involved in cell adhesion, cell motility, wound healing, and maintenance of cell shape. 
Inhibition of the gene mediates inhibition of cell adhesion. ITGAV has an important role 
in mediating cell-adhesion to extra cellular matrix or to other cells, through hetero-
dimerization and connecting to the cytoskeleton and various signaling molecules within 
cells. COL8A1 has a role in the formation of the major component of the basement 
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membrane. The AMPH gene may participate in mechanisms of regulated exocytosis in 
synapses. It may control the properties of the membrane associated cytoskeleton.  
Another group of genes, SRFP1, KFL10, NDN, that play a major role of cell 
growth regulation was also within this 83 downregulated gene list (figure 33). SRFP1 has 
a role in cell growth regulation and differentiation. KFL10 is involved in the regulation of 
cell growth by inhibition. The NDN gene is another growth suppressor that facilitates the 
entry of the cell into cell cycle arrest. Functionally it is similar to the retinoblastoma 
protein as it binds to and represses the activity of cell-cycle- promoting proteins.  
Some of the genes involved with transportation were downregulated in all three 
OSCC cell lines. These genes are GJB6, SLC2A1, FOLR3, ANXA6, and RAB4B. GJB6 
has a role in forming one gap junction that consists of a cluster of closely packed pairs of 
transmembrane channels, the connexons, through which materials of low molecular 
weight diffuse from one cell to a neighboring cell. SLC2A1 is the glucose transporter in 
the cell. FOLR3 mediates delivery of 5-methyltetrahydrofolate to the interior of cells and 
ANXA6 regulates the release of Ca2+ from intracellular stores. The RAB4B gene is 
effective in protein transport within the cell.  
Genes of immune response such as SERPINB3, SEPP1, and IL1F9 were also within 
the 83 commonly downregulated genes in the three OSCC cell lines (figure 33). The 
SERPINB3 gene may act as a protease inhibitor to modulate the host immune response 
against tumor cells. SEPP1 might be responsible for some of the extracellular antioxidant 
defense properties.  IL1F9 could constitute part of an independent signaling system 
analogous to interleukin-1 alpha, beta receptor agonist and interleukin-1 receptor type I, 
that is present in epithelial barriers and takes part in the local inflammatory response. 
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The RGS17 and PTPNS1 genes were downregulated signal transduction inhibitor 
genes within the 83 downregulated genes (figure 33). RGS17 inhibits signal transduction 
by increasing the activity of G protein. PTPNS1 plays an important role in signal 
transduction cascades. 
Other listed genes have various different functions in the cell. Some of the 
important ones are CFHL1, SPRR1B, RHBDL2, MAF, and CALD1. The CFHL1 gene 
might be involved in complement regulation and can associate with lipoproteins and may 
play a role in lipid metabolism. The SPRR1B gene produces a keratinocyte protein that 
first appears in the cell cytosol. RHBDL2 is involved in regulated intramembrane 
proteolysis. MAF has a role in transcription and the CALD1 gene plays an essential role 
during cellular mitosis and receptor capping. 
5.3.3. Pathway analysis of three OSCC cell lines based on cDNA microarray results 
Pathway analyses of each OSCC cell line was performed to be able to better 
understand the invasion, lymph node metastasis and distant organ metastatic mechanisms 
of OSCC. Pathway upregulation in cell lines was most pronounced in metabolic 
pathways including cell nucleotide metabolism and oxidative phosphorylation. Signaling 
pathways involved in adhesion and communication of cultured cancer cells were 
downregulated. Based on the expression levels of the genes in the microarray analysis, 
different pathways were analyzed on each OSCC cell line by using the Kyoto 
Encyclopedia of Gene and Genomes (KEGG). The pathway analysis was performed 




5.3.3.1. BHY cell line 
Seven pathways based on the p values (p<0.05) of both upregulated and 
downregulated genes (Figure 40), 8 pathways based on the p values (p<0.05) of only the 
upregulated genes (Figure 41) and 3 pathways based on the p values (p<0.05) of only 
downregulated genes (Figure 42) were influenced in the BHY cell line. The most 
important pathways that were upregulated in the BHY cell line were; regulation of actin 
cytoskeleton, TGF-beta signaling pathway, dentatorubropallidoluysian atrophy, hedgehog 
signaling pathway, focal adhesion, Jak-STAT signaling pathway, Parkinson’s disease, 
and the mitogen-activated protein kinase (MAPK) signaling pathway.   
In regulation of the actin cytoskeleton pathway, the actin cytoskeleton mediates a 
variety of essential biological functions in the cell. In addition to providing a structural 
framework around which cell shape and polarity are defined, its dynamic properties 
provide the driving force for cells to move and to divide. Members of the Rho family of 
small guanosine triphosphatases have emerged as key regulators of the actin 
cytoskeleton, and furthermore, through their interaction with multiple target proteins, 
they ensure coordinated control of other cellular activities such as gene transcription and 
adhesion (172). Actomyosin-mediated cell retraction and formation of intercellular gaps 
occurs through this pathway (173). Actin filaments play important roles in mitosis, cell 
signaling, and motility. Thus they are the targets of anti-cancer drugs. These drugs target 
microtubules, and actin filaments to inhibit cell proliferation by blocking mitosis at the 
mitotic checkpoint and inducing apoptosis (174). Activation of cell surface proteins 
implicated in cell adhesions can cause the alteration of the actin cytoskeleton, which is 
required for the function of cell-to-cell or cell-to-extracellular matrix interactions. The 
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actin cytoskeleton is a dynamic structural entity and constantly undergoes assembly or 
disassembly. The assembled actin filaments can be further cross-linked to form either 
actin bundles or actin meshwork. The over activation of this system can cause bone 
metastasis in breast cancer (175). This pathway was upregulated in all three OSCC cell 
lines. 
TGF-beta signaling pathway activation is common in malignancies. Carcinomas 
often secrete excess TGF-β1 and respond to it by enhanced invasion and metastasis. Pre-
treatment of adenocarcinoma cells with TGF-β1 in vitro enhanced their subsequent 
metastatic ability when injected into rats. The TGF-β-treated carcinoma cells became 
more invasive in vitro, and this was attributed to increased expression of gelatinases (or 
matrix metalloproteases), enhancing tumor cell migration and invasion. TGF-β1 not only 
has transforming potential, but can also drive malignant progression, invasion and 
metastasis both in vitro and in vivo. However TGF-β can act as both a tumor suppressor 
and as a significant stimulator of tumor progression, invasion and metastasis. At the 
initial stage of the cancer TGF-β acts as a tumor suppressor whereas as the tumor 
progresses, genetic changes allow TGF-β to stimulate tumor progression by its 
pleiotropic activities on both the cancer cells and on non-malignant stromal cell types of 
the tumor (176). This may be a clue that the bone invasion phase of the OSCC is an 
advanced phase of the cancer.  
Dentatorubropallidoluysian Atrophy (DRPLA) affects both the mind and body. It is 
characterized by abrupt muscle jerking, involuntary movements, and eventual dementia. 
The protein product of the DRPLA gene is called atrophin-1. Although its function is 
unclear, the leading theory is that atrophin-1 is involved in the pathway that helps insulin 
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take effect in the body’s cells. Since insulin helps determine how cells utilize their 
energy, it is essential that this pathway work smoothly so that cells can function 
efficiently (177). There are some cases in the literature with DRPLA and where patients 
died due to lung cancer or prostate cancer, however there is no proven relation between 
this pathway and cancer. 
The Hedgehog signaling pathway is involved in the mechanisms that control cell 
proliferation and cell differentiation during morphogenesis of the endochondral skeleton 
of vertebrates. The Hedgehog signaling pathway has a role in the control of chondrocyte 
maturation by way of feedback control of a second secreted factor which is parathyroid 
hormone-related protein (PTHrP). Patients with solid tumors and hypercalcemia have 
increased serum PTHrP. Its production by a tumor is associated with increased tumor size 
and rate of growth. This pathway coordinates diverse aspects of skeletal morphogenesis 
through PTHrP-dependent and independent processes. Over expression of PTHrP in 
chondrocytes causes a delay in chondrocyte maturation and bone formation (178). Tumor 
necrosis factor (TNF) enhances PTHrP-induced hypercalcemia which causes bone 
resorption. This effect is due to the increased production of committed osteoclast 
precursors with a subsequent increase in osteoclastic bone resorption. It was shown that 
blockage of this pathway suppresses the growth of breast carcinoma cells (179). The 
upregulation of this pathway is a common process for OSCC (180). 
The focal adhesion pathway has a role in mechanical adhesion of the cells to the 
extracellular matrix which is important for cell growth, survival and migration.  Analysis 
of primary human prostate cancer cells isolated from 16 surgical specimens showed that 
these cells expressed the focal adhesion pathway, whereas normal prostate epithelial cells 
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did not. Also, PC3, which is a prostate cancer cell line was found to invade mature bone 
and highly express focal adhesion pathway (181). However, to the best of our knowledge 
there has been no study relating invasion of OSCC to bone and this pathway. 
The Jak-STAT signaling pathway was another pathway that was upregulated in the 
BHY cell line. A wide variety of extracellular signals activate the signal transducers and 
activators of transcription (STAT) class of transcription factors. Many cytokines, 
lymphokines, and growth factors signal through a related superfamily of cell surface 
receptor tyrosine kinases that are associated with and activate Janus kinases (JAKs) 
(182). The urokinase-type plasminogen activator receptor (uPAR) generates a proteolytic 
cascade important for matrix degradation in tumor invasion and tissue remodeling. 
Binding of uPA to uPAR at the cell surface stimulated cell migration. In contrast to 
normal cells, malignant tumor cells usually overexpress uPAR. uPAR, together with its 
signaling functions, coordinate tumor cell adhesion and invasive migration through the 
extracellular matrix (ECM) and to determine whether tumor cells will, or will not, grow 
in vivo. The Jak-STAT signaling pathway is one of the pathways that can be activated by 
the uPA- uPAR interaction (183). The activation of this pathway has been shown to be 
involved in bone metastasis in prostate cancer (184). One other role of this pathway is 
activation of MMP which has a role in bone invasion of OSCC. Upregulation of MMPs 
in the BHY cell line can be due to the activation of this pathway. 
The mitogen-activated protein kinase signaling pathways transduce a large variety 
of external signals, leading to a wide range of cellular responses, including growth, 
differentiation, inflammation and apoptosis. It is thought that the balance between distinct 
MAPK pathways regulates cell growth, differentiation, survival, and death. They also 
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have a role in the regulation of MMP gene expression, especially MMP-1 and MMP-3. In 
addition to MMP-1 and MMP-3, increased transcriptional activity of MMP-9 can be 
regulated by the MAPK signaling pathway in malignant cells. Invasive cancer cells and 
stromal cells at the invading edge of tumors are under physical stress, such as hypoxia 
and hyperthermia. Stress activates MAPKs which is responsible for regulation of MMP 
expression (185). Inhibition of the MAPK pathway could serve as a therapeutic target to 
specifically prevent tumor cell invasion. 
Based on the downregulated genes in BHY cell lines there were 3 downregulated 
pathways (p<0.05) (Figure 42). These pathways were olfactory transduction, taste 
transduction and ECM-receptor interaction pathways. No relation was found in the 
literature between OSCC and either the olfactory or the taste transduction pathway. 
Pathways that were downregulated in cell lines compared to tumor and normal tissue 
included cell communication, cell adhesion molecules (CAMs), and ECM-receptor 
interaction. Degradation of ECM is one of the essential steps in invasion and metastasis 
of the tumor (186). Integrins and growth factors play an important part in maintaining 
tissue architecture. Disruption of the balance of signaling results in dramatic changes in 
the way cells interact with each other and with the extracellular matrix, leading to cancer. 
The extracellular matrix itself plays a central role in coordinating these signaling 
processes. Downregulation of this pathway helps tumor cells migrate to distant organs 
thus, metastasis and invasion. ECM-receptor interaction was found to be of relevance to 
head and neck SCC (187). This pathway was not only downregulated in the BHY cell 
line but also in the HN and HSC-3 cell lines according to the results of this study.  
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5.3.3.2. HN cell line 
Ten different pathways showed upregulation in the HN cell line (p<0.05) (Figure 
44). Seven of them, which are MAPK signaling pathway, regulation of actin 
cytoskeleton, antigen processing and presentation, focal adhesion, cell cycle, calcium 
signaling pathway, and axon guidance, were closely related with invasion and metastasis 
of the cancer.   
As previously explained, MAPK pathway regulates cell growth, differentiation, 
survival, and death. This pathway was also upregulated in the BHY and HSC-3 cell lines. 
As it regulates MMP expression, this pathway may be involved in distant organ and 
lymph node metastasis of OSCC. Transfection studies indicate that many genes can 
induce metastatic ability, including familiar oncogenes such as RAS and MYC that have 
a role in the MAPK signaling pathway. The metastatic process requires a complex set of 
cellular functions such as changes in adhesion, and initiation of motility and extracellular 
matrix proteolysis, which culminates in the shedding of cells into the circulation either 
directly or via the lymphatics. A hyperactive Raf/MAPK pathway is required for 
epithelial mesenchymal transition that correlates with metastasis (188). This pathway was 
upregulated in all three OSCC cell lines. This may mean that the MAPK signaling 
pathway is one of the major pathways related to OSCC invasion and metastasis.   
Regulation of the actin cytoskeleton was another important pathway that was 
upregulated in all three OSCC cell lines. As it was mentioned before, regulation of the 
actin cytoskeleton provides the driving force for cells to move and to divide. Cell-cell 
adherence junctions, the most common type of intercellular adhesions, are important for 
maintaining tissue architecture and cell polarity, and can limit cell movement and 
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proliferation. Cell-cell adherence junctions assemble via homophilic interactions between 
the extracellular domains of calcium-dependent cadherin receptors on the surface of 
neighboring cells. The cytoplasmic domains of cadherins bind to the submembranal 
plaque proteins β-catenin or plakoglobin (γ -catenin), which are linked to the actin 
cytoskeleton via α-catenin. The transmembrane assembly of cadherin receptors with the 
cytoskeleton is necessary for the stabilization of cell-cell adhesions and normal cell 
physiology. Malignant transformation is often characterized by major changes in the 
organization of the cytoskeleton, decreased adhesion, and aberrant adhesion-mediated 
signaling. Disruption of normal cell-cell adhesion in transformed cells may contribute to 
enhance tumor cell migration and proliferation, leading to invasion and metastasis. This 
disruption can be achieved by downregulating the expression of cadherin or catenin 
family members or by activation of signaling pathways that prevent the assembly of cell-
cell adherence junctions such as the actin cytoskeleton. Thus, regulation of the actin 
cytoskeleton is important in cell-cell adherence junction (173). 
Antigen processing and presentation are processes that occur within a cell that 
result in fragmentation (proteolysis) of proteins, association of the fragments with major 
histocompatibility complex (MHC) molecules, and expression of the peptide-MHC 
molecules at the cell surface where they can be recognized by the T cell receptor. 
However, the path leading to the association of protein fragments with MHC molecules 
differs for class I and class II MHC. MHC class I molecules present degradation products 
derived from intracellular (endogenous) proteins in the cytosol. MHC class II molecules 
present fragments derived from extracellular (exogenous) proteins that are located in an 
intracellular compartment. Dendritic cells are antigen-presenting cells with a unique 
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ability to cross prime T cells and generate strong anti-tumor responses. Reichert et al. 
reported that dendritic cell infiltrates were low in 20% of OSCC specimens, intermediate 
in 42% of OSCC specimens, and high in 37% of OSCC specimens (189). The 
upregulation of this pathway only in the HN cell line may suggest that the immune 
system reacts against OSCC in advanced stages of the tumor.     
The focal adhesion pathway serves as the mechanical linkage to the ECM, and as a 
biochemical signalling hub to concentrate and direct numerous signaling proteins at sites 
of integrin binding and clustering. The activation of this pathway may cause metastasis 
by OSCC (23). Integrins are cell surface receptors that mediate the adhesion of cells to 
the extracellular matrix.  They are essential for tissue organization and survival. They 
allow normal, nontransformed cells to sense that they are adhered to the extracellular 
matrix, thus providing a cell survival signal. Focal adhesion kinase (FAK) becomes 
phosphorylated and activated during integrin-mediated cell adhesion. Focal adhesion 
kinase is a signal transducer of integrins.  Enhanced expression of focal adhesion kinase 
in oral carcinoma cells may cause growth and increased invasive potential of the primary 
oral tumor (190). High expression of this pathway may be associated with distant 
metastasis of OSCC.  
The cell cycle pathway is the series of events in a eukaryotic cell between one cell 
division and the next. The cell cycle consists of four distinct phases:G1 phase, S phase, G2 
phase (collectively known as interphase) and M phase. M phase is itself composed of two 
tightly coupled processes: mitosis, in which the cell's chromosomes are divided between 
the two daughter cells, and cytokinesis, in which the cell's cytoplasm physically divides. 
Cells that have temporarily or reversibly stopped dividing are said to have entered a state 
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of quiescence called G0 phase. Some cells may permanently stop dividing due to age or 
accumulated DNA damage. Some cell types in mature organisms, such as parenchymal 
cells of the liver and kidney, enter the G0 phase semi-permanently and can only be 
induced to begin dividing again under very specific circumstances; other types, such as 
epithelial cells, continue to divide throughout an organism's life. The G1 phase is a period 
in the cell cycle during interphase, before mitosis, cytokinesis and the S phase. For many 
cells, this phase is the major period of cell growth during its lifespan. During this stage 
new organelles are being synthesized, so the cell requires both structural proteins and 
enzymes, resulting in great amounts of protein synthesis. The metabolic rate of the cell is 
high. The S phase, designated by DNA synthesis, is a period in the cell cycle during 
interphase, between G1 phase and the G2 phase. Following G1, the cell enters the S stage, 
when DNA synthesis or replication occurs. At the beginning of the S stage, each 
chromosome is composed of one coiled DNA double helix molecule, which is called a 
chromatid. At the end of this stage, each chromosome has two identical DNA double 
helix molecules, and therefore is composed of two sister chromatids. During the S phase, 
the centrosome is also duplicated. Damage to DNA often occurs during this phase. DNA 
repair is initiated following the completion of replication. The G2 phase is the third, final, 
and usually the shortest subphase during interphase within the cell cycle. It follows 
successful completion of DNA synthesis and chromosomal replication during the S 
phase. The G2 phase prepares the cell for mitosis (M phase) which is initiated by 
prophase. The G2 checkpoint determines if the cell can proceed to the M phase and 
divide. The G2 checkpoint prevents cells from entering mitosis with DNA damage since 
the last division, providing an opportunity for DNA repair and stopping the proliferation 
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of damaged cells. Because the G2 checkpoint helps to maintain genomic stability, it is an 
important focus in understanding the molecular causes of cancer. Mitosis (M phase) is the 
process by which a cell separates its duplicated  genome into two identical halves. It is 
generally followed immediately by cytokinesis which divides the cytoplasm and cell 
membrane. This results in two identical daughter cells with a roughly equal distribution 
of organelles and other cellular components. Mitosis and cytokinesis together is defined 
as the M phase of the cell cycle, the division of the mother cell into two daughter cells, 
each the genetic equivalent of the parent cell. There are two key classes of regulatory 
molecules that determine a cell's progress through the cell cycle: cyclins and cyclin-
dependent kinases (191). The cyclin family members interact with CDKs, and these 
complexes are required to pass through specific phases of the cell cycle. D-type cyclins 
interact with CDK4 and CDK6 and are necessary for G0/G1 transition. Cyclin E binds to 
CDK2 and mediates S phase entry. The cyclin A/CDK2 complex regulates passage 
through the S-phase. Later, in conjunction with CDC 2, cyclin A also induces the G2 
phase of the cell cycle. Cyclin B1 and CDC2 trigger the molecular events associated with 
mitosis (192). Cell cycle pathway upregulation is common in cancers with high 
metastatic rates. Cellular proliferation depends on the rates of both cell division and cell 
death. All tumors have decreased cell death and increased cell proliferation. Genetic 
changes may cause the loss of apoptosis.  This change is a major component of 
tumorigenesis. Many of the gene products that appear to control apoptotic tendencies are 
regulators of cell cycle progression; thus, cell cycle control and cell death appear to be 
tightly linked processes. p53 protein is an example of a gene product which affects both 
cell cycle progression and apoptosis. The ability of p53 overexpression to induce 
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apoptosis may be a major reason why tumor cells frequently disable p53 during the 
transformation process. Unfortunately, the same genetic changes which cause loss of 
apoptosis during tumor development, may also result in tumor cell resistance to anti-
neoplastic therapies which kill tumor cells by apoptosis (46, 58, 68). The upregulation of 
both cyclins and cyclin-dependent kinase genes were observed in the HN cell line. 
Cyclins and cyclin-dependent kinases could be another two groups of genes that are 
responsible for metastasis of OSCC.  
Calcium signaling pathway is another activated pathway in the HN cell line. It has 
been shown that prostate cancer frequently metastasizes to bone. Elevated extracellular 
Ca+2 can enhance proliferation of skeletal metastases (193). Increased Ca+2  signaling 
pathway plays an important role in cancer progression and metastasis (194).  
 The axon guidance pathway is an important process in the development of the 
nervous system. It was shown that semaphorin 4D (Sema4D) protein, which is 
responsible in the development of the central nervous system and regulates axonal 
growth, is highly expressed in cell lines derived from head and neck squamous cell 
carcinomas. Sema4D stimulates endothelial cell migration and angiogenesis (195). A 
similar pattern was observed in malignant cells from prostate, colon, breast, and lung 
cancer tissues (196, 197). Axon guidance was highly upregulated only in the HN cell 
line. This suggests that upregulation of this pathway may occur in advance stages of 
OSCC and may have a role in metastasis of OSCC.  
Based on the downregulated genes in the HN cell lines there were 9 downregulated 
pathways (p<0.05) (Figure 45). These pathways were Hedgehog signaling pathway, 
circadian rhythm, olfactory transduction, Wnt signaling pathway, notch signaling 
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pathway, ECM receptor interaction, insulin signaling pathway, taste transduction, and 
amyotrophic lateral sclerosis. 
The hedgehog signaling pathway was a downregulated pathway in this cell line. 
The Wnt and hedgehog signaling pathways have long been known to direct growth and 
patterning during embryonic development. There are some studies that show the 
activation of the hedgehog signaling pathway in various types of malignancies, however, 
it remains unclear whether this pathway is activated in all cancer types (179). This 
pathway was upregulated in the BHY cell line whereas it was downregulated in the HN 
cell line. Thus, this pathway may be involved in bone invasion but not metastasis. 
Circadian rhythm is a roughly-24-hour cycle in the physiological processes of living 
beings. Jones et al. reported the expression of per-1, which is a circadian rhythm gene, in 
oral dysplasias and OSCC for the first time (198). There was significantly reduced 
expression of per-1 protein in OSCC compared to normal epithelial controls and 
dysplasias based on Jones et al. study (198). Downregulation of this pathway in the HN 
cell line was also a result of this study. Thus, circadian rhythm may play a role in oral 
carcinogenesis. Circadian rhythm is a changeable process during the day. It was proven 
that there is a statistically significant variation in the nuclear expression of all of normal 
oral epithelial cell cycle associated proteins during a day. The time of day for maximum 
p53 expression for normal epithelial cell (late G1 phase) is in the morning. This is 
followed 4 hours later by maximum cyclin E expression (G1/S phase), and 5 hours later 
by maximum cyclin A expression (G2 phase), whereas the maximum expression for 
cyclin B1 (M phase) is 10 hours later in the evening. The importance of this information 
for cancer treatment is the timing of chemotherapy. Several chemotherapic drugs have 
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cell cycle phase dependent effects. The greatest radiosensitivity for cells is in G2 and M 
phases, which occurs in the late afternoon/evening.  Thus, the timing of chemotherapy 
and radiotherapy during the day might be important in terms of the effectiveness of the 
treatment (199). 
Wnt signaling pathway proteins form a family of highly conserved secreted 
signaling molecules that regulate cell-to-cell interactions during embryogenesis. 
Leethanakul et al. found that most head and neck SCC overexpress members of the Wnt 
and notch growth and differentiation regulatory system (200). However, Yeh et al. 
concluded that Wnt pathway related genes play a very limited role in the development of 
OSCC (201). Deregulation of the Wnt pathway has been shown to occur by several 
different mutational mechanisms in human cancers (202). 
The notch signaling pathway is a gene regulatory pathway involved in multiple 
differentiation processes. The notch protein sits like a trigger penetrating the cell 
membrane, with part of it inside and part outside. Proteins when binding to the exterior 
part cause the release of a portion of the interior part, which then makes its way to the 
cell nucleus to alter gene expression. This pathway is a highly conserved pathway for 
cell-cell communication. It is involved in the regulation of cellular differentiation, 
proliferation, and specification. According to a study MAPK in head and neck SCC cells 
triggered notch signaling activation in neighboring endothelial cells and promotes 
angiogenesis (203). The Wnt, TGF-beta, BMP, Notch, and Par polarity pathways are the 
major players in homeostatic control of the adult epithelium. Several hereditary cancer 
syndromes deregulate these same signaling cascades through mutation. It was shown that 
JAGGED1, a NOTCH receptor ligand, is significantly more highly expressed in 
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metastatic prostate cancer as compared with localized prostate cancer or benign prostatic 
tissues (204). However this pathway was downregulated in the HN cell line based on the 
cDNA microarray analysis performed in this study. 
ECM receptor interaction was another downregulated pathway in the HN cell line. 
As explained previously in the BHY cell line, ECM receptor interaction has a role in 
integrins and growth factors signaling process and was downregulated in all three OSCC 
cell lines. No correlations have been found between the formation of OSCC and other 
downregulated pathways, including insulin signaling pathway, taste transduction, and 
amyotrophic lateral sclerosis, in the HN cell line.  
5.3.3.3. HSC-3 cell line 
The 3 upregulated pathways in the HSC-3 cell line (p<0.05) (Figure 47), were 
regulation of actin cytoskeleton, MAPK signaling pathway, and Toll like receptor 
signaling pathway, and were closely related with the invasion and metastatic potential of 
the cancer. The MAPK signaling pathway and regulation of actin cytoskeleton pathway 
was not only upregulated in HSC-3 cell line but also in BHY and HN cell lines as 
described previously. This may mean that the MAPK signaling pathway and regulation of 
actin cytoskeleton pathway are the major pathways related to OSCC invasion and 
metastasis. Toll like receptor signaling pathway was the only pathway that was only 
upregulated in HSC-3 cell line. This pathway is a novel pathway that engages the 
apoptotic machinery (205). Toll-like receptors recognize many pathogens that are 
involved in the induction of anti-cancer immunity. TLR4 signaling, which is a member of 
toll-like receptor, is intimately involved in anti-cancer immunity (206). 
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Six pathways were downregulated in the HSC-3 cell line (p<0.05) (Figure 48). 
These pathways were ECM-receptor interaction, olfactory transduction, taste 
transduction, Huntington’s disease, GAP junction and cell adhesion molecules. The 
ECM-receptor interaction pathway has a role in integrins and growth factors signaling 
process and was downregulated in all three OSCC cell lines. Thus, this pathway could be 
a common pathway that downregulates during the invasion and metastatic process of 
OSCC.      
The gap junction is a junction between certain cell-types that allows different 
molecules and ions to pass freely between cells. The junction connects the cytoplasm of 
adjacent cells. Cell-cell interaction via gap junctions is a key factor in tissue homeostasis 
as they mediate intercellular communication in control of cell growth. Growth rates of 
tumor cells are negatively correlated with strength of intercellular communication. Thus, 
alteration of the gap junction may cause pathology (207). Downregulation of this 
pathway may cause tumor cells to move freely and penetrate into lymph vessels, thus 
causing lymph node metastasis.  
Cell adhesion molecules are proteins located on the cell surface involved with the 
binding with other cells or with the ECM. These molecules have a role in cell division, 
migration, and differentiation. The expression of cell adhesion molecules is normally 
tightly regulated, thereby controlling cell proliferation, mobility, differentiation, and 
survival. Many of these processes are misregulated in malignant tumors, and it has been 
shown that many of the characteristics of tumor cells are attributable to the abnormal 
expression or function of cell adhesion molecules (208). Like the Gap junction pathway 
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inhibition, the inhibition of the cell adhesion molecules might help tumor cells to 
metastasize to lymph nodes.   
No correlation between OSCC and olfactory transduction, taste transduction, and 
Huntington’s disease pathway whatsoever has been found in the literature. Interestingly 
olfactory and taste transductions were downregulated in all the three OSCC cell lines. 
5.3.4. Real Time PCR analysis 
Real Time PCR analysis helps to determine the quantitative differences in mRNA 
expression. This method is the most sensitive method and can discriminate closely related 
mRNAs. Thus, this makes the technique an excellent one to confirm the results of cDNA 
microarray results. The most upregulated three genes from each cell line were chosen to 
run the Real Time PCR. The results of cDNA microarray analysis corelated with Real 
Time PCR results (figure 49), which makes the results of cDNA microarray analysis 
reliable.   
5.4. Recommendations  
The results of this study will help to better understand the invasion and metastatic 
mechanisms of OSCC, however, further studies need to be performed. Studies that will 
focus on the specific pathways that are upregulated and downregulated in these three 
OSCC cell lines may be a part of the future studies. Based on the results of this study the 
pathways that needs to be focused on are cell cycle, Jak-STAT, regulation of actin 
cytoskeleton, MAPK signaling, hedgehog signaling, focal adhesion, Wnt signaling and 
notch signaling pathways. The effect of chemotherapeutic drugs on these pathways may 
be helpful to make a better drug choice in the clinic.  
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This study focused on the gene expression profile of three OSCC cell lines with 
different invasion and metastatic capacities. Another study may be performed by 
investigating the protein expression profile of these cell lines. Thus, invasion and 
metastasis of OSCC can be understood in greater detail and also a better drug target can 
be identified. Proteomics might be an excellent means for such a study.  
The cDNA microarray technique with laser microdissection can also be used in the 
clinic by using patients’ tissue samples. Instead of using cell lines, by using tissue 
samples more accurete gene expression profile of OSCC can be determined. Also, a gene 
data bank can be formed which may assist in determining a better target gene to treat the 
OSCC. In addition to this, it may to find a gene for early diagnosis of OSCC. If a gene 
data bank can be formed, based be possible on the gene expression profile of each patient 
a better assumption can be done about the prognosis of the patients.   
















































Table 1: Normal and pathological processes involving MMPs (21). 
Pathological Normal 
1.Tissue Destruction 
 Rheumatoid arthritis 
Osteoarthritis 
 Cancer invasion 
 Cancer metastasis 
 Ulcer 
 Periodontal diseases 
 
1.Development 
 •Blastocyst implantation 
 •Embryonic development 
 •Nerve growth 
 •Bone growth 
 •Enamel maturation 
 •Primary tooth root resorption 
 
2.Fibrotic Diseases 
 Liver cirrhosis 
 Fibrotic lung diseases 
 Otosclerosis 
 Atherosclerosis 
 Multiple sclerosis 
 
2.Reproduction 
 •Endometrial cycling 
 •Graafian follicle rupture 
 •Cervical dilatation 
 •Postpartum uterine involution 
 •Mammary gland morphogenesis 
 •Mammary gland involution 
 •Rupture of fetal membrane 
 
3.Weakening of Matrix 
 Dilated cardiomyopathy 
 Epidermolysis bullosa 
 Aortic aneurysm 
 
3.Maintenance 
 •Remodeling of bone 
 •Hair follicle cycle 
 •Wound healing 
 •Angiogenesis 
 •Apoptosis 
 •Macrophage function 




















Table 2: Common highly expressed genes in normal oral squamous epithelium (93). 
 
Symbol of gene Description 
GTT1 GTT1 protein 
RPL12 Ribosomal protein L12 
EMP1 Epithelial membrane protein 1 
CSTB Cystatin B (stefin B) 
OCIA Ovarian carcinoma immunoreactive antigen 
PRKWNK1 Protein kinase, lysine deficient 1 
BRF1 Butyrate response factor 1 (EGF-response factor 1) 
UBA2 SUMO-1 activating enzyme subunit 2 
H4FG H4 histone family, membrane G 
ECM1 Extracellular matrix protein 1 
RPS29 Ribosomal protein S29 
TGM3 Transglutaminase 3 (E polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
KIAA0336 K1AA0336 gene product 
FLJ11090 Hypothetical protein FLJ11090 
IK IK cytokine, down-regulator of HLA II 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 
LOC55893 Papillomavirus regulatory factor PRF-1 
FLJ13081 Hypothetical protein FLJ 13081 
IVL Involucrin 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
FLJ10375 Hypothetical protein FLJ 10375 
STAG2 Stromal antigen 2 



















Table 3: Common highly expressed genes in OSCC (93). 
 
Symbol of gene Description 
RPL37A Ribosomal protein L37a 
ACTB Actin, beta 
H3F3A H3 histone, family 3A 
S100A7 S100 calcium-binding protein A7 (psoriasin 1) 
NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 
RPL21 Ribosomal protein L21 
RPS6 Ribosomal protein S6 
GTF2I General transcription factor II 
HMG1 High-mobility group (nonhistone chromosomal) protein 
UCH37 Ubiquitin C- terminal hydrolase UCH37 
LAMR1 Laminin receptor 1 (67 kD, ribosomal protein SA) 
GSTP1 Gluthathione S-transferase pi 
CTNNA1 Catenin (cadherin-associated protein), alpha1 
LOC51142 16.7 Kd protein 
IL4R Interleukin 4 receptor 
FXYD3 FXYD domain-containing ion transport regular 3 
SPRR2A Small protein-rich protein 2A 
ANXA5 Annexin A5 
RPS21 Ribosomal protein S21 
QP-C Low molecular mass ubiquinone-binding protein (9.5 kD) 
RPL4 Ribosomal protein L4 
D6S81E HLA-B associated transcript-1 





















Table 4: 16 genes that are highly upregulated in tongue SCC cases (109). 
 
Gene  Molecular Function Chromosomal Position 
Hypothetical protein  Unknown Chromosomes 19 
IGHM Immune system 14q32.33 
SPONI Extracellular Matrix protein 11p14-p15.2 
PKM2 Catalyses the production of 
phosphoenolpyruvate  
15q22 
IGKC Immune system 2p12 
KIAA0007 Unknown  2p23.2 
C3orf6 Unknown Chromosomes 3 




P4HB Protein disulphide 
isomerase 
17q25 
CALR Calciumstrage, transcription 
co-repressor 
19p13.3-p13.2 
CAPZB Actin Binding 1pG6.1 
Rabla (RAS oncogene 
family) 
RAB small monomeric 
GTPase 
2p14 
RALBPI GTPase activator 1sp11.3 























Table 5: Upregulated and downregulated gene list of 9 OSCC patients (136).  
 
Upregulated Genes Downregulated Genes 
Category Gene Category Gene 
Adhesion CDH3 Apoptosis MAL 
Adhesion TGFB1 Biosynthesis IMPDH2 
Apoptosis FADD Biosynthesis MRPL16 
Apoptosis LGALS1 Biosynthesis RPL15 
Biosynthesis C20orf3 Cell cycle DUSP1 
Cell cycle DKC1 Metabolism ALDH9A1 
Cell cycle SH3BP4 Metabolism DPYSL2 
Growth PLAU Metabolism H11 
Growth TGF Metabolism MGLL 
Metabolism BRS3 Metabolism PAM 
Metabolism FLJ13855 Transcription FOS 
Transcription EN1 Transcription NOTCH1 
Transcription HSF1 Transcription SF1 
Transcription HMGB1 Other GPX3 
Transcription MCM4 Other IK 
Transcription RFX5 Other VAV3 
Transcription TEAD4 Unknown GLTSCR2 
Other ARPC1B Unknown LLGL2 
Other DSS1 Unknown TXNIP 
Other IFI30   
Other NXN   
Unknown CAV1   
Unknown FLJ13031   
Unknown GPCR41   
Unknown LAPTM4B   
Unknown LYRIC   
Unknown MGC2477   












Table 6: Common upregulated genes in head and neck SCC (111). 
 
Upregulated genes name Symbol 
Cadherin 11, type 2, OB-cadherin (osteoblast) CDH11 
Cathepsin L CTSL 
Chemokine (C-X-C motif) ligand 10 CXCL10 
Chemokine (C-X-C motif) ligand 1 (melanoma growthstimulating activity, alpha) CXCL1 
Collagen, type I, alpha 1 COL1A1 
Collagen, type IV, alpha 1 COL4A1 
Collagen, type IV, alpha 2 COL4A2 
Collagen, type V, alpha 2 COL5A2 
Fibronectin 1 FN1 
Integrin, alpha 6 ITGA6 
Integrin, beta 4 ITGB4 
Interferon, alpha-inducible protein (clone IFI-6-16) G1P3 
Interleukin-6 (interferon, beta 2) IL6 
Interleukin-8 IL8 
Matrix metalloproteinase 1 (interstitial collagenase) MMP1 
Matrix metalloproteinase 3 (stromelysin 1, progelatinase) MMP3 
Matrix metalloproteinase 10 (stromelysin 2) MMP10 
Matrix metalloproteinase 12 (macrophage elastase) MMP12 
Microfibrillar-associated protein 2 MFAB2 
Parathyroid hormone-like hormone PTHLH 
Periostin, osteoblast-specific factor POSTN 
Profilin 2 PFN2 
ras homolog gene family, member C RHOC 
Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) RUNX1 
Secreted phosphoprotein 1 (osteopontin, bone sialoproteinI, early T-lymphocyte 
activation 1) 
SPP1 
Secreted protein, acidic, cysteine rich (osteonectin) SPARC 
Serine (or cysteine) proteinase inhibitor, clade E, member 1 SERPINE1
Superoxide dismutase 2, mitochondrial SOD2 
Tenascin C (hexabrachion) TNC 
Thrombospondin 2 THBS2 
Transforming growth factor, beta-induced, 68 kD TGFBI 









Table 7: Common down regulated genes in head and neck SCC (111). 
 
Downregulated genes name Symbol 
Absent in melanoma 1 AIM1 
Actin binding LIM protein 1 ABLIM1 
Aldehyde dehydrogenase 9 family, member A1 ALDH9A1 
Annexin A1 ANXA1 
BENE protein BENE 
Carcinoembryonic antigen-related cell adhesion molecule 1 CEACAM1 
Clusterin CLU 
Creatine kinase, mitochondrial 1 (ubiquitous) CKMT1 
Cyclin G2 CCNG2 
Cystatin B CSTB 
Deoxyribonuclease I-like 3 DNASE1L3
Dual specificity phosphatase 5 DUSP5 
Envoplakin EVPL 
Epithelial membrane protein 1 EMP1 
ECM protein 1 ECM1 
Hydroxyprostaglandin dehydrogenase 15-(NAD) HPGD 
Interleukin-1 receptor antagonist IL1RN 
Keratin 13 KRT13 
Keratin 15 KRT15 
Keratin 4 KRT4 
KIAA0089 protein (GPD1L: glycerol-3-phosphate dehydrogenase 1-like) GPD1L 
Mal, T-cell differentiation protein MAL 
Monoamine oxidase B MAOB 
Monoglyceride lipase MGLL 
Neuromedin U NMU 
Paired-like homeodomain transcription factor 1 PITX1 
Periplakin PPL 
Sciellin SCEL 
Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 SERPINB1 
Serine protease inhibitor, Kazal type 5 SPINK5 
Tetranectin (plasminogen binding protein) TNA 
Transglutaminase 3 (E polypeptide, protein-glutaminegamma-
glutamyltransferase) 
TGM3 








Table 8: List of genes with conflicting expression data in head and neck SCC (111).  





Carcinoembryonic antigen-related cell adhesion molecule 5 5 down, 
1 up 
CEACAM5
Collagen, type I, alpha 2 9 down, 
1 up 
COL1A2 
Cystatin A (stefin A) 6 down, 
1 up 
CSTA 
Dual specificity phosphatase 6 4 down, 
1 up 
DUSP6 
FAT tumor suppressor homolog 1 6 down, 
1 up 
FAT 
Fibroblast activation protein, alpha 4 down, 
1 up 
FAP 





Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen 




Keratin 16 (focal nonepidermolytic palmoplantar keratoderma) 4 down, 
2 up 
KRT16 
Keratin 17 5 down, 
2 up 
KRT17 
Laminin, alpha 3 4 down, 
2 up 
LAMA3 
Laminin, beta 3 5 down, 
1 up 
LAMB3 
Laminin, gamma 2 6 down, 
1 up 
LAMC2 
Lumican 4 down, 
1 up 
LUM 
Plasminogen activator, urokinase 10down, 
1 up 
PLAU 
Tumor necrosis factor, alpha-induced protein 3 5 down, 
1 up 
TNFAIP3 
TYRO3 protein tyrosine kinase 4down, 
1 up 
TYRO3 
v-fos FBJ murine osteosarcoma viral oncogene homolog 3 down, 
2 up 
FOS 











Extracellular matrix 22 COL1A1, COL1A2, COL4A1, COL4A2, COL5A2, ECM1, 
FN1, LAMA3, LAMB3, LAMC2, LUM, MFAP2, 
MMP1, MMP3, MMP10, MMP12, POSTN, SPARC, SPP1, 
TGFB1, THBS2, TNC 
Cell adhesion 20 CDH11, CEACAM1, CEACAM5, FAT, FN1, IL8, ITGA3, 
ITGA6, ITGB1, ITGB4, LAMA3, LAMB3, LAMC2, 
POSTN, SPP1, TGFB1, THBS2, TNC, TPBG, TYRO3 
Integral to 
membrane 
16 BENE, CDH11, CEACAM1, CEACAM5, EMP1, FAP, 
FAT, G1P3, ITGA3, ITGA6, ITGB1, ITGB4, MAL, 




12 COL1A1, EMP1, EVPL, KRT13, KRT15, KRT16, KRT17, 
LAMA3, LAMB3, LAMC2, PTHLH, SCEL, TGM3 
Signal transduction 11 ANXA1, CXCL1, CXCL10, IL6, IL8, LAMA3, MAL, 
NMU, PLAU, RHOC, TYRO3 
Ca2+ binding 10 ANXA1, CDH11, DNASE1L3, FAT, MMP1, MMP3, 
MMP12, SPARC, TGM3, THBS2 
Cytoskeleton 10 ABLIM1, CXCL1, EVPL, KRT4, KRT13, KRT15, KRT16, 
KRT17, PFN2, PPL 
Cell growth and 
proliferation 
9 CXCL1, CXCL10, EMP1, IL6, IL8, KRT16, MYC, PTHLH, 
TGFB1 
Inflammation 9 ANXA1, CXCL1, CXCL10, FOS, IL1RN, IL8, MGLL, 
SPINK5, SPP1 
Zn2+ binding 9 ABLIM1, MMP1, MMP3, MMP10, MMP12, RUNX1, 
SCEL, TNFAIP3, ZNF185 
Cell 
motility/chemotaxis 
8 ANXA1, CXCL1, CXCL10, IL8, MMP12, PLAU, SPP1, 
TPBG 
Proteolysis 7 CTSL, FAP, MMP1, MMP3, MMP10, MMP12, PLAU 
Basement membrane 6 COL4A1, COL4A2, LAMA3, LAMB3, LAMC2, SPARC 
DNA binding 6 DNASE1L3, FOS, MYC, PITX1, RUNX1, TNFAIP3 
Skeletal 
development 
6 CDH11, COL1A1, COL1A2, PITX1, POSTN, TNA 
Transcriptional 
regulation  
6 FOS, MYC, PITX1, RUNX1, SOD2, TNFAIP3 
 






Table 10: List of proteins with increased and decreased expressions in OSCC (131).  
 
Proteins with increased expression Proteins with decreased expression 
     1- Cofilin 
     2- C-reactive protein 
     3- Creatine kinase, M-chain 
     4- Cytokeratin 6B 
     5- Fatty acid-binding protein 
     6- Galectin-7 
     7- Glutathione-S-transferase 
     8- HSP27 
     9- Keratin type II 
    10- NME1 
    11- Phosphoglucerate mutase 1  
    12- Pyruvate kinase M1 
    13- Retinoic acid-binding protein II 
    14- SCCA-1 
 
1- Annexin 1 (ANXA1) 
2- Heat shock 20 kDa like protein p20 
3- Myosin light chain 1 
4- Myosin light chain 2 
5- Myosin light chain 3 
6- Plakoglobin 
 
Table 11: The expression levels of proteolytic enzymes by using immunocytochemistry. 
 
OSCC Cell Lines 
Proteolytic Enzymes BHY HN HSC-3 
MMP-1 +++ +++ +++ 
MMP-2 +++ ++++ ++++ 
MMP-3 +++ +++ ++++ 
MMP-9 +++ ++ - 
EMMPRIN ++++ +++ +++ 
Cathepsin B ++++ ++++ ++++ 













 (-) Shows the same intensity in tumor cells as normal epithelium cells; (+) less than 10% 
stronger intensity in tumor cells than normal epithelium cells; (++) between 10% to 50% 
stronger intensity in tumor cells than normal epithelium cells; (+++) between 50% to 
90% stronger intensity in tumor cells than normal epithelium cells; (++++) more than 
90% stronger intensity in tumor cells than normal epithelium cells. 
 118
Table 12: The expression levels of proteolytic enzymes in three different OSCC cell lines 
by using flow cytometry. 
 
 OSCC Cell Lines 
Proteolytic Enzymes HNEC BHY HN HSC-3 
MMP-1 97% + 99.8% + 99.9% + 99.9% + 
MMP-2 98.8% + 99.1% + 99.6% + 99.9% + 
MMP-3 98.4% + 99.9% + 99.8% + 99.9% + 
MMP-9 0.5 % +  33.3% + 18.6% + 0.05% + 
EMMPRIN 70.1% + 85.8% + 67.5% + 73.4% + 












































Table 13: 139 upregulated genes in BHY cell line. The gene list is from the most 
upregulated gene to least upregulated gene.  
Name of the upregulated gene 
in BHY cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H300004818_MAGEA9 2.9835 0.740776 0.248291 4 7.909026
H200001373_Q96AL8_HUMAN 2.9755 0.472755 0.158883 4 7.86529
H200005842_GFI1 2.75875 0.799114 0.289665 4 6.768096
opHsV0400005829_OAS1 2.6725 0.637914 0.238695 4 6.37533
H200007111_NP_689700.1 2.60575 0.633773 0.243221 4 6.087079
H200005801_MAGEA1 2.55525 0.884437 0.346125 4 5.877693
opHsV0400002611_PRAME 2.5525 0.286732 0.112334 4 5.8665
opHsV0400006088_NOV 2.5515 1.062371 0.416371 4 5.862435
H200011702_HOXA10 2.54125 0.590219 0.232255 4 5.820931
H200012712_BIRC3 2.3735 0.457046 0.192562 4 5.181968
H200004378_MAGEA8 2.36275 1.281263 0.542276 4 5.143499
H200000112_DLX2 2.354 0.63516 0.269822 4 5.112397
H200003290_DEPDC1B 2.3485 0.45264 0.192736 4 5.092945
H200000421_DPYD 2.30175 0.37118 0.16126 4 4.930555
H200000404_IRK2_HUMAN 2.298 0.313003 0.136207 4 4.917755
opHsV0400006060_ 2.2975 0.500092 0.217668 4 4.916051
H200011805_NMES1_HUMAN 2.2625 0.600718 0.265511 4 4.798222
H300010220_ID2 2.253 0.213936 0.094956 4 4.76673
H200005149_NP_116262.2 2.2435 0.25993 0.115859 4 4.735445
H200006112_NP_006811.1 2.21625 0.780182 0.352028 4 4.64684
opHsV0400002553_MAGEA11 2.20675 0.859448 0.389463 4 4.616342
H200010620_IL6 2.1545 0.45013 0.208925 4 4.452143
H200013568_COL5A1 2.13175 0.640914 0.300651 4 4.382488
H200015644_GDA 2.114 0.824693 0.39011 4 4.328899
opHsV0400011773_ 2.09725 0.642212 0.306216 4 4.27893
H200008768_FGF2 2.096 0.885641 0.422539 4 4.275224
opHsV0400000818_IL8 2.09075 0.32249 0.154246 4 4.259695
opHsV0400008521_ 2.0825 0.909608 0.436787 4 4.235405
H300018275_NP_620711.2 2.07625 0.734066 0.353554 4 4.217096
H200004597_XM_374020.2 2.0475 0.611487 0.298651 4 4.13389
opHsV0400006084_MAGEB2 2.033 0.494992 0.243478 4 4.09255
H300009117_OSR2 2.01225 0.586449 0.291439 4 4.034109
H200008845_STMN3 2.0065 0.517001 0.257663 4 4.018062
H200011948_EREG 2.0015 0.586814 0.293187 4 4.004161
opHsV0400006083_MAGEA4 1.9765 0.681241 0.344671 4 3.935372
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Table 13 continued 
Name of the upregulated gene in 
BHY cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200010289_C6orf139 1.97175 0.330586 0.167661 4 3.922436
H300000884_ 1.96425 0.607126 0.309088 4 3.902098
H300006722_NP_003513.1 1.96325 0.456425 0.232484 4 3.899394
H300021964_SLCO1B3 1.93075 0.370317 0.1918 4 3.812533
H200005669_LY96 1.922 0.493631 0.256832 4 3.78948
H200012463_MAGEC2 1.917 0.726043 0.378739 4 3.77637
H300006646_ZNF326 1.90925 0.249361 0.130607 4 3.756138
H200000708_MMP13 1.908 0.726138 0.380576 4 3.752885
H200006097_ID1 1.901 0.40408 0.212562 4 3.73472
H200002977_NP_065726.1 1.88775 0.296147 0.156878 4 3.700576
H300020557_GLMN 1.88725 0.507303 0.268805 4 3.699294
opHsV0400007188_ 1.8805 1.083741 0.576304 4 3.682026
H200016568_CLDN14 1.8765 0.718913 0.383114 4 3.671832
H300008891_IFIT1 1.8465 0.7824 0.423721 4 3.596267
H200011533_KLF2 1.846 0.510175 0.276368 4 3.595021
H200006581_XK 1.84475 0.958007 0.519315 4 3.591907
H200017806_TDRD7 1.8415 0.569578 0.309301 4 3.583825
H200003668_HERC5 1.83375 0.526164 0.286933 4 3.564624
H300006703_LY6K 1.8335 0.639148 0.348595 4 3.564007
H300009194_ABHD7 1.8225 0.878164 0.481846 4 3.536936
H300002344_NP_777601.2 1.8175 0.603638 0.332126 4 3.524699
opHsV0400003040_LCK 1.81625 1.093485 0.602056 4 3.521646
H300018519_IRF7 1.7895 0.259885 0.145228 4 3.456951
H300015308_ 1.786 0.648679 0.363202 4 3.448574
H300009179_MAGEA9 1.77325 0.761064 0.429192 4 3.418231
H200005573_CALB1 1.765 1.087427 0.616106 4 3.39874
opHsV0400008078_ 1.7645 0.641701 0.363673 4 3.397562
H200006891_NR4A2 1.73525 0.893226 0.514754 4 3.329372
H200004856_BAL_HUMAN 1.732 0.407424 0.235233 4 3.32188
opHsV0400011488_ 1.729 0.991203 0.573281 4 3.31498
H200005324_FYB 1.72525 0.471569 0.273334 4 3.306374
H200001951_LAMP3 1.7175 0.474952 0.276537 4 3.28866
H200007266_LHX1 1.7165 0.637868 0.371609 4 3.286382
opHsV0400001371_PTE2B_HUMAN 1.7125 0.549354 0.320791 4 3.277282
H200002223_TXNRD1 1.70925 0.277703 0.162471 4 3.269908
H200014971_HELLS 1.70325 0.459937 0.270035 4 3.256337
H200006072_RRM2 1.70275 0.284603 0.167143 4 3.255209
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Table 13 continued 
Name of the upregulated gene in 
BHY cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200005594_CC14A_HUMAN 1.7 0.761705 0.448062 4 3.24901
H300013260_DPYD 1.7 0.677127 0.39831 4 3.24901
H300015190_BIRC3 1.6985 1.104304 0.650165 4 3.245633
H200004706_FOXF2 1.6945 0.947529 0.559179 4 3.236647
H200006824_FZD2 1.6905 0.503315 0.297731 4 3.227685
opHsV0400007038_ 1.68775 0.459065 0.271998 4 3.221539
H200008051_ANKRD10 1.68475 0.396982 0.235633 4 3.214847
H300019089_NP_060408.2 1.68 0.448588 0.267017 4 3.20428
opHsV0400003583_BRI3BP 1.67925 0.488002 0.290607 4 3.202614
H300007499_HRASLS3 1.66875 0.61295 0.367311 4 3.17939
H200017104_NP_001007528.1 1.6475 0.402604 0.244372 4 3.132903
H300000210_IFIT2 1.64375 0.614255 0.373691 4 3.12477
opHsV0400002734_NP_848664.1 1.641 0.426324 0.259795 4 3.118819
opHsV0400003034_KLK10 1.63875 0.462452 0.282198 4 3.113959
H200013657_NP_076942.1 1.634 0.45373 0.277681 4 3.103723
H200015606_IL7R 1.62775 0.323239 0.19858 4 3.090307
H200020534_TRIM6 1.61625 0.286686 0.177377 4 3.065771
opHsV0400010212_ 1.61425 0.797001 0.493728 4 3.061524
H200017773_GTPBP1 1.6135 0.556646 0.344993 4 3.059933
H300013986_PSG10 1.613 0.520234 0.322525 3 3.058873
H300018167_AMID 1.6125 0.512751 0.317985 4 3.057813
H300021783_NP_149081.1 1.60925 0.356157 0.221318 4 3.050932
H200005813_IL7 1.59975 0.409299 0.255852 4 3.030908
opHsV0400003905_IL7R 1.597 0.760413 0.476151 4 3.025136
H200004431_MLF1IP 1.58425 0.551219 0.347937 4 2.998519
opHsV0400000049_XP_291989.3 1.58175 0.30548 0.193128 4 2.993327
H200007026_GBG11_HUMAN 1.579 0.385193 0.243948 4 2.987627
H200000576_MMP10 1.578 0.272033 0.172391 4 2.985557
opHsV0400013002_ 1.57575 0.443983 0.28176 4 2.980904
H300018946_DR1 1.56675 0.381593 0.243557 4 2.962366
H300022249_GP110_HUMAN 1.56 0.391751 0.251122 4 2.948538
H200007011_MMP1 1.534 0.649902 0.423665 4 2.895876
opHsV0400010717_ 1.53275 0.676085 0.441093 4 2.893368
opHsV0400007760_ 1.532 0.597638 0.390103 4 2.891865
H200013536_C20orf29 1.521 0.718596 0.47245 4 2.869899
H200013521_DDX58 1.513 0.858988 0.567738 4 2.854029
H200007019_MMP3 1.5075 0.368524 0.24446 4 2.843169
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Table 13 continued 
Name of the upregulated gene in 
BHY cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H300001749_AQP11 1.50725 0.380475 0.25243 4 2.842677
H300016431_CT022_HUMAN 1.504 0.343714 0.228533 4 2.83628
H300009288_NP_653185.1 1.5 0.611704 0.407803 4 2.828427
H300002737_GBP4 1.497 0.772955 0.516336 4 2.822552
H200020305_PARP10 1.492 0.318087 0.213195 4 2.812786
opHsV0400005063_ 1.49025 0.467101 0.313438 4 2.809377
opHsV0400005091_ACYP1 1.489 0.505898 0.339757 4 2.806943
H200008827_NP_982274.1 1.48725 0.498681 0.335304 4 2.803541
H200005110_SULT1E1 1.4835 1.056875 0.71242 4 2.796263
H300007730_MAGEA6 1.48175 0.313321 0.211454 4 2.792873
H300008499_IRF1 1.4795 0.368059 0.248773 4 2.788521
H300015276_Q96H22_HUMAN 1.4765 0.432985 0.293251 4 2.782728
H200004209_RAMP1 1.4745 0.362929 0.246137 4 2.778873
H200006368_OCTN1_HUMAN 1.47375 0.659172 0.447275 4 2.777429
H300018045_PRIM1 1.47375 0.120801 0.081969 4 2.777429
opHsV0400009665_ 1.4735 0.544974 0.36985 4 2.776948
H300013149_CDKN3 1.46925 0.718136 0.488777 4 2.768779
H300021781_CENPA 1.46525 0.37843 0.25827 4 2.761113
H200003417_RAD51AP1 1.46175 0.479901 0.328306 4 2.754423
H300000747_ 1.4615 0.462733 0.316615 4 2.753945
H200005018_GATA6 1.45775 0.375212 0.257391 4 2.746796
opHsV0400008467_ 1.453 1.443222 0.99327 3 2.737768
opHsV0400007148_ 1.451 0.798016 0.549977 4 2.733975
opHsV0400000522_NP_689663.1 1.4505 0.945205 0.651641 4 2.733028
H200011351_AIM2 1.44825 0.49706 0.343214 4 2.728768
H300008871_NP_001008708.1 1.447 0.398061 0.275094 4 2.726405
H300019216_SPAG1 1.44525 0.81659 0.565016 4 2.7231
H200007081_SLCO2A1 1.44425 1.022917 0.708268 4 2.721213
opHsV0400003953_HIST1H1C 1.43925 0.426934 0.296637 4 2.711799










Table 14: 117 downregulated genes in BHY cell line. The gene list is from the least 
downregulated gene to most downregulated gene.  
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H300000194_CSPG2 -1.5935 0.414519 -0.26013 4 0.331367
H200001115_ZNF25 -1.60125 1.06914 -0.66769 4 0.329591
opHsV0400000079Q6NZ63_HUMAN -1.60525 1.161 -0.72325 4 0.328679
H200005961_DPYSL3 -1.60625 1.348248 -0.83938 4 0.328451
H300012616_ANPEP -1.6075 1.109451 -0.69017 4 0.328167
H200005275_KLK11 -1.60875 0.747015 -0.46434 4 0.327882
H200002000_RHBDL2 -1.60875 0.80247 -0.49882 4 0.327882
H300013882_AES -1.6105 0.222317 -0.13804 4 0.327485
H300017884_SLC37A2 -1.6105 0.830395 -0.51561 4 0.327485
H300000561_CBS -1.611 0.79006 -0.49042 4 0.327371
opHsV0400003752_ -1.61333 1.595829 -0.98915 3 0.326842
opHsV0400008056_ -1.61425 1.405615 -0.87075 4 0.326635
H300009655_ -1.62125 0.757105 -0.46699 4 0.325054
H200019593_ZNF626 -1.62825 1.358063 -0.83406 4 0.32348
H300002980_ -1.63125 0.475368 -0.29141 4 0.322808
H300005674_Q8IZ15_HUMAN -1.63375 0.569106 -0.34834 4 0.322249
opHsV0400012118_ -1.63425 0.388394 -0.23766 4 0.322138
H200017197_HSD11B1 -1.63925 0.945894 -0.57703 4 0.321023
H300013100_SLC4A3 -1.64067 1.063076 -0.64795 3 0.320708
H200012598_LRRN1_HUMAN -1.64725 1.302948 -0.79098 4 0.319248
H200010619_CNGB1 -1.65375 1.394051 -0.84296 4 0.317813
opHsV0400000628_ARTS1_HUMAN -1.655 1.123805 -0.67904 4 0.317538
opHsV0400010774_ -1.65525 0.921909 -0.55696 4 0.317483
H300006889_XP_059037.4 -1.65725 0.827554 -0.49935 4 0.317043
opHsV0400001923_IDH2 -1.66275 0.145039 -0.08723 4 0.315837
H200003299_SLC16A4 -1.6675 0.557852 -0.33454 4 0.314798
H300018412_MGST1 -1.67525 0.171506 -0.10238 4 0.313112
H200006867_SHC1 -1.67525 0.206479 -0.12325 4 0.313112
H200009585_NP_001007190.1 -1.68125 0.641676 -0.38167 4 0.311812
H200006995_ -1.69275 0.925138 -0.54653 4 0.309337
H200013065_ -1.6945 0.3687 -0.21759 4 0.308962
opHsV0400002007_NM_000407.3 -1.69925 0.446025 -0.26248 4 0.307946
H200004912_GJB6 -1.70075 0.667052 -0.39221 4 0.307626
H200011169_TCF7L1 -1.7025 0.381282 -0.22395 4 0.307253
H200001141_EFEMP2 -1.71625 0.77124 -0.44938 4 0.304339
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Table 14 continued 
Name of the downregulated gene in 
BHY cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200012556_THY1 -1.718 0.763368 -0.44434 4 0.30397
H200007876_SLC2A1 -1.73925 0.295673 -0.17 4 0.299525
opHsV0400011936_ -1.7445 1.036602 -0.59421 4 0.298437
H200011421_CDKN1C -1.762 1.210316 -0.6869 4 0.294839
opHsV0400007762_ -1.76267 1.587394 -0.90056 3 0.294703
H200005983_Q6PJ56_HUMAN -1.7635 0.973849 -0.55223 4 0.294533
H300009738_Q14922_HUMAN -1.76775 1.295378 -0.73278 4 0.293666
opHsV0400003654_NP_001004313.1 -1.76925 1.763672 -0.99685 4 0.293361
H200015626_RRAGD -1.78425 1.706914 -0.95666 4 0.290327
H200013543_Q96MI4_HUMAN -1.7895 1.351199 -0.75507 4 0.289272
H200001865_TNS -1.79925 1.745972 -0.97039 4 0.287324
opHsV0400002303_NDN -1.818 0.954687 -0.52513 4 0.283614
opHsV0400002365_PTPRM -1.82 0.215937 -0.11865 4 0.283221
H200013711_BTEB1_HUMAN -1.82125 0.492802 -0.27058 4 0.282976
H300008702_ITGB6 -1.8265 0.969306 -0.53069 4 0.281948
H200000104_ADH7 -1.8265 1.742103 -0.95379 4 0.281948
H200008152_ODZ2 -1.8325 0.203169 -0.11087 4 0.280778
H200004216_PLXDC2 -1.84025 0.7515 -0.40837 4 0.279273
H300014602_IL1R1 -1.8415 1.208037 -0.65601 4 0.279032
H200014313_BEXL1 -1.86125 0.515799 -0.27712 4 0.275238
H200015831_THAP2_HUMAN -1.86175 1.36207 -0.73161 4 0.275142
H200000465_CD1D -1.862 1.781241 -0.95663 4 0.275095
H200003796_FNDC4 -1.865 0.738472 -0.39596 4 0.274523
H200004211_COBL -1.871 1.174565 -0.62777 4 0.273384
opHsV0400006329_PALMD -1.8845 1.320225 -0.70057 4 0.270838
H200009642_ITGAV -1.88625 0.352733 -0.187 4 0.270509
H200000047_IGFBP2 -1.89925 0.382519 -0.20141 4 0.268083
H200013755_KLK7 -1.90075 0.692081 -0.36411 4 0.267804
H200011925_COL8A1 -1.90625 0.820488 -0.43042 4 0.266785
H200005569_LIPG -1.90825 0.367554 -0.19261 4 0.266416
opHsV0400005248_FAM46B -1.91225 0.347777 -0.18187 4 0.265678
H200000073_GALC -1.913 0.965822 -0.50487 4 0.26554
H300000923_POSTN -1.91725 0.686764 -0.3582 4 0.264759
opHsV0400012721_ -1.92225 0.923278 -0.48031 4 0.263843
H200005130_ -1.928 1.441162 -0.74749 4 0.262793
H200005198_GALNT5 -1.93175 1.069411 -0.5536 4 0.262111
opHsV0400012479_ -1.941 1.744599 -0.89881 4 0.260436
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Table 14 continued 
Name of the downregulated gene in 
BHY cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200008006_SEMA3C -1.948 0.383193 -0.19671 4 0.259175
H200012177_RAB4A -1.992 0.911509 -0.45758 4 0.25139
opHsV0400006127_TNFRSF6B -2.00025 0.446626 -0.22329 4 0.249957
H200000491_PRG1 -2.001 0.48489 -0.24232 4 0.249827
opHsV0400006528_ -2.00375 1.463535 -0.7304 4 0.249351
H300003568_CPS1 -2.016 1.306051 -0.64784 4 0.247243
H200004031_NP_945120.1 -2.022 0.617709 -0.30549 4 0.246217
H200001783_PLEA4_HUMAN -2.061 0.715854 -0.34733 4 0.23965
opHsV0400011552_ -2.0615 0.559359 -0.27134 4 0.239567
H200016573_ADPN -2.08425 0.67585 -0.32427 4 0.235819
opHsV0400003414_GSPT2 -2.097 1.624817 -0.77483 4 0.233744
H200001094_NP_057702.1 -2.1075 0.738391 -0.35036 4 0.232049
H300021562_FN1 -2.1185 0.873318 -0.41223 4 0.230286
opHsV0400010233_ -2.1275 1.897333 -0.89181 4 0.228854
opHsV0400011241_ -2.13425 1.663044 -0.77922 4 0.227786
H300006196_MAF -2.13725 0.559296 -0.26169 4 0.227313
H200020242_C9orf26 -2.151 0.471467 -0.21918 4 0.225156
H200013413_LRP3 -2.151 0.63614 -0.29574 4 0.225156
H200011379_NPDC1 -2.17125 0.710231 -0.32711 4 0.222018
H300006645_Q8IYY5_HUMAN -2.18875 0.303208 -0.13853 4 0.219341
H300010137_CALML3 -2.208 0.427549 -0.19364 4 0.216434
H300006447_MT1K -2.23625 1.764254 -0.78893 4 0.212237
H200001726_KRT23 -2.26975 0.479364 -0.2112 4 0.207366
H200009653_RAB4A -2.2805 0.739566 -0.3243 4 0.205826
H300016644_WASPIP -2.2925 1.087845 -0.47452 4 0.204121
H300018293_SLC38A5 -2.29475 0.431198 -0.18791 4 0.203803
H200001823_ARMCX1 -2.299 0.708874 -0.30834 4 0.203204
H200011330_RKHD3 -2.3195 1.852087 -0.79849 4 0.200337
H300021749_FOLR3 -2.33525 0.541148 -0.23173 4 0.198162
H200001408_SFRP1 -2.35767 0.264814 -0.11232 3 0.195106
H300021145_ANGPTL4 -2.3915 0.448694 -0.18762 4 0.190584
H200016276_ESPN -2.4205 1.3472 -0.55658 4 0.186791
H300016617_THY1 -2.42475 1.65256 -0.68154 4 0.186242
H200018944_KLF8 -2.425 0.698834 -0.28818 4 0.18621
H200005423_Q9H7B6_HUMAN -2.43525 1.371003 -0.56298 4 0.184891
H200001686_TM4SF10 -2.5915 1.26025 -0.4863 4 0.165913
H200004832_C3orf14 -2.64375 1.162073 -0.43955 4 0.160012
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Table 14 continued 
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H200011635_LXN -2.689 1.396491 -0.51933 4 0.155071
opHsV0400010653_ -2.73375 1.220994 -0.44664 4 0.150335
H200005947_GJA1 -2.948 0.575297 -0.19515 4 0.129588
H200017869_ -2.99633 2.483282 -0.82877 3 0.125318
H200014307_FADS2 -3.02275 0.370271 -0.12249 4 0.123044
H300017162_Q9H7B6_HUMAN -3.079 0.937163 -0.30437 4 0.118339
opHsV0400010227_Q96NA9HUMAN -3.3075 0.735836 -0.22248 4 0.101005


































Table 15: 214 upregulated genes in HN cell line. The gene list is from the most 
upregulated gene to least upregulated gene. 
Name of the upregulated gene 
in HN cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200011805_NMES1_HUMAN 3.61425 0.344629 0.095353 4 12.2461
H200005801_MAGEA1 3.4955 0.938984 0.268627 4 11.27847
H200001373_Q96AL8_HUMAN 3.39425 0.559974 0.164977 4 10.51407
opHsV0400013404_ 3.1775 0.278336 0.087596 4 9.04738
H200004165_FSTL5 2.96775 0.964376 0.324952 4 7.823152
opHsV0400005829_OAS1 2.86425 0.337914 0.117976 4 7.281572
H200010620_IL6 2.84925 0.652263 0.228924 4 7.206256
H200010289_C6orf139 2.83925 0.44019 0.155037 4 7.156479
H300005969_COX7B2 2.744 1.244172 0.453416 4 6.699252
opHsV0400002611_PRAME 2.72925 0.998202 0.365742 4 6.631108
H300006342_NP_775969.1 2.69225 0.843384 0.313264 4 6.463206
H200010916_NP_114156.1 2.59475 0.43994 0.16955 4 6.040843
H200012712_BIRC3 2.52475 0.986658 0.390795 4 5.754737
H300006447_MT1K 2.503 0.519416 0.207517 4 5.66863
H200007081_SLCO2A1 2.49425 1.343249 0.538538 4 5.634353
H200002977_NP_065726.1 2.46325 0.945773 0.383953 4 5.514576
H200004279_ID4 2.42325 0.553582 0.228446 4 5.36378
H200008845_STMN3 2.3605 0.871202 0.369075 4 5.135483
H300022894_NP_002116.2 2.34725 0.319804 0.136246 4 5.088534
opHsV0400000818_IL8 2.341 1.005232 0.429403 3 5.066537
H200011575_BSPRY 2.33875 1.31912 0.564028 4 5.058641
H300022533_HLA-J 2.312 0.155681 0.067336 4 4.96571
opHsV0400003040_LCK 2.278 1.654258 0.726189 4 4.850051
H200001951_LAMP3 2.26225 0.660399 0.291921 4 4.797391
H200010376_CYP24A1 2.2595 0.469224 0.207667 4 4.788255
H200017806_TDRD7 2.24575 0.4908 0.218546 4 4.742836
H200015633_SLC16A9 2.2445 0.649934 0.289567 4 4.738728
H300000210_IFIT2 2.2225 0.6966 0.313431 4 4.667015
H200003668_HERC5 2.205 0.464972 0.210872 4 4.610745
H200006478_ACTH_HUMAN 2.1895 0.428789 0.195839 4 4.561474
H300006703_LY6K 2.18225 0.368532 0.168877 4 4.538608
H200006112_NP_006811.1 2.17775 0.582087 0.267288 4 4.524474
H200011702_HOXA10 2.155 1.423344 0.660485 4 4.453686
H200005362_NP_115724.1 2.13875 1.128071 0.527444 4 4.403803
H200000708_MMP13 2.135 1.48257 0.694412 4 4.392371
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Table 15 continued 
Name of the upregulated gene in 
HN cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
opHsV0400003753_PLSCR1 2.128 0.567288 0.266583 4 4.371111
opHsV0400006084_MAGEB2 2.12175 1.118117 0.526979 4 4.352216
H300016329_MMP25 2.12 0.43629 0.205797 4 4.346939
H200013521_DDX58 2.1155 0.525671 0.248485 4 4.333402
H200011983_Q9BT26_HUMAN 2.11175 0.947054 0.448469 4 4.322153
H200006368_OCTN1_HUMAN 2.0795 0.933586 0.448947 4 4.226607
H300022436_HLA-DRB3 2.07225 0.396335 0.191258 4 4.20542
opHsV0400012005_ 2.06625 1.134699 0.549159 4 4.187967
opHsV0400008956_ 2.06575 0.416258 0.201505 4 4.186516
H200006072_RRM2 2.059 0.43027 0.208971 4 4.166974
H200001243_TRHDE_HUMAN 2.05475 1.08619 0.528624 4 4.154716
H300008891_IFIT1 2.05375 0.571091 0.278072 4 4.151838
H300001406_CNN1 2.04075 0.963906 0.472329 4 4.114594
H300001612_PCOLCE2 2.038 0.648625 0.318265 4 4.106758
opHsV0400008211_XM_375042.2 2.02375 1.433107 0.708144 4 4.066394
opHsV0400006097_PTPRR 2.00625 1.242772 0.61945 4 4.017366
H300018045_PRIM1 2.002667 0.267808 0.133726 3 4.0074
H300001976_NMI 1.99775 0.512455 0.256516 4 3.993767
H200014971_HELLS 1.992 0.413372 0.207516 4 3.977881
H300018428_BID 1.981 0.522077 0.263542 4 3.947666
H200011914_CDC45L 1.961 0.197314 0.100619 4 3.893317
H200010772_GPR160 1.95375 1.3282 0.679821 4 3.873801
H200004597_XM_374020.2 1.95175 0.752455 0.385528 4 3.868435
opHsV0400006060_ 1.9475 0.915296 0.469985 4 3.857056
H200007582_CXCL6 1.943 0.714921 0.367947 4 3.845044
H300010511_SOD2 1.943 0.611604 0.314773 4 3.845044
opHsV0400003953_HIST1H1C 1.939 0.293976 0.151612 4 3.834398
H200014073_MCM6 1.93275 0.407792 0.210991 4 3.817822
H300010084_FBXO27 1.928 0.424222 0.220032 3 3.805273
H200015506_CDCA1 1.927 0.807785 0.419193 4 3.802636
H300007731_ 1.924 0.499857 0.259801 4 3.794737
H300012772_C10orf94 1.91325 1.093819 0.571708 4 3.766566
opHsV0400011941_ 1.896 0.817471 0.431156 4 3.721799
opHsV0400012784_ 1.8955 0.275088 0.145127 4 3.720509
H300001248_PROM1 1.8955 1.149884 0.606639 4 3.720509
H200005842_GFI1 1.8945 1.099902 0.580576 4 3.717931
H200011351_AIM2 1.887 0.542437 0.28746 4 3.698653
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Table 15 continued 
Name of the upregulated gene in 
HN cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H300006205_S100P 1.88575 0.585973 0.310737 4 3.69545
H200016569_PCDHB2 1.884 0.913877 0.485073 4 3.69097
H200012959_ 1.88175 0.65093 0.345918 4 3.685218
H200000046_CDH2 1.877 1.130349 0.60221 4 3.673105
H200004431_MLF1IP 1.86075 0.273527 0.146998 4 3.631964
opHsV0400006094_HHEX 1.85425 0.975674 0.526183 4 3.615637
opHsV0400006196_ 1.849333 0.678552 0.366917 3 3.603336
H300009187_PSMB9 1.84125 0.322845 0.17534 4 3.583204
H200004856_BAL_HUMAN 1.83875 0.337235 0.183405 4 3.577
H300001485_HLA-DPA1 1.833 0.716288 0.390773 4 3.562772
opHsV0400003771_HB2K_HUMAN 1.82175 0.347382 0.190686 4 3.535097
H200006657_MEST 1.81925 0.457504 0.251479 4 3.528977
H200015731_CCL5 1.79575 0.493276 0.274691 4 3.471959
H300019551_UGCGL2 1.79525 0.490762 0.273367 4 3.470756
H200006581_XK 1.79175 1.672909 0.933673 4 3.462346
H300009288_NP_653185.1 1.7885 0.303107 0.169475 4 3.454555
H300022475_CRYZL1 1.78575 0.435806 0.244047 4 3.447977
H200010475_PFDN4 1.78425 0.368762 0.206676 4 3.444394
H200018923_SOD2 1.7835 0.363238 0.203666 4 3.442603
H300021066_Q96H22_HUMAN 1.7805 0.407449 0.22884 4 3.435452
H200020305_PARP10 1.78 0.568335 0.319289 4 3.434262
H300002968_SYT14 1.77975 1.597834 0.897786 4 3.433667
H200013760_KIAA1524 1.77825 0.540236 0.303802 4 3.430098
H300018167_AMID 1.777 0.953326 0.53648 4 3.427128
H200010704_CPVL 1.77575 0.52984 0.298376 4 3.42416
H200000491_PRG1 1.76525 0.284848 0.161364 4 3.399329
H300007730_MAGEA6 1.76425 1.020558 0.578466 4 3.396974
H200014902_Q96RF1_HUMAN 1.764 1.100442 0.623833 3 3.396385
H300011169_GPR160 1.75625 1.453927 0.827859 4 3.378189
opHsV0400003583_BRI3BP 1.751 0.992618 0.566887 4 3.365918
H200004874_HS3ST3A1 1.74225 0.75636 0.434128 4 3.345565
H200008652_ICMT 1.73875 0.232372 0.133643 4 3.337459
H200017455_NP_060582.1 1.73075 0.5441 0.314372 4 3.319003
H200005223_NP_996794.1 1.72925 0.510066 0.294963 4 3.315554
H200016778_FBXO5 1.729 0.526669 0.304609 4 3.31498
H300020866_Q7Z545_HUMAN 1.728 0.976577 0.565149 4 3.312683
H200000405_DCLRE1A 1.72375 0.645755 0.374622 4 3.302938
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Table 15 continued 
Name of the upregulated gene in HN




4 slides STD CV 
Count of 
slides  Ratio 
H200001011_NP_054895.1 1.71825 0.833375 0.485014 4 3.29037
H200002434_QKI 1.7125 0.643398 0.375707 4 3.277282
H200002164_ZC3HDC1 1.71025 0.301587 0.176341 4 3.272175
H300001924_ATAD2 1.70625 0.622159 0.364635 4 3.263115
H200019857_NCOA7 1.69975 0.495825 0.291705 4 3.248447
opHsV0400004769Q9NT91_HUMAN 1.6965 0.531851 0.313499 4 3.241137
H300002301_HES4 1.68925 0.313784 0.185753 4 3.22489
H200000203_ 1.686 0.146806 0.087074 4 3.217633
opHsV0400001953_XP_495896.1 1.683333 1.325827 0.78762 3 3.211692
H300015276_Q96H22_HUMAN 1.67325 0.295831 0.176801 4 3.189323
H200012301_TRIM36 1.672 0.745459 0.445849 4 3.18656
H200011999_OIP5 1.66975 0.565244 0.33852 4 3.181595
H200011533_KLF2 1.6645 0.628264 0.377449 4 3.170038
H200008556_IFIT3 1.65625 0.746136 0.450497 4 3.151962
opHsV0400000541_TMED4 1.65525 0.339298 0.204983 4 3.149778
H200017505_FANCL 1.6525 0.397534 0.240565 4 3.143779
H200000621_ANGPT1 1.64775 1.626822 0.987299 4 3.133446
H300015308_ 1.6395 0.224063 0.136666 4 3.115578
H200006611_QPCT 1.63775 0.402911 0.246015 4 3.111801
H300009117_OSR2 1.63625 0.558735 0.341473 4 3.108568
H300001290_SUNC1 1.634 0.527525 0.322843 3 3.103723
H200007111_NP_689700.1 1.6325 1.570719 0.962156 4 3.100498
H300017820_GLS 1.63125 0.453618 0.27808 4 3.097813
opHsV0400012444_ 1.63 0.557309 0.341907 3 3.09513
opHsV0400002734_NP_848664.1 1.62675 0.832261 0.51161 4 3.088165
H300003538_Q9NYD4_HUMAN 1.6265 1.258498 0.773746 4 3.08763
opHsV0400004371_HLA-DRA 1.62475 0.737985 0.454215 4 3.083887
H200009565_IFIH1 1.6205 0.799292 0.493238 4 3.074816
opHsV0400000732_C6orf148 1.61975 1.121724 0.692529 4 3.073218
H200006282_SERPINA5 1.619 1.310318 0.809338 4 3.071621
H200006302_MAL2 1.61775 0.421879 0.260781 4 3.06896
H200000169_TACSTD1 1.6175 0.876741 0.542035 4 3.068429
H300007499_HRASLS3 1.6165 0.663349 0.410361 4 3.066302
H200005162_BAG2 1.61025 0.6921 0.429809 4 3.053047
H300015490_TRIM14 1.60975 0.854371 0.530748 4 3.05199
H300015757_PPM2C 1.6095 0.64351 0.39982 4 3.051461
H200014344_IL27B_HUMAN 1.60625 1.055639 0.657207 4 3.044594
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Table 15 continued 
Name of the upregulated gene in HN




4 slides STD CV 
Count of 
slides  Ratio 
H200004487_DKK1 1.60575 0.596592 0.371535 4 3.043539
H300005881_CTCFL 1.60425 1.235159 0.769929 4 3.040377
H300020304_PLAC8 1.5955 0.829325 0.51979 4 3.021992
H200016697_EMILIN2 1.5935 1.428029 0.896159 4 3.017806
H200010947_POLE2 1.581 0.423762 0.268034 4 2.991772
H200005687_CDC6_HUMAN 1.58025 0.908132 0.574676 4 2.990217
opHsV0400000033_USP18 1.57925 0.465642 0.29485 4 2.988145
H200006576_RNF144 1.5765 0.782792 0.496538 4 2.982454
H300019419_SP110 1.566 0.855142 0.546068 4 2.960827
H200007266_LHX1 1.566 1.433402 0.915327 4 2.960827
H200000387_MSX1 1.565 0.862229 0.550945 4 2.958775
opHsV0400006517_LIMS3 1.56475 1.375443 0.879017 4 2.958262
H200006824_FZD2 1.56425 0.881607 0.563597 4 2.957237
H200004906_CDCA8 1.558 0.622277 0.399408 4 2.944454
H200019588_CDC2 1.54775 0.564203 0.364531 4 2.923608
H200005202_OAS3 1.54725 0.767262 0.495888 4 2.922595
H200012133_OASL 1.544 0.360654 0.233584 4 2.916019
H300020240_Q7Z7J6_HUMAN 1.54275 1.035721 0.671348 4 2.913493
H200006623_SEMA4D 1.5405 0.920567 0.597577 4 2.908953
H300001211_ARVCF 1.53925 0.769145 0.499688 4 2.906434
opHsV0400007148_ 1.53675 0.901378 0.586548 4 2.901402
H200000423_RPA3 1.53675 0.384891 0.250458 4 2.901402
opHsV0400003019_NP_115749.2 1.5365 0.639597 0.416269 4 2.900899
H200011709_DEK 1.5345 0.681863 0.444355 4 2.89688
H200009876_EEF1E1 1.53275 0.359703 0.234678 4 2.893368
opHsV0400007760_ 1.52125 0.468175 0.307757 4 2.870396
opHsV0400004148_BGN 1.5195 1.341237 0.882683 4 2.866917
H200002273_NP_620134.2 1.5185 0.378022 0.248944 4 2.86493
H300002362_HOXA7 1.51675 0.845497 0.55744 4 2.861457
opHsV0400010984_ 1.51375 0.37722 0.249196 4 2.855513
H200002104_NP_116195.2 1.51275 0.902294 0.59646 4 2.853534
H300002650_LSM5 1.511 0.465699 0.308206 4 2.850075
H200020265_KIAA1914 1.5055 0.458942 0.304844 4 2.839231
H200015533_GMNN 1.504 0.840186 0.558635 4 2.83628
H200001910_RHOBTB3 1.50375 0.422485 0.280954 4 2.835789
H300017088_Q9P2H4_HUMAN 1.50275 0.634124 0.421976 4 2.833824
H200008732_C9orf76 1.50125 0.473563 0.315446 4 2.830879
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Name of the upregulated gene in HN




4 slides STD CV 
Count of 
slides  Ratio 
H300021781_CENPA 1.499 0.448031 0.298886 4 2.826467
H300001620_HLA-DRA 1.49575 0.567848 0.379641 4 2.820107
H200012628_Q9NW34_HUMAN 1.49475 0.546389 0.365539 4 2.818153
H200000353_CSF2 1.49475 1.097309 0.734109 4 2.818153
H200007874_UBE2L6 1.494 0.280316 0.187628 4 2.816688
H200014214_80_ 1.492 0.366445 0.245607 4 2.812786
H300000884_ 1.48925 0.503138 0.337846 4 2.80743
opHsV0400001961_CRIP1 1.4865 0.428895 0.288527 4 2.802084
opHsV0400006256_ATP6V0A2 1.4855 0.946856 0.637399 4 2.800142
opHsV0400006563_CTHRC1 1.47725 0.686588 0.464774 4 2.784175
opHsV0400006261_ZNF180 1.4765 0.488886 0.331112 4 2.782728
opHsV0400001268_LCP1 1.47475 0.467856 0.317244 4 2.779355
opHsV0400006299_MRPS18C 1.474 0.239612 0.162559 4 2.77791
H300006103_NP_872297.1 1.4725 0.534455 0.362957 4 2.775024
H200006020_NP_001009567.1 1.46925 1.162508 0.791225 4 2.768779
opHsV0400000242_RSAD2 1.46725 0.436163 0.297266 4 2.764943
opHsV0400012866_ 1.4665 0.795741 0.542612 4 2.763506
opHsV0400001371_PTE2B_HUMAN 1.46375 0.887962 0.606635 4 2.758244
H200003290_DEPDC1B 1.462 0.88802 0.607401 4 2.7549
H200018907_TRIM22 1.46125 0.430851 0.294851 4 2.753468
opHsV0400000079_Q6NZ63HUMAN 1.4525 0.568938 0.391696 4 2.736819
H200003131_PPM2C 1.447 0.64873 0.448327 4 2.726405
H200014355_NP_945185.1 1.44525 1.123801 0.777582 4 2.7231
H200009537_RBP7 1.44425 0.729837 0.50534 4 2.721213
H300004315_XP_372200.1 1.44375 0.204927 0.141941 4 2.72027
H300013841_RAD51AP1 1.441333 1.307693 0.90728 3 2.715717
H200013413_LRP3 1.43925 0.238458 0.165682 4 2.711799
H300020946_BRIX_HUMAN 1.438 0.890683 0.61939 4 2.70945
H200006095_90_ 1.4365 0.413611 0.287929 4 2.706634
opHsV0400002785_Q86TT0HUMAN 1.4365 1.357682 0.945132 4 2.706634






Table 16: 262 downregulated genes in HN cell line. The gene list is from the least 
downregulated gene to most downregulated gene.  
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H300019074_WRNIP1 -1.59875 1.383307 -0.86524 4 0.330163
H200016212_DLL1 -1.5995 0.75427 -0.47157 4 0.329991
opHsV0400002581_C14orf78 -1.6 1.305228 -0.81577 3 0.329877
H300014158_DOCK9 -1.603 1.419751 -0.88568 3 0.329192
opHsV0400004066_ -1.60625 0.469854 -0.29252 4 0.328451
H300019058_ANXA6 -1.609 0.960446 -0.59692 4 0.327826
H200006821_IL1RN -1.60925 1.012012 -0.62887 4 0.327769
opHsV0400002604_Q96FP4_HUMAN -1.61175 0.725436 -0.45009 4 0.327201
H200017253_PLXNB1 -1.6135 0.858486 -0.53206 4 0.326805
opHsV0400003246_XP_497922.1 -1.61725 0.884012 -0.54661 4 0.325956
H200006140_CCND2 -1.61975 0.396532 -0.24481 4 0.325392
H200019789_NP_001060.1 -1.6245 0.419842 -0.25844 4 0.324322
H200002453_SRPX -1.62525 0.903225 -0.55575 4 0.324154
H300003388_ETS2 -1.6265 1.082986 -0.66584 4 0.323873
H200002000_RHBDL2 -1.62775 0.806054 -0.49519 4 0.323592
opHsV0400004958_KLF10_HUMAN -1.62925 1.289555 -0.7915 4 0.323256
H200006008_PRSS11 -1.62925 0.384313 -0.23588 4 0.323256
H200002536_CDYL -1.63625 0.844779 -0.51629 4 0.321692
H200017078_TUBB6 -1.63775 0.438952 -0.26802 4 0.321357
H300002496_NOTCH2NL -1.63825 0.768268 -0.46896 4 0.321246
H200006868_DAB2 -1.64125 1.419207 -0.86471 4 0.320579
opHsV0400009653_ -1.64167 1.064244 -0.64827 3 0.320486
H200002949_C6orf117 -1.64175 1.555972 -0.94775 4 0.320468
H300012687_IPYR2_HUMAN -1.6435 0.991842 -0.60349 4 0.320079
H200006008_PRSS11 -1.64775 0.37658 -0.22854 4 0.319137
H200012241_NP_689893.1 -1.64875 0.668634 -0.40554 4 0.318916
opHsV0400011304_ -1.64975 0.543631 -0.32952 4 0.318695
opHsV0400002608_ -1.657 1.091706 -0.65885 3 0.317098
H200011608_CRYL1 -1.66075 1.226167 -0.73832 4 0.316275
H200008160_NP_001001701.1 -1.66075 0.452508 -0.27247 4 0.316275
opHsV0400005657_ -1.66125 0.922962 -0.55558 4 0.316165
opHsV0400012140_ -1.66675 1.337455 -0.80243 4 0.314962
opHsV0400011469_ -1.66925 1.384516 -0.82942 4 0.314417
opHsV0400002357_GBP6 -1.66925 1.006323 -0.60286 4 0.314417
H200012925_ -1.67225 0.50195 -0.30016 4 0.313764
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Name of the downregulated gene in 
HN cell line  
Average 
value of 
4 slides STD CV 
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H300014718_DUSP6 -1.6765 0.836957 -0.49923 4 0.312841
H200010650_DSG2 -1.67675 0.840799 -0.50145 4 0.312786
H300003254_TM4SF1 -1.679 0.469498 -0.27963 4 0.312299
H200000493_DSG3 -1.68525 0.600096 -0.35609 4 0.310949
H200001205_NP_057659.1 -1.68675 0.780043 -0.46245 4 0.310626
H200004941_LPXN -1.68675 0.865594 -0.51317 4 0.310626
H200001079_EGFL5 -1.68875 0.893202 -0.52891 4 0.310196
H300022632_PAM -1.6895 0.908499 -0.53773 4 0.310034
H200001094_NP_057702.1 -1.694 0.666506 -0.39345 4 0.309069
opHsV0400005724_ -1.702 1.596677 -0.93812 3 0.30736
H300020881_PTPN13 -1.7025 1.469151 -0.86294 4 0.307253
H200007830_80_ -1.703 1.316424 -0.773 4 0.307147
H300009483_NHLH2 -1.70525 1.646993 -0.96584 4 0.306668
H200005895_NQO2 -1.70675 1.421316 -0.83276 4 0.306349
H200012177_RAB4A -1.7155 0.919008 -0.53571 4 0.304497
H300019976_IPYR2_HUMAN -1.71875 0.370455 -0.21554 4 0.303812
H300009845_RNASE7 -1.72025 0.897532 -0.52174 4 0.303496
opHsV0400000833_NET1 -1.7255 1.398363 -0.81041 4 0.302394
H300022102_AMPH -1.72975 1.302425 -0.75296 4 0.301504
H200004702_SLC6A15 -1.733 0.668861 -0.38596 4 0.300826
H300000194_CSPG2 -1.73325 0.690035 -0.39812 4 0.300774
opHsV0400012025_ -1.735 0.736238 -0.42434 4 0.300409
H300017847_FN1 -1.73575 0.744819 -0.4291 4 0.300253
opHsV0400002147_Q86XE2HUMAN -1.73625 1.403075 -0.80811 4 0.300149
H200003613_NLGN2 -1.7445 1.690551 -0.96907 4 0.298437
opHsV0400004135_NOTCH2 -1.7465 0.867778 -0.49687 4 0.298024
opHsV0400006289_ -1.75025 0.524869 -0.29988 4 0.29725
opHsV0400000971_WBSCR1 -1.751 1.682545 -0.96091 4 0.297096
H300014817_LAMA3 -1.752 0.985253 -0.56236 4 0.29689
opHsV0400010474_ -1.75625 1.164768 -0.66321 4 0.296017
H200005804_CDKN2B -1.763 1.059426 -0.60092 3 0.294635
H200013653_PADI3 -1.7655 1.54012 -0.87234 4 0.294125
opHsV0400012141_ -1.768 0.323393 -0.18291 4 0.293615
H300014940_B3GNT5 -1.76825 1.385017 -0.78327 4 0.293565
H200003299_SLC16A4 -1.7685 0.985443 -0.55722 4 0.293514
H200007001_IL18 -1.77075 0.600791 -0.33929 4 0.293056
H200015568_NP_060945.2 -1.771 0.833682 -0.47074 4 0.293006
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H200000289_LTBR -1.7725 1.539506 -0.86855 4 0.292701
H200009840_VIM -1.773 1.472988 -0.83079 4 0.2926
H300013119_NP_065682.2 -1.78775 0.722342 -0.40405 4 0.289623
H300021562_FN1 -1.79 0.725466 -0.40529 4 0.289172
opHsV0400001891_ALDH1A3 -1.793 1.146318 -0.63933 4 0.288571
H300020771_SQSTM1 -1.79875 0.724315 -0.40268 4 0.287424
H200008177_IL1RAP -1.799 0.359881 -0.20004 4 0.287374
opHsV0400006351_ -1.804 1.021688 -0.56635 4 0.286379
H300017962_CTBP2 -1.8085 1.727057 -0.95497 4 0.285488
H300005700_KRT8 -1.81075 0.937817 -0.51792 4 0.285043
H300006159_OR10Z1 -1.81125 1.342866 -0.7414 4 0.284944
H300003817_NP_006207.1 -1.816 0.369494 -0.20347 4 0.284007
H200009720_GDF15 -1.8165 1.713194 -0.94313 4 0.283909
opHsV0400007052_DMRTA2 -1.817 1.027746 -0.56563 4 0.283811
H200006151_Q5T9X8_HUMAN -1.8195 1.323231 -0.72725 4 0.283319
H200011042_S100A8 -1.82025 0.464048 -0.25494 4 0.283172
opHsV0400001839_ -1.82375 0.613236 -0.33625 4 0.282486
H300014334_NP_079082.2 -1.82625 1.394609 -0.76365 4 0.281997
H300021172_HOP_HUMAN -1.8305 1.707345 -0.93272 4 0.281167
H300009457_GADD45B -1.8385 0.788505 -0.42888 4 0.279612
H200006750_NP_067651.2 -1.84025 0.677885 -0.36837 4 0.279273
opHsV0400005248_FAM46B -1.84425 0.621962 -0.33724 4 0.2785
H300010985_XP_056455.4 -1.84475 1.191614 -0.64595 4 0.278404
H200007913_GLUL -1.84525 0.727058 -0.39402 4 0.278307
opHsV0400005180_ -1.84875 1.707691 -0.9237 4 0.277633
H300008877_IRX1 -1.85325 1.157741 -0.62471 4 0.276768
H200014313_BEXL1 -1.85625 0.813239 -0.43811 4 0.276193
opHsV0400000674_SPRE1_HUMAN -1.864 1.535201 -0.82361 4 0.274714
H300011977_UGP2 -1.867 0.531943 -0.28492 4 0.274143
H300012294_NP_996918.1 -1.86775 1.234636 -0.66103 4 0.274
opHsV0400007640_ -1.87125 1.308335 -0.69918 4 0.273336
H200011819_NP_002956.1 -1.8715 0.452331 -0.24169 4 0.273289
opHsV0400012111_ -1.874 0.467187 -0.2493 4 0.272816
H200009653_RAB4A -1.8775 1.208294 -0.64357 4 0.272155
H300013341_ARI5B_HUMAN -1.88067 1.431925 -0.76139 3 0.271558
H200003061_SLC22A15 -1.8835 0.345235 -0.18329 4 0.271025
H200015766_CLCA2 -1.89025 1.41579 -0.749 4 0.26976
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4 slides STD CV 
Count of 
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H300019778_PFKP -1.8905 0.441144 -0.23335 4 0.269714
H300002182_FEZ1 -1.89725 0.352279 -0.18568 4 0.268455
H300015033_MAGED2 -1.9015 1.104153 -0.58067 4 0.267665
opHsV0400000309_PRKX -1.90175 1.079995 -0.5679 4 0.267619
H300003420_XP_114621.3 -1.906 0.795925 -0.41759 4 0.266831
H300015331_CALD1 -1.9095 0.600979 -0.31473 4 0.266185
H200001479_Q8IW73_HUMAN -1.9105 0.81507 -0.42663 4 0.266
H200000578_SGNE1 -1.9115 1.342315 -0.70223 4 0.265816
H300018512_DDX3Y -1.91325 1.374225 -0.71827 4 0.265494
H200006912_TRIM29 -1.9135 0.46742 -0.24428 4 0.265448
H200010727_IRS1 -1.9155 0.956011 -0.49909 4 0.26508
H200016641_MN1 -1.9165 1.734132 -0.90484 4 0.264896
H200001041_CA12 -1.92375 1.209104 -0.62851 4 0.263569
opHsV0400008763_ -1.92525 1.671196 -0.86804 4 0.263295
opHsV0400012807_ -1.9255 1.44655 -0.75126 4 0.263249
H300002442_SPAG4L -1.926 1.575548 -0.81804 3 0.263158
H300019695_BICD2_HUMAN -1.93333 1.714992 -0.88706 3 0.261824
opHsV0400000862_ -1.937 0.627197 -0.3238 4 0.261159
H200013276_SERPINB7 -1.9395 1.250102 -0.64455 4 0.260707
H200011747_MMP2 -1.94133 1.266238 -0.65225 3 0.260376
H300006466_SGCB -1.94775 0.48478 -0.24889 4 0.25922
H200006031_IPKA_HUMAN -1.95125 1.027964 -0.52682 4 0.258592
H200013147_NP_079045.1 -1.95125 1.613092 -0.8267 4 0.258592
H200009840_VIM -1.95225 1.347477 -0.69022 4 0.258413
opHsV0400000719_KRT16 -1.954 0.677366 -0.34666 4 0.2581
opHsV0400000067_Q8WWJ9_HUMAN -1.964 1.440904 -0.73366 3 0.256317
H300011685_ -1.96925 0.791119 -0.40174 4 0.255386
H200015680_DSC2 -1.97375 0.82822 -0.41962 4 0.25459
H300020530_SERPINB3 -1.974 1.412462 -0.71553 4 0.254546
H200011421_CDKN1C -1.97425 1.74466 -0.88371 4 0.254502
H200008269_CD99 -1.979 0.568187 -0.28711 4 0.253666
opHsV0400005505_Q8N1M2_HUMAN -1.97975 0.916015 -0.46269 4 0.253534
H200009233_SIA7B_HUMAN -1.9845 0.563657 -0.28403 4 0.2527
H300004503_NP_076415.2 -1.98675 1.388697 -0.69898 4 0.252307
H300002800_AHNAK -1.9885 1.011638 -0.50874 4 0.252001
H200005431_DIXDC1 -1.9885 1.306747 -0.65715 4 0.252001
opHsV0400000907_ -1.9915 0.91352 -0.45871 4 0.251477
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opHsV0400003043_MYADM -1.993 1.074113 -0.53894 4 0.251216
H300015953_SH3TC1 -1.99525 0.816961 -0.40945 4 0.250824
opHsV0400003766_NP_710154.1 -1.997 0.569637 -0.28525 4 0.25052
H200010435_SPAG7 -1.99725 1.183802 -0.59272 4 0.250477
H200000006_FECH -2 1.136739 -0.56837 3 0.25
H300002958_JAG1 -2.0005 0.980535 -0.49014 4 0.249913
H200017303_THIC_HUMAN -2.0045 1.227046 -0.61215 4 0.249221
H200017197_HSD11B1 -2.008 1.799181 -0.89601 4 0.248618
opHsV0400000692_Q96HF5_HUMAN -2.0175 1.505647 -0.74629 4 0.246986
opHsV0400004098_S100A14 -2.0225 0.647593 -0.32019 4 0.246131
H300008020_XP_294590.1 -2.023 1.021751 -0.50507 4 0.246046
H200014140_PTPNS1 -2.0295 0.915507 -0.4511 4 0.24494
opHsV0400005956_ -2.03025 1.987607 -0.979 4 0.244813
H300010309_MYADM -2.03125 0.793007 -0.3904 4 0.244643
H200017469_RHCG -2.0325 1.47413 -0.72528 4 0.244431
opHsV0400006431_SNURF -2.035 1.122016 -0.55136 4 0.244008
opHsV0400009072_ -2.04975 0.847366 -0.4134 4 0.241526
H200006884_SERPINE1 -2.05525 0.878614 -0.4275 4 0.240607
opHsV0400013047_ -2.077 1.65584 -0.79723 4 0.237007
opHsV0400002303_NDN -2.102 1.514516 -0.72051 4 0.232935
opHsV0400011802_ -2.11075 0.990842 -0.46943 4 0.231527
opHsV0400003761_SAT -2.12375 0.674588 -0.31764 4 0.22945
H200020570_SESN3 -2.1265 1.558735 -0.733 4 0.229013
H200004216_PLXDC2 -2.13375 1.498274 -0.70218 4 0.227865
opHsV0400000655_GJB2 -2.13575 1.589741 -0.74435 4 0.227549
opHsV0400007539_ -2.13667 1.170169 -0.54766 3 0.227405
H300019732_PRKY -2.14125 1.288663 -0.60183 4 0.226683
H300008679_EGLN3 -2.14575 1.567392 -0.73046 4 0.225977
H300006003_SLC25A6 -2.15325 0.568798 -0.26416 4 0.224806
opHsV0400000393_COL16A1 -2.1535 0.408445 -0.18967 4 0.224767
H300009738_Q14922_HUMAN -2.159 1.707737 -0.79099 4 0.223911
opHsV0400011805_ -2.16475 1.242039 -0.57376 4 0.223021
H200012019_AKR1B10 -2.1675 1.019482 -0.47035 4 0.222596
opHsV0400002365_PTPRM -2.16825 0.521267 -0.24041 4 0.22248
H200001587_NP_996918.1 -2.169 0.508558 -0.23447 4 0.222365
H200006902_KLF10_HUMAN -2.16925 0.651168 -0.30018 4 0.222326
H200006867_SHC1 -2.18975 0.62549 -0.28564 4 0.219189
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opHsV0400012682_ -2.1915 1.25688 -0.57353 4 0.218924
H300016644_WASPIP -2.20725 1.987152 -0.90028 4 0.216547
H300002193_ZFP36L2 -2.21575 0.47565 -0.21467 4 0.215275
H200008152_ODZ2 -2.216 0.481832 -0.21743 4 0.215237
H300002481_ZBTB34 -2.23325 1.45323 -0.65072 4 0.212679
H200010061_RPS6KA2 -2.23625 1.708891 -0.76418 4 0.212237
opHsV0400001284_ -2.24625 1.297053 -0.57743 4 0.210771
opHsV0400007647_ -2.25667 1.907378 -0.84522 3 0.209255
opHsV0400000170_MT1L -2.25975 0.362426 -0.16038 4 0.208808
H300000923_POSTN -2.26175 1.625951 -0.71889 4 0.208519
H300014335_KRT6B -2.2635 0.877822 -0.38782 4 0.208266
H300020178_ -2.26375 0.710005 -0.31364 4 0.20823
H200012731_F2R -2.273 1.46346 -0.64385 4 0.206899
H200007876_SLC2A1 -2.2955 0.738457 -0.3217 4 0.203697
H200015364_GSTP1 -2.301 0.589462 -0.25618 4 0.202922
H300021749_FOLR3 -2.30675 0.871734 -0.37791 4 0.202115
H200014031_HSD17B2 -2.30675 0.762819 -0.33069 4 0.202115
H300000043_RGS17 -2.31825 1.010659 -0.43596 4 0.200511
H200000430_COL7A1 -2.36225 0.65418 -0.27693 4 0.194488
opHsV0400005864_SEPP1 -2.3655 1.345137 -0.56865 4 0.19405
H300022249_GP110_HUMAN -2.37275 2.22949 -0.93962 4 0.193077
H300022236_Q9BSP9_HUMAN -2.37325 0.970672 -0.40901 4 0.19301
H200006097_ID1 -2.40875 1.092811 -0.45368 4 0.188319
H300012916_MAOA -2.4185 1.992456 -0.82384 4 0.187051
H200001408_SFRP1 -2.43325 1.071149 -0.44021 4 0.185148
H200008006_SEMA3C -2.4605 0.55147 -0.22413 4 0.181684
H300021145_ANGPTL4 -2.475 0.780793 -0.31547 4 0.179867
H200018876_IL24 -2.4765 1.466241 -0.59206 4 0.17968
H200000153_Q9BSP9_HUMAN -2.48525 1.071613 -0.43119 4 0.178593
H200011925_COL8A1 -2.498 1.49758 -0.59951 4 0.177022
opHsV0400006127_TNFRSF6B -2.5015 0.365641 -0.14617 4 0.176593
H300003213_GOLPH3L -2.50675 1.333089 -0.5318 4 0.175952
H200015098_IL1F9 -2.51975 1.041925 -0.4135 4 0.174373
H200004912_GJB6 -2.52425 1.61561 -0.64004 4 0.17383
H200005918_SYK -2.52775 1.763101 -0.6975 4 0.173409
H200006177_SERPINB2 -2.559 0.795586 -0.3109 4 0.169693
H300005637_NP_689532.1 -2.5665 1.81099 -0.70563 4 0.168813
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H200006699_FBN2 -2.58725 0.790933 -0.3057 4 0.166403
opHsV0400012721_ -2.61325 2.010573 -0.76938 4 0.163431
H300013272_DDX3Y -2.6735 1.555192 -0.58171 4 0.156746
H300010096_AKR1C2 -2.6785 0.993972 -0.37109 4 0.156204
H200014446_P2RY5 -2.68125 1.943099 -0.7247 4 0.155906
H300013882_AES -2.6825 0.454182 -0.16931 4 0.155771
opHsV0400011550_ -2.686 2.445253 -0.91037 3 0.155394
H200016719_AREG -2.70425 0.555952 -0.20558 4 0.15344
opHsV0400011776_ -2.7105 2.555899 -0.94296 4 0.152777
H200005781_NP_056234.1 -2.71325 1.705237 -0.62849 4 0.152486
H200000280_SPRR1B -2.735 1.000044 -0.36565 4 0.150205
H200005198_GALNT5 -2.76025 1.335756 -0.48393 4 0.147599
opHsV0400002884_ -2.76625 2.725509 -0.98527 4 0.146986
opHsV0400010653_ -2.79075 1.439192 -0.5157 4 0.144511
H200003227_CMKOR1 -2.8075 0.905171 -0.32241 4 0.142843
H200012184_COL4A1 -2.82025 0.634544 -0.225 4 0.141586
H200002398_HCLS1 -2.8465 1.290239 -0.45327 4 0.139033
H300006645_Q8IYY5_HUMAN -2.85 0.85245 -0.29911 4 0.138696
H200012016_EVA1 -2.8505 0.68078 -0.23883 4 0.138648
H200011635_LXN -2.86425 2.020295 -0.70535 4 0.137333
opHsV0400006073_CFHL1 -2.86475 0.87589 -0.30575 4 0.137285
H200007909_Q86XJ2_HUMAN -2.872 0.595409 -0.20731 4 0.136597
H200014027_CA2 -2.93825 1.069223 -0.3639 4 0.130466
opHsV0400010774_ -2.9685 1.306912 -0.44026 4 0.127759
H200000301_CDKN2A -2.97475 1.792289 -0.6025 4 0.127207
H200011169_TCF7L1 -2.99475 1.037295 -0.34637 4 0.125456
H200006236_CDH11 -3.0245 1.237091 -0.40902 4 0.122895
H200006995_ -3.052 0.953395 -0.31238 4 0.120575
H200004653_SULF2 -3.06 1.158361 -0.37855 4 0.119908
H300003117_Q8N4W5_HUMAN -3.06767 2.914295 -0.95 3 0.119272
H200016561_NP_060910.2 -3.071 1.721832 -0.56067 4 0.118997
H200020242_C9orf26 -3.0795 1.212845 -0.39384 4 0.118298
H300006196_MAF -3.124 1.538379 -0.49244 4 0.114705
H200007907_FOXO1A -3.13275 1.02355 -0.32673 4 0.114011
H200014307_FADS2 -3.1405 0.463705 -0.14765 4 0.113401
opHsV0400011317_ -3.20067 3.195774 -0.99847 3 0.108769
H300004073_AKR1C1 -3.28425 0.748321 -0.22785 4 0.102646
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H300004901_RPS4Y1 -3.3215 1.307476 -0.39364 4 0.10003
H200014029_EIF1AY -3.58 1.302563 -0.36384 4 0.08362
H300021913_AKR1C3 -3.734 1.248393 -0.33433 4 0.075154
H200005947_GJA1 -3.869 1.115312 -0.28827 4 0.068441




















Table 17: 128 upregulated genes in HSC-3 cell line. The gene list is from the most 
upregulated gene to least upregulated gene. 
Name of the upregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H200004378_MAGEA8 3.152 0.849621 0.26955 4 8.88887
H200005801_MAGEA1 3.03575 0.936701 0.308557 4 8.200717
H200011948_EREG 2.597 0.780137 0.300399 4 6.050272
H200011983_Q9BT26_HUMAN 2.59275 1.084013 0.418094 4 6.032475
opHsV0400002734_NP_848664.1 2.547 0.915678 0.359512 4 5.844178
H200004597_XM_374020.2 2.44275 0.932021 0.381546 4 5.436771
H200002223_TXNRD1 2.39975 0.65304 0.272128 4 5.277117
opHsV0400008521_ 2.36525 1.704137 0.720489 4 5.152419
H200017455_NP_060582.1 2.2765 0.326759 0.143536 4 4.845011
opHsV0400003034_KLK10 2.27275 0.695054 0.305821 4 4.832434
H200004485_HOXC9 2.267 1.211413 0.534369 4 4.813212
H200009720_GDF15 2.19 0.475102 0.216942 4 4.563055
opHsV0400003019_NP_115749.2 2.1475 0.334409 0.15572 4 4.430594
H300004818_MAGEA9 2.14725 1.140736 0.531254 4 4.429826
opHsV0400001562_IGSF4 2.10425 0.735674 0.349613 4 4.299742
H300006703_LY6K 2.0865 0.680104 0.325955 4 4.247165
H300022245_PHF15 2.05875 0.78175 0.379721 4 4.166252
opHsV0400000415_NP_149024.1 2.045 0.503042 0.245986 4 4.126733
opHsV0400004777_NP_998889.1 2.01425 1.010318 0.501585 4 4.039705
opHsV0400001984_XP_377060.1 1.9955 0.737407 0.369535 4 3.987543
H300015028_NMNAT3 1.9795 0.698805 0.353021 4 3.943564
H300022040_SH3YL1 1.97 0.476095 0.241673 4 3.917681
H300017088_Q9P2H4_HUMAN 1.96975 0.513645 0.260766 4 3.917002
opHsV0400006083_MAGEA4 1.9685 0.824239 0.418714 4 3.91361
H300006491_NP_940887.1 1.95075 0.90601 0.464442 4 3.865754
opHsV0400003953_HIST1H1C 1.9215 0.423402 0.22035 4 3.788167
opHsV0400007760_ 1.92075 0.563209 0.293223 4 3.786198
H300008288_NP_443726.1 1.91625 0.43419 0.226583 4 3.774407
H200014299_RHPN2 1.9135 0.454259 0.237397 4 3.767219
H200011351_AIM2 1.90825 1.427721 0.748183 4 3.753535
opHsV0400010848_ 1.88475 0.534614 0.283653 4 3.692889
H200006887_PSIP1 1.88475 0.326691 0.173334 4 3.692889
H300001921_PKD1L2 1.87575 1.677794 0.894466 4 3.669924
opHsV0400000818_IL8 1.8655 0.570452 0.30579 4 3.643942
H200006441_OLR1 1.862 1.144727 0.614783 4 3.635112
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Table 17 continued 
Name of the upregulated gene in HSC-
3 cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H300005599_NP_705835.1 1.86175 0.966071 0.518905 4 3.634483
H300021371_Q9P2H4_HUMAN 1.8485 0.707264 0.382615 4 3.601256
H200013441_KCNJ14 1.846 1.040101 0.563435 4 3.595021
H300020946_BRIX_HUMAN 1.8405 0.397678 0.216071 4 3.581341
H300021118_BBC3 1.824 0.587338 0.322006 4 3.540615
opHsV0400002065_Q86YU6_HUMAN 1.81675 0.672504 0.370169 4 3.522867
H200000454_INHBB 1.80425 1.785077 0.989374 4 3.492476
H200014850_STK39 1.79125 0.621751 0.347105 4 3.461146
H200013135_UCN 1.78225 1.208734 0.678207 4 3.439622
H200006680_EMP1 1.7745 0.571015 0.321789 4 3.421194
H200011423_PKIB 1.764 0.507071 0.287455 4 3.396385
H200010852_ITCH_HUMAN 1.7505 0.444094 0.253696 4 3.364752
opHsV0400003702_COX8C 1.75025 1.599525 0.913884 4 3.364169
H200007980_USMG5 1.74175 0.568977 0.32667 4 3.344406
opHsV0400011949_ 1.7305 0.339008 0.195902 4 3.318428
H300003162_ANKRD18A 1.7195 0.567176 0.32985 4 3.293223
H300010199_EIF5A2 1.7175 0.63642 0.37055 4 3.28866
H300011213_Q9NSQ0_HUMAN 1.70825 1.174061 0.687289 4 3.267642
opHsV0400003313_NP_003513.1 1.6915 0.457245 0.270319 4 3.229924
opHsV0400011821_ 1.686 0.751921 0.445979 4 3.217633
H200006097_ID1 1.68225 0.546952 0.325131 4 3.209281
H200004662_PELI2 1.682 1.000514 0.594836 4 3.208725
H200000169_TACSTD1 1.68 0.297876 0.177307 4 3.20428
H200021283_NANOS1 1.6795 0.536871 0.319661 4 3.203169
H200017773_GTPBP1 1.6745 1.163442 0.6948 4 3.192087
opHsV0400004721_HIST1H2BH 1.6675 0.606325 0.363613 4 3.176636
H300004810_PTENP1 1.6675 0.556886 0.333964 4 3.176636
H200006754_KRT15 1.653 0.513669 0.310749 4 3.144869
H200004708_PNN 1.641 1.23787 0.754339 4 3.118819
H200010772_GPR160 1.6405 0.936346 0.570768 4 3.117739
opHsV0400010379_ 1.63925 0.657288 0.400969 4 3.115039
H200017587_RIOK1 1.639 0.569017 0.347173 4 3.114499
H300004419_HSC20_HUMAN 1.630333 0.374844 0.229919 3 3.095845
H300010303_TMEM41B 1.62875 0.279295 0.171478 4 3.092449
H200008677_SERPINB1 1.623667 0.414045 0.255006 3 3.081572
H200000756_XCL1 1.6205 1.11755 0.689633 4 3.074816
opHsV0400002545_C9orf75 1.6185 0.569555 0.351903 4 3.070556
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Table 17 continued 
Name of the upregulated gene in HSC-
3 cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200006453_RNF38 1.6165 0.338344 0.209306 4 3.066302
opHsV0400006608_NP_689497.1 1.6135 0.691395 0.428506 4 3.059933
H300020977_PSIP1 1.606 0.371028 0.231026 4 3.044067
opHsV0400008140_ 1.6015 0.515305 0.321764 4 3.034587
H300019484_MRPS18B 1.601 0.471496 0.294501 4 3.033535
H200006623_SEMA4D 1.60025 1.241406 0.775758 4 3.031958
H200000524_SLC25A4 1.599 0.420158 0.262763 4 3.029333
opHsV0400003565_NP_006638.1 1.5965 0.829345 0.519477 4 3.024088
opHsV0400011837_ 1.59475 0.943297 0.591501 4 3.020422
H300002440_ 1.56625 0.361304 0.230681 4 2.96134
H300000318_HIST1H2BK 1.55725 0.41875 0.268904 4 2.942923
H300001749_AQP11 1.55375 1.13034 0.727492 4 2.935792
H200020534_TRIM6 1.5485 0.425175 0.274572 4 2.925128
H200002977_NP_065726.1 1.5465 0.770006 0.497903 4 2.921076
H200002273_NP_620134.2 1.54575 0.342185 0.221371 4 2.919558
H200011237_C10orf45 1.54325 0.454406 0.294448 4 2.914503
H300013839_Q8N601_HUMAN 1.5355 0.402652 0.262229 4 2.898889
H300018428_BID 1.5315 0.627854 0.40996 4 2.890863
opHsV0400001983_ 1.531 0.47726 0.311731 4 2.889861
H300005107_C10orf116 1.53025 0.548939 0.358725 4 2.888359
H300018167_AMID 1.5295 0.785779 0.513749 4 2.886858
H200007656_ELF3 1.51475 0.340044 0.224489 4 2.857493
H300008564_RASSF6 1.51125 0.362357 0.239773 4 2.850569
opHsV0400001907_ 1.51075 0.501022 0.331638 4 2.849581
H200014940_SYCP2 1.502 1.161495 0.773299 4 2.832351
opHsV0400005403_HIST1H2BM 1.5 0.980374 0.653583 4 2.828427
opHsV0400003794_Q71RB1_HUMAN 1.49575 0.399363 0.266999 4 2.820107
H200019082_TIMM9 1.4935 0.359623 0.240792 4 2.815712
H300010984_PHF15 1.4935 0.450442 0.301601 4 2.815712
opHsV0400002715_Q68G75_HUMAN 1.49275 0.562713 0.376964 4 2.814249
H300007931_NP_057385.2 1.4915 0.450681 0.302167 4 2.811812
H300020380_TATDN1 1.491 0.640439 0.429536 4 2.810837
opHsV0400003875_Q8NHD1_HUMAN 1.48975 0.663412 0.445317 4 2.808403
opHsV0400001186_NP_254280.1 1.48925 0.294015 0.197425 4 2.80743
H200010529_AMOTL2 1.489 0.369736 0.248312 4 2.806943
H200003398_CWF19L2 1.481 1.349314 0.911083 4 2.791422
H200004072_SIRT1_HUMAN 1.48025 0.515023 0.347929 4 2.789971
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Table 17 continued 
Name of the upregulated gene in HSC-
3 cell line  
Average 
value of 
4 slides STD CV 
Count of 
slides  Ratio 
H200006199_EDG2 1.48 0.40603 0.274345 4 2.789487
H200003664_C20orf100 1.4785 0.933017 0.631056 4 2.786589
H200005619_DIPA_HUMAN 1.4765 0.563093 0.38137 4 2.782728
H200001173_NP_932062.1 1.47275 0.496299 0.336988 4 2.775504
H200010289_C6orf139 1.46625 0.579713 0.395371 4 2.763028
H200000560_CEBPG 1.464 0.409896 0.279984 4 2.758722
H300021980_RHOT1 1.46075 0.371909 0.254601 4 2.752514
H200009826_KRTHA4 1.45975 0.9836 0.673814 4 2.750607
H200006824_FZD2 1.4565 0.584051 0.400996 4 2.744418
opHsV0400013404_ 1.44975 0.433341 0.298907 4 2.731607
H300000063_ANKRD22 1.44725 0.878237 0.606832 4 2.726878
H200020107_PSMA3 1.4455 0.455472 0.315096 4 2.723572
H200001621_STRBP 1.445 0.783382 0.542133 4 2.722628
H300001211_ARVCF 1.44375 0.753391 0.521829 4 2.72027
H200003385_PARP2 1.44275 0.926379 0.642093 4 2.718385
H300005845_ 1.44225 0.643212 0.445978 4 2.717443
H300006484_CYP1A1 1.44 0.984089 0.683395 4 2.713209
H300001097_ 1.4365 0.434289 0.302324 4 2.706634












Table 18: 117 downregulated genes in HSC-3 cell line. The gene list is from the least 
downregulated gene to most downregulated gene.  
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H300004618_LGALS7 -1.59825 0.652359 -0.40817 4 0.330277
H300001203_GLIPR1 -1.6 0.633926 -0.3962 4 0.329877
H300009606_ISG20_HUMAN -1.60025 0.636049 -0.39747 4 0.32982
opHsV0400001923_IDH2 -1.60425 0.757475 -0.47217 4 0.328907
H200013160_CARD15 -1.60725 1.224737 -0.76201 4 0.328223
opHsV0400003766_NP_710154.1 -1.60875 0.487525 -0.30305 4 0.327882
H200000491_PRG1 -1.60975 0.736354 -0.45743 4 0.327655
H300003923_DIAPH2 -1.6105 0.696324 -0.43237 4 0.327485
opHsV0400003043_MYADM -1.61525 0.581445 -0.35997 4 0.326408
H200005275_KLK11 -1.6155 1.168752 -0.72346 4 0.326352
H200000280_SPRR1B -1.6335 1.10972 -0.67935 4 0.322305
H200011042_S100A8 -1.64 1.123603 -0.68512 4 0.320856
H300014335_KRT6B -1.64675 0.782004 -0.47488 4 0.319359
opHsV0400002054_RARB -1.647 1.398813 -0.84931 4 0.319303
H200006117_TP53INP1 -1.66175 0.708937 -0.42662 4 0.316056
H300020154_TUBB3 -1.668 0.663706 -0.39791 4 0.314689
H200005378_NP_612398.1 -1.669 0.449427 -0.26928 4 0.314471
H200005918_SYK -1.66975 1.210319 -0.72485 4 0.314308
H300007287_GCNT1 -1.6715 1.245413 -0.74509 4 0.313927
opHsV0400005920_ITGB6 -1.67825 0.791641 -0.47171 4 0.312461
H200003227_CMKOR1 -1.68625 0.819594 -0.48605 4 0.310734
H200006265_EFEMP1 -1.688 0.832564 -0.49322 4 0.310357
H300016617_THY1 -1.693 1.424375 -0.84133 4 0.309283
H200012016_EVA1 -1.69325 0.522671 -0.30868 4 0.30923
H200001136_NP_775925.1 -1.69675 0.554422 -0.32676 4 0.30848
H200000047_IGFBP2 -1.6995 0.581298 -0.34204 4 0.307893
H300010309_MYADM -1.6995 0.748583 -0.44047 4 0.307893
opHsV0400006248_SCMH1 -1.70275 1.414602 -0.83077 4 0.3072
H200014262_DSCR1 -1.7075 0.495285 -0.29006 4 0.30619
H300010992_RBPMS -1.715 0.429382 -0.25037 4 0.304603
H200011819_NP_002956.1 -1.72275 1.028266 -0.59687 4 0.302971
H300010137_CALML3 -1.7315 1.122493 -0.64828 4 0.301139
opHsV0400005864_SEPP1 -1.74075 0.803666 -0.46168 4 0.299214
opHsV0400011936_ -1.747 1.360383 -0.7787 3 0.297921
H200005431_DIXDC1 -1.756 1.022538 -0.58231 4 0.296068
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Table 18 continued 
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H300000194_CSPG2 -1.757 0.801492 -0.45617 4 0.295863
H300000923_POSTN -1.7605 0.694177 -0.39431 4 0.295146
H300018412_MGST1 -1.7615 0.822925 -0.46717 4 0.294941
opHsV0400010804_ -1.76175 0.760455 -0.43165 4 0.29489
H200013413_LRP3 -1.7665 0.715098 -0.40481 4 0.293921
H200014313_BEXL1 -1.771 0.709235 -0.40047 4 0.293006
H200017501_MAGEH1 -1.77275 0.725866 -0.40946 4 0.29265
H300003004_NP_006465.3 -1.788 0.671364 -0.37548 4 0.289573
H200000850_FKBP10 -1.80325 0.670965 -0.37209 4 0.286528
H300003809_CTGF -1.818 0.659317 -0.36266 4 0.283614
opHsV0400002995_BCL2A1 -1.8235 1.294393 -0.70984 4 0.282535
opHsV0400004303_MXD4 -1.82425 0.722652 -0.39614 4 0.282388
H300003568_CPS1 -1.82675 1.062375 -0.58157 4 0.281899
H200004216_PLXDC2 -1.82975 0.755352 -0.41282 4 0.281313
H200001726_KRT23 -1.834 0.87163 -0.47526 4 0.280486
opHsV0400012721_ -1.85175 1.48234 -0.80051 4 0.277056
H200013065_ -1.85225 0.9005 -0.48617 4 0.27696
opHsV0400010233_ -1.8585 1.76167 -0.9479 4 0.275763
H200011416_A4GALT -1.8655 0.72525 -0.38877 4 0.274428
H200000073_GALC -1.87525 1.044675 -0.55709 4 0.27258
H200010239_CTSL2 -1.8785 0.774282 -0.41218 4 0.271966
H200000789_NP_056359.1 -1.88175 0.858455 -0.4562 4 0.271354
H200011433_SNX10 -1.88875 0.754188 -0.39931 4 0.270041
H200010620_IL6 -1.8895 1.383369 -0.73214 4 0.269901
H200013672_ZNF569 -1.895 1.521567 -0.80294 4 0.268874
H200014737_PTGS2 -1.8985 0.67565 -0.35589 4 0.268222
H200008429_Q8TAW3_HUMAN -1.901 1.625141 -0.85489 4 0.267758
opHsV0400005248_FAM46B -1.9065 0.885208 -0.46431 4 0.266739
H200009421_NP_775823.1 -1.93 0.606021 -0.314 4 0.262429
opHsV0400012118_ -1.9465 0.605055 -0.31084 4 0.259445
opHsV0400000655_GJB2 -1.95175 0.743374 -0.38088 4 0.258502
H200002119_ADCY6 -1.9525 0.916307 -0.4693 4 0.258368
H200014431_Y0961_HUMAN -1.9755 0.760543 -0.38499 4 0.254282
opHsV0400011667_ -1.99475 0.714675 -0.35828 4 0.250911
H200011635_LXN -2.00975 1.066807 -0.53082 4 0.248316
H200009088_ZNF606 -2.012 1.487884 -0.73951 4 0.247929
H200004653_SULF2 -2.01375 0.747939 -0.37142 4 0.247629
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Table 18 continued 
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H300013721_TPM4_HUMAN -2.021 0.612298 -0.30297 4 0.246387
H300003220_THBS1 -2.0215 1.036309 -0.51264 4 0.246302
H300021562_FN1 -2.022 0.948529 -0.4691 4 0.246217
H200005569_LIPG -2.04625 0.550896 -0.26922 4 0.242113
H300006196_MAF -2.0505 0.813085 -0.39653 4 0.2414
H200012876_HYAL3 -2.0525 0.589862 -0.28739 4 0.241066
opHsV0400010566_ -2.0745 1.480604 -0.71372 4 0.237418
H200002091_PGBD5 -2.07575 1.316248 -0.63411 4 0.237212
opHsV0400006127_TNFRSF6B -2.09875 0.750611 -0.35765 4 0.23346
H200006334_ID3 -2.1125 0.668089 -0.31626 4 0.231246
H200006031_IPKA_HUMAN -2.13125 0.959348 -0.45013 4 0.22826
H200005423_Q9H7B6_HUMAN -2.133 1.512657 -0.70917 4 0.227983
H200007909_Q86XJ2_HUMAN -2.14075 0.764061 -0.35691 4 0.226762
H200011334_DER7_HUMAN -2.14425 1.85577 -0.86546 4 0.226212
H300021749_FOLR3 -2.15275 0.651404 -0.30259 4 0.224884
H200005198_GALNT5 -2.15775 0.771067 -0.35735 4 0.224106
H300018293_SLC38A5 -2.16125 0.50926 -0.23563 4 0.223562
H200016573_ADPN -2.16325 0.577262 -0.26685 4 0.223253
opHsV0400010774_ -2.16425 0.597593 -0.27612 4 0.223098
H300021145_ANGPTL4 -2.20475 0.76283 -0.34599 4 0.216922
opHsV0400012764_ -2.23 0.580492 -0.26031 4 0.213159
H200006995_ -2.2485 0.791391 -0.35196 4 0.210443
H200006600_PTPRK -2.2635 0.981011 -0.4334 4 0.208266
H200004031_NP_945120.1 -2.264 0.729965 -0.32242 4 0.208194
H200004612_PDGFC -2.283 0.625134 -0.27382 4 0.20547
H200001686_TM4SF10 -2.30975 1.356076 -0.58711 4 0.201695
H200018197_ZNF83 -2.31775 0.474314 -0.20464 4 0.20058
opHsV0400012111_ -2.356 0.525024 -0.22285 4 0.195332
H200015098_IL1F9 -2.38625 1.008139 -0.42248 4 0.191279
H200009642_ITGAV -2.3925 0.630469 -0.26352 4 0.190452
H200004832_C3orf14 -2.4275 0.846863 -0.34886 4 0.185887
H300015331_CALD1 -2.43825 0.623359 -0.25566 4 0.184507
H200012184_COL4A1 -2.46775 0.999759 -0.40513 4 0.180773
opHsV0400000212_SH3BGRL -2.47625 0.893669 -0.3609 4 0.179711
H300016644_WASPIP -2.58325 1.607772 -0.62238 4 0.166865
H200005947_GJA1 -2.6245 1.273362 -0.48518 4 0.162161
H200020242_C9orf26 -2.63075 1.189428 -0.45213 4 0.16146
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Table 18 continued 
Name of the downregulated gene in




4 slides STD CV 
Count of 
slides  Ratio 
H300000043_RGS17 -2.63425 0.842874 -0.31997 4 0.161069
opHsV0400010227_Q96NA9_HUMAN -2.65575 1.140632 -0.4295 4 0.158686
H300017162_Q9H7B6_HUMAN -2.658 0.852331 -0.32067 4 0.158439
H200006236_CDH11 -2.69325 1.264642 -0.46956 4 0.154615
opHsV0400010653_ -2.7575 1.222115 -0.4432 4 0.14788
H200008006_SEMA3C -2.841 0.770015 -0.27104 4 0.139564
H200014307_FADS2 -3.011 1.080029 -0.35869 4 0.124051


















Table 19: The most upregulated and downregulated 20 genes in BHY cell line and the 
expression levels of these 20 genes in the other two OSCC cell lines. 
Name of the most upregulated 20 
gene in BHY cell line. The gene list is 
from the more upregulated gene to 
less upregulated gene.  
 
Expression 
ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HN 
cell  
Expression 
ratio of the 
gene in HSC-3 
cell  
H300004818_MAGEA9 7.909026 2.070171 4.429825 
H200001373_Q96AL8_HUMAN 7.86529 10.51407 2.0145 
H200005842_GFI1 6.768096 3.717931 1.04215 
opHsV0400005829_OAS1 6.37533 7.281572 0.71254 
H200007111_NP_689700.1 6.087079 3.100498 1.2456 
H200005801_MAGEA1 5.877693 11.27847 1.8964 
opHsV0400002611_PRAME 5.8665 6.631108 8.2007 
opHsV0400006088_NOV 5.862435 2.455471 0.94251 
H200011702_HOXA10 5.820931 4.453686 0.76598 
H200012712_BIRC3 5.181968 5.754737 0.5627 
H200004378_MAGEA8 5.143499 2.806943 8.88886 
H200000112_DLX2 5.112397 1.306312 2.20014 
H200003290_DEPDC1B 5.092945 2.7549 1.46598 
H200000421_DPYD 4.930555 0.622437 1.00124 
H200000404_IRK2_HUMAN 4.917755 0.53016 2.01245 
opHsV0400006060_ 4.916051 3.857056 0.8854 
H200011805_NMES1_HUMAN 4.798222 12.48826 0.7645 
H300010220_ID2 4.76673 1.236704 1.0235 
H200005149_NP_116262.2 4.735445 1.304503 0.450547 
H200006112_NP_006811.1 4.64684 4.524474 0.96325 
Name of the most downregulated 20 
gene in BHY cell line. The gene list is 
from the less downregulated gene to 
more downregulated gene.  
 
Expression 
ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HN  
Expression 
ratio of the 
gene in HSC-3 
cell  
H300018293_SLC38A5 0.203803 0.742905 0.223562 
H200001823_ARMCX1 0.203204 0.508299 0.373907 
H200011330_RKHD3 0.200337 0.195095 1.235689 
H300021749_FOLR3 0.198162 0.202115 0.224884 
H200001408_SFRP1 0.195106 0.185148 0.366148 
H300021145_ANGPTL4 0.190584 0.179867 0.216922 
H200016276_ESPN 0.186791 0.726734 0.342043 
H300016617_THY1 0.186242 0.872665 0.309283 
H200018944_KLF8 0.18621 0.272013 0.434522 
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Table 19 continued 
Name of the most downregulated 20 
gene in BHY cell line. The gene list is 
from the less downregulated gene to 
more downregulated gene.  
 
Expression 
ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HN  
Expression 
ratio of the 
gene in HSC-3 
cell  
H200005423_Q9H7B6_HUMAN 0.184891 0.449845 0.227983 
H200001686_TM4SF10 0.165913 0.607413 0.201695 
H200004832_C3orf14 0.160012 2.255192 0.185887 
H200011635_LXN 0.155071 0.137333 0.248316 
opHsV0400010653_ 0.150335 0.144511 0.14788 
H200005947_GJA1 0.129588 0.068441 0.162161 
H200017869_ 0.125318 0.634635 1.469785 
H200014307_FADS2 0.123044 0.113401 0.124051 
H300017162_Q9H7B6_HUMAN 0.118339 0.498011 0.158439 
opHsV0400010227_Q96NA9_HUMAN 0.101005 0.066951 0.158686 
















Table 20: The most upregulated and downregulated 20 genes in HN cell line and the 
expression levels of these 20 genes in the other two OSCC cell lines. 
Name of the most upregulated 20 
gene in HN cell line. The gene list is 
from the more upregulated gene to 
less upregulated gene.  
 
Expression 
ratio of the 
gene in HN  
Expression 
ratio of the 
gene in BHY 
cell  
Expression 
ratio of the 
gene in HSC-3 
cell  
H200011805_NMES1_HUMAN 12.2461 4.798222 0.98746 
H200005801_MAGEA1 11.27847 5.877693 8.200717 
H200001373_Q96AL8_HUMAN 10.51407 7.86529 2.04345 
opHsV0400013404_ 9.04738 1.330529 2.731607 
H200004165_FSTL5 7.823152 2.39828 2.18635 
opHsV0400005829_OAS1 7.281572 6.37533 1.90835 
H200010620_IL6 7.206256 4.452143 0.269901 
H200010289_C6orf139 7.156479 3.922436 2.763028 
H300005969_COX7B2 6.699252 1.24387 1.82643 
opHsV0400002611_PRAME 6.631108 5.8665 1.02386 
H300006342_NP_775969.1 6.463206 1.7436 1.19476 
H200010916_NP_114156.1 6.040843 1.03434 1.90345 
H200012712_BIRC3 5.754737 5.181968 1.56723 
H300006447_MT1K 5.66863 0.212237 1.87352 
H200007081_SLCO2A1 5.634353 2.721213 1.90032 
H200002977_NP_065726.1 5.514576 3.700576 2.921076 
H200004279_ID4 5.36378 1.00232 2.28734 
H200008845_STMN3 5.135483 4.018062 1.78253 
H300022894_NP_002116.2 5.088534 1.84334 1.1872 
opHsV0400000818_IL8 5.066537 4.259695 3.643942 
Name of the most downregulated 20 
gene in HN cell line. The gene list is 
from the less downregulated gene to 
more downregulated gene.  
 
Expression 
ratio of the 
gene in HN  
Expression 
ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HSC-3 
cell  
H200014027_CA2 0.130466 0.53432 0.724973 
opHsV0400010774_ 0.127759 0.317483 0.223098 
H200000301_CDKN2A 0.127207 0.6617 1.600475 
H200011169_TCF7L1 0.125456 0.307253 0.398527 
H200006236_CDH11 0.122895 0.65293 0.154615 
H200006995_ 0.120575 0.309337 0.210443 
H200004653_SULF2 0.119908 0.493116 0.247629 
H300003117_Q8N4W5_HUMAN 0.119272 2.763506 0.4214 
H200016561_NP_060910.2 0.118997 2.204192 0.600714 
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Table 20 continued 
Name of the most downregulated 20 
gene in HN cell line. The gene list is 
from the less downregulated gene to 
more downregulated gene.  
 
Expression 
ratio of the 
gene in HN  
Expression 
ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HSC-3 
cell  
H200020242_C9orf26 0.118298 0.225156 0.16146 
H300006196_MAF 0.114705 0.227313 0.2414 
H200007907_FOXO1A 0.114011 0.4355 0.67354 
H200014307_FADS2 0.113401 0.123044 0.124051 
opHsV0400011317_ 0.108769 0.63243 0.71256 
H300004073_AKR1C1 0.102646 2.305373 2.441893 
H300004901_RPS4Y1 0.10003 0.43224 0.39214 
H200014029_EIF1AY 0.08362 0.817052 1.464847 
H300021913_AKR1C3 0.075154 0.6213 2.628974 
H200005947_GJA1 0.068441 0.129588 0.162161 
















Table 21: The most upregulated and downregulated 20 genes in HSC-3 cell line and the 
expression levels of these 20 genes in the other two OSCC cell lines. 
Name of the most upregulated 20 
gene in HSC-3 cell line. The gene list 
is from the more upregulated gene to 
less upregulated gene.  
 
Expression 




ratio of the 
gene in BHY 
cell  
Expression 
ratio of the 
gene in HN 
cell  
H200004378_MAGEA8 8.88887 5.143499 2.806943 
H200005801_MAGEA1 8.200717 5.877693 11.27847 
H200011948_EREG 6.050272 4.004161 1.490969 
H200011983_Q9BT26_HUMAN 6.032475 1.2334 4.322153 
opHsV0400002734_NP_848664.1 5.844178 3.118819 3.088165 
H200004597_XM_374020.2 5.436771 4.13389 3.868435 
H200002223_TXNRD1 5.277117 3.269908 2.587843 
opHsV0400008521_ 5.152419 4.235405 1.431969 
H200017455_NP_060582.1 4.845011 2.378002 3.319003 
opHsV0400003034_KLK10 4.832434 3.113959 1.801252 
H200004485_HOXC9 4.813212 2.113304 1.42652 
H200009720_GDF15 4.563055 1.647467 3.522257 
opHsV0400003019_NP_115749.2 4.430594 1.642052 2.900899 
H300004818_MAGEA9 4.429826 7.909026 2.070171 
opHsV0400001562_IGSF4 4.299742 1.313576 2.159579 
H300006703_LY6K 4.247165 3.564007 4.538608 
H300022245_PHF15 4.166252 1.7834 0.777007 
opHsV0400000415_NP_149024.1 4.126733 2.03424 0.80413 
opHsV0400004777_NP_998889.1 4.039705 1.819762 1.706452 
opHsV0400001984_XP_377060.1 3.987543 1.834962 1.318594 
Name of the most downregulated 20 
gene in HSC-3 cell line. The gene list 
is from the less downregulated gene to 
more downregulated gene.  
 
Expression 




ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HN 
cell  
H200001686_TM4SF10 0.201695 0.165913 0.607413 
H200018197_ZNF83 0.20058 0.543085 0.598221 
opHsV0400012111_ 0.195332 0.379258 0.272816 
H200015098_IL1F9 0.191279 0.40669 0.174373 
H200009642_ITGAV 0.190452 0.270509 0.330908 
H200004832_C3orf14 0.185887 0.160012 2.255192 
H300015331_CALD1 0.184507 0.402902 0.267479 
H200012184_COL4A1 0.180773 0.493116 0.141586 
opHsV0400000212_SH3BGRL 0.179711 0.383421 0.427427 
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Table 21 continued 
Name of the most downregulated 20 
gene in HSC-3 cell line. The gene list 
is from the less downregulated gene to 
more downregulated gene.  
 
Expression 




ratio of the 
gene in BHY  
Expression 
ratio of the 
gene in HN 
cell  
H300016644_WASPIP 0.166865 0.204121 0.216547 
H200005947_GJA1 0.162161 0.129588 0.068441 
H200020242_C9orf26 0.16146 0.225156 0.118298 
H300000043_RGS17 0.161069 0.093121 0.200511 
opHsV0400010227_Q96NA9_HUMAN 0.158686 0.101005 0.066951 
H300017162_Q9H7B6_HUMAN 0.158439 0.118339 0.498011 
H200006236_CDH11 0.154615 0.65293 0.122895 
opHsV0400010653_ 0.14788 0.150335 0.144511 
H200008006_SEMA3C 0.139564 0.259175 0.181684 
H200014307_FADS2 0.124051 0.123044 0.113401 
























Figure 1: Schematic drawing showing the relationship between tumor cells, osteoclast 
precursor cells, stromal cells, and extracellular matrix. Osteoclast precursor cells are 
apposed to tumor cells in some instances (a), but stromal cells and/or extracellular matrix 
usually exits between the two cells (b), (c), (d). (T, tumor cells; SC, stromal cells; ECM, 
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Figure 2: The organs to which BHY, HN, and HSC-3 cells invade and/or metastasize are 

























































igure 4a: Total RNA samples before the synthesis of cDNA for Real Time PCR. Column 1: 




Figure 4b: Glucose-6-phosphate gene expression levels of cDNA samples used for Real Time 
PCR. Column 1:Marker, Column 2: HNEC, Column 3: BHY, Column 4: HN, Column 5: HSC-3. 
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Figure 5: A left sagittal PET image of a mouse with HNEC cell line injection. No malignancy 










Figure 7: An axial PET/CT image of a mouse with HNEC cell line injection. No malignancy was 















Figure 8: A left sagittal PET image of a mouse with BHY cell line injection. Arrow shows the 
mandibular bone resorption due to invasion of OSCC to the bone.     
 
 





igure 10: A left sagittal PET image of a mouse with HN cell line injection. Yellow arrow shows 
lung metastasis, blue arrow shows kidney metastasis and white arrow shows the distant lymph 







igure 11: A left sagittal PET/CT image of a mouse with HN cell line injection. Yellow arrow 
shows lung metastasis, blue arrow shows kidney metastasis and white arrow shows the cervical 





igure 12: A left sagittal PET image of a mouse with HSC-3 cell line injection. White arrow 






igure13: An axial PET/CT  image of a mouse with HSC-3 cell line injection. White arrow 
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   C      D 
NEC, B: 
BHY, C: HN, D: HSC-3. Original magnification is 100x. 
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igure 15: Immunocytochemistry images showing MMP-2 expression. A: HNEC, B: 
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EC, B: 
 
igure 16: Immunocytochemistry images showing MMP-3 expression. A: HNF
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EC, B: 
 
igure 17: Immunocytochemistry images showing MMP-9 expression. A: HNF












       





      
   C      D 
igure 18: Immunocytochemistry images showing EMMPRIN expression. A: HNEC, B: 
















       






      
   C      D 
igure 19: Immunocytochemistry images showing cathepsin B expression. A: HNEC, B: 
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igure 20: Immunocytochemistry images showing cathepsin L expression. A: HNEC, B: 




































igure 21: Flow cytometry results of (-) control, MMP-1, MMP-2, and MMP-3 






















Figure 22: Flow cytometry results of MMP-9 and EMMPRIN expression in HNEC, 














            
Figure 23: Electron microscopy picture 




Figure 25: Electron microscopy picture 





Figure 24: Electron microscopy picture 




Figure 26: Electron microscopy picture 

































Figure 31: Aldolase and β-actin genes expression on three OSCC cell lines and HNEC cell line. 
Column 1:  Aldolase (-) control; Column 2:  Aldolase (+) control; Column 3:  Aldolase in BHY 
cell line; Column 4:  Aldolase in HNEC cell line; Column 5:  Aldolase in HN cell line; Column 
6:  Aldolase in HSC-3 cell line; Column 7:  β-actin (-) control; Column 8:  β-actin (+) control; 
Column 9:  β-actin in BHY; Column 10:  β-actin in HNEC; Column 11:  β-actin in HN; Column 
12:  β-actin in HSC-3; Column 13:  IH marker. 
 
 




Figure 33: Clusterization of 83 downregulated genes in all three OSCC cell lines. 
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Figure 34: Clusterization of the top 20-upregulated (A) and downregulated (B) genes of 
BHY cell line with other two OSCC cell lines, HN and HSC-3.    


















    
  A       B 
 
Figure 35: Clusterization of the top 20-upregulated (A) and downregulated (B) genes of 
HN cell line with other two OSCC cell lines, BHY and HSC-3.   
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Figure 36: Clusterization of the top 20-upregulated (A) and downregulated (B) genes of HSC-3 






Figure 37: 57 upregulated genes and 42 
downregulated genes on both BHY and HN cell 
lines. 
  
















Figure 40: Pathway analysis of the BHY cell line based on both upregulated and 













Figure 41: Pathway analysis of the BHY cell line based on upregulated gene data by 














Figure 42: Pathway analysis of theBHY cell line based on downregulated gene data by 















Figure 43: Pathway analysis of the HN cell line based on both upregulated and 













Figure 44: Pathway analysis of the HN cell line based on upregulated gene data by using 


















Figure 45: Pathway analysis of the HN cell line based on downregulated gene data by 














Figure 46: Pathway analysis of the HSC-3 cell line based on both upregulated and 














Figure 47: Pathway analysis of the HSC-3 cell line based on upregulated gene data by 



















Figure 48: Pathway analysis of the HSC-3 cell line based on downregulated gene data by 



































































Figure 49: RT-PCR Analysis results. Blue columns represent the BHY, red columns 
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